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Résumé	grand	public:	
Exploiter	les	microRNAs	pour	les	immunothérapies	contre	le	cancer	
	
Ces	 dernières	 années,	 l’immunothérapie	 contre	 le	 cancer	 s’est	 faite	 connaître	 du	 grand	
public,	notamment	grâce	au	magazine	Science,	qui	 l’a	nommée	«	découverte	de	 l’année	»	
en	2013.	
En	effet,	 cette	approche	est	une	révolution	dans	 les	 traitements	contre	 le	cancer,	car	elle	
s’attache	 à	 réactiver	 le	 système	 immunitaire	 du	 patient	 pour	 qu’il	 attaque	 sa	 propre	
tumeur.	 En	 l’occurrence,	 les	 immunothérapies	 telles	 que	 les	 inhibiteurs	 de	 points	 de	
contrôle	immunitaire,	ont	démontré	des	effets	à	long	terme	impressionnants,	avec	certains	
patients	n’ayant	à	ce	jour	pas	développé	de	récurrence	de	leur	cancer.	
Il	existe	plusieurs	types	d’immunothérapies.	L’une	d’elle	consiste	à	extraire	des	cellules	du	
système	immunitaire	du	patient	et	à	 les	modifier	génétiquement	pour	qu’elles	deviennent	
spécifiques	 pour	 la	 tumeur.	 Une	 fois	 re-transférées	 dans	 le	 patient,	 ces	 cellules	 peuvent	
attaquer	 la	 tumeur	 et	 la	 détruire.	 Cette	 technique	 se	 nomme	 le	 transfert	 adoptif	
thérapeutique.	
Mon	 projet	 s’est	 attelé	 à	 étudier	 l’importance	 des	microRNAs	 dans	 la	 fonctionnalité	 des	
cellules	 T	 CD8+	 et	 à	 utiliser	 ces	 connaissances	 pour	 améliorer	 les	 thérapies	 de	 transfert	
adoptif.	 Les	 microRNAs	 sont	 des	 petites	 molécules	 qui	 s’attachent	 spécifiquement	 aux	
molécules	d’ARN	messager,	et	qui	de	cette	façon	bloquent	la	traduction	de	l’ARN	messager	
en	protéines.	Les	microRNAs	sont	 très	 importants	pour	 les	 fonctionnements	cellulaires,	et	
permettent	aux	cellules	de	passer	plus	rapidement	d’un	état	à	un	autre.	
Durant	 mon	 projet	 de	 thèse,	 j’ai	 tout	 d’abord	 observé	 que	 la	 présence	 du	 cluster	 de	
microRNAs	 miR-17-92	 était	 cruciale	 pour	 la	 bonne	 fonctionnalité	 des	 cellules	 CD8+.	 En	
particulier,	 pour	 leur	 capacité	 à	 répondre	 à	 une	 infection	 et	 à	 produire	 des	 cytokines	 qui	
sont	les	molécules	effectrices	de	la	réponse	immunitaire.	Nous	avons	aussi	observé	que	les	
cellules	CD8+	ne	possédant	pas	de	miR-17-92	montraient	un	phénotype	«	mémoire	».	
Deuxièmement,	nous	avons	étudié	la	surexpression	d’un	autre	microRNA,	miR-155,	dans	les	
cellules	CD8+,	et	l’impact	de	cette	surexpression	dans	la	capacité	des	cellules	à	induire	une	
régression	 tumorale.	Nous	 avons	 observé	dans	 un	modèle	murin	 que	 la	 surexpression	de	
miR-155	 pouvait	 améliorer	 la	 régression	 tumorale	 lorsque	 les	 tumeurs	 exprimaient	 un	
antigène	 de	 basse	 affinité.	 Ceci	 est	 intéressant	 pour	 les	 thérapies	 humaines,	 car	 les	
antigènes	tumoraux	sont	souvent	de	basse	affinité	puisqu’ils	sont	des	molécules	du	«	soi	»	
contre	lesquelles	le	système	immunitaire	est	tolérant	contrairement	aux	pathogènes.	
Finalement,	 nous	 avons	 étudié	 la	 surexpression	 de	 miR-155	 en	 combinaison	 avec	 les	
thérapies	de	récepteur	d’antigène	chimérique	(CAR).	Dans	le	modèle	murin	que	nous	avons	
utilisé,	 la	 surexpression	 de	 miR-155	 ne	 changeait	 pas	 l’efficacité	 du	 traitement	 avec	 des	
cellules	CAR	qui	probablement	était	déjà	optimale.	
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De	 par	 leur	 capacité	 à	 réguler	 l’expression	 de	 plusieurs	 protéines	 à	 la	 fois	 et	 de	 façon	
extrêmement	rapide,	les	microRNAs	sont	des	molécules	qui	comportent	un	fort	potentiel	de	
manipulation	à	des	fins	thérapeutiques.	Dans	mon	travail,	j’ai	démontré	que	les	microRNAs	
miR-17-92	 ainsi	 que	 miR-155	 pourraient	 être	 des	 cibles	 intéressantes	 pour	 améliorer	 les	
immunothérapies	contre	le	cancer.	 	
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Résumé	
Ces	 dernières	 années,	 la	 recherche	 de	 thérapies	 contre	 le	 cancer	 a	 pris	 un	 nouveau	
tournant.	Ceci	a	eu	pour	conséquence	la	nomination	de	l’immunothérapie	contre	le	cancer	
en	tant	que	«	découverte	de	l’année	2013	»	par	le	magazine	Science.	En	effet,	les	dernières	
publications	 démontrent	 une	 efficacité	 clinique	 sans	 précédent	 pour	 plusieurs	
immunothérapies	 contre	 le	 cancer.	 En	 particulier,	 le	 transfert	 adoptif	 de	 lymphocytes	
infiltrants	 de	 la	 tumeur	 ou	 de	 lymphocytes	 génétiquement	 modifiés	 pour	 attaquer	 la	
tumeur.	Ces	technologies	ont	suscité	l’intérêt	des	immunologistes	ainsi	que	du	grand	public	
car	 ces	 approches	 ont	 montré	 des	 résultats	 extrêmement	 encourageants.	 Pourtant,	 les	
tumeurs	 solides	 restent	 les	plus	difficiles	à	 traiter.	Ceci	démontre	 la	nécessité	d’améliorer	
les	fonctions	effectrices	des	lymphocytes	transférés.	
Pour	ce	faire,	nous	avons	étudié	l’influence	des	microRNAs	sur	les	fonctions	effectrices	des	
lymphocytes	T	CD8+,	ainsi	que	les	façons	de	moduler	l’expression	de	ceux-ci	pour	améliorer	
les	immunothérapies	contre	le	cancer.	
Dans	 le	 premier	 chapitre,	 nous	 avons	 observé	 l’importance	 pour	 la	 fonctionnalité	 des	
cellules	 T	 CD8+	 du	 cluster	 de	 microRNAs	 miR-17-92.	 L’expression	 de	 ce	 cluster	 est	
augmentée	 dans	 les	 cellules	 T	 CD8+	 après	 leur	 activation.	 Nous	 avons	 utilisé	 un	modèle	
murin	 de	 délétion	 du	 cluster	 dans	 les	 lymphocytes	 T,	 et	 observé	 une	 diminution	 de	 la	
fonctionnalité	des	cellules	T	CD8+	en	son	absence.	Sans	le	cluster	miR-17-92,	 les	cellules	T	
CD8+	avaient	une	capacité	diminuée	de	prolifération	et	de	production	de	cytokines.	De	plus,	
leur	 différentiation	 en	 cellules	 effectrices	 était	 compromise.	 En	 effet,	 les	 cellules	
exprimaient	en	majorité	des	marqueurs	phénotypiques	des	cellules	de	la	mémoire	centrale.	
Dans	le	second	chapitre,	nous	avons	étudié	comment	la	surexpression	de	miR-155	a	affecté	
le	 potentiel	 antitumoral	 des	 cellules	 T	 CD8+	 dans	 un	 modèle	 murin	 de	 vaccination	
thérapeutique,	ainsi	que	leur	habilité	a	réagir	à	des	antigènes	de	basse	affinité.	Nous	avons	
observé	que	la	surexpression	de	miR-155	permettait	aux	cellules	T	CD8+	d’augmenter	 leur	
capacité	 proliférative	 ainsi	 que	 leur	 production	 de	 cytokines	 après	 activation.	 De	 plus,	 la	
surexpression	 de	 miR-155	 a	 permis	 d’améliorer	 le	 contrôle	 des	 tumeurs	 exprimant	 un	
antigène	de	basse	affinité.		
Dans	 le	 troisième	 chapitre,	 nous	 avons	mesuré	 la	 fonctionnalité	 des	 cellules	 humaines	 T	
CD8+	 transduites	pour	exprimer	un	 récepteur	d’antigène	chimérique	 (CAR)	ainsi	que	miR-
155.	Nous	avons	pu	augmenter	légèrement	la	quantité	relative	de	miR-155	dans	ces	cellules,	
et	ceci	a	suffi	pour	améliorer	leur	potentiel	de	prolifération	après	activation.	Malgré	tout,	la	
surexpression	 de	 miR-155	 n’a	 pas	 induit	 d’amélioration	 dans	 la	 régression	 des	 tumeurs	
médiée	par	les	cellules	T	CAR+	CD8+	dans	un	modèle	de	xénogreffe.	
Dans	 sa	 globalité,	 ce	 travail	 de	 thèse	 démontre	 l’importance	 de	 l’expression	 et	 de	 la	
régulation	 des	microRNAs	 pour	 la	 fonctionnalité	 des	 cellules	 T	 CD8+	 et	 pour	 leur	 activité	
antitumorale.	 	
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Summary	
In	the	last	few	years,	the	fight	against	cancer	has	reached	a	turning	point,	which	led	to	the	
proclamation	of	cancer	immunotherapy	as	the	“2013	Breakthrough	of	the	year”	by	Science	
magazine.	 Indeed,	 recent	 results	 have	 shown	 clinical	 efficacy	 of	 several	 approaches	 to	
specific	 immunotherapy	 of	 cancer,	 such	 as,	 adoptive	 transfer	 of	 tumour	 infiltrating	
lymphocytes	or	 lymphocytes	 genetically	modified	 to	 attack	 the	 tumour.	 This	 has	not	only	
been	 sparking	 the	 interest	 of	 immunologists	 themselves,	 but	 also	 of	 the	 general	 public.	
Although	these	approaches	show	encouraging	 results,	not	all	patients	can	benefit	 from	 it,	
and	especially	solid	tumours	have	proven	to	be	more	difficult	to	treat.	
For	 this	 reason,	 there	 is	an	 interest	 in	 improving	 the	effector	 functions	of	 the	 transferred	
cells.	To	do	so,	we	have	studied	the	potential	of	modulating	the	expression	of	microRNAs	in	
CD8+	T	lymphocytes.	
In	the	first	chapter	of	this	thesis,	we	studied	the	importance	of	the	microRNA	cluster	miR-
17-92	 in	 the	 functionality	 of	 CD8+	 T	 cells.	 This	 cluster	 was	 shown	 to	 be	 selectively	
upregulated	 after	 T	 cell	 activation,	 which	 indicated	 a	 potential	 function	 of	 this	 cluster	 in	
CD8+	T	 cells	effector	 functions.	To	 study	 this,	we	used	a	CD4	conditional	 knockout	of	 the	
miR-17-92	cluster	and	observed	a	decreased	functionality	of	CD8+	T	cells	in	its	the	absence.	
We	 found	 that	 the	 deletion	 of	miR-17-92	 impaired	 the	 CD8+	 T	 cells	 in	 their	 proliferative	
ability	upon	activation	and	decreased	their	production	of	cytokines.	Moreover,	we	observed	
that	 CD8+	 T	 cells	 were	 impaired	 in	 their	 effector	 cells	 differentiation	 and	 showed	 a	
phenotype	of	central	memory	cells.	
In	the	second	chapter,	we	studied	how	overexpression	of	miR-155	affected	the	CD8+	T	cells	
antitumour	efficiency	upon	vaccination.	Moreover,	we	observed	the	influence	of	miR-155	in	
modulating	the	functional	avidity	of	CD8+	T	cells.	We	found	that	CD8+	T	cells	overexpressing	
miR-155	had	 an	 increased	proliferative	 capacity	 and	 cytokine	production	upon	 activation.	
We	also	observed	that	overexpression	of	miR-155	improved	tumour	control	when	tumours	
expressed	a	 low	affinity	 ligand.	Our	 findings	 indicate	 that	miR-155	overexpression	rescues	
CD8+	T	cells	that	have	been	suboptimally	activated	or	restimulated	by	a	low	affinity	ligand.	
In	the	third	chapter,	we	assessed	miR-155	overexpression	in	human	CD8+	T	cells	expressing	
a	chimeric	antigen	receptor	(CAR)	against	a	prostate	surface	antigen	(PSMA).	We	managed	
to	 induce	a	 small	 increase	of	miR-155	 levels	 in	 those	 cells.	 This	 increase	was	 sufficient	 to	
improve	 the	ability	of	CAR+	CD8+	T	 cells	 to	proliferate	 in	 vitro	 upon	activation.	However,	
miR-155	 expression	 did	 not	 improve	 the	 efficiency	 of	 the	 CAR+	 CD8+	 T	 cells	 in	 a	mouse	
xenograft	model.	
As	a	whole,	this	thesis	work	demonstrates	the	importance	of	the	expression	and	regulation	
of	microRNAs	for	the	functionality	of	CD8+	T	cells	and	their	antitumour	efficiency.	 	
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Abbreviations	
APCs	 Antigen	presenting	cells	
ADCC	 Antibody-dependant	cell-mediated	cytotoxicity	
BrdU	 Bromodeoxyuridine	
CD	 Cluster	of	differenciation	
CFU	 Colonie-forming	unit	
CpG	 Unmethylated	deoxycytidylate-phosphate-
deoxyguanylate	
CTL	 Cytotoxic	T	lymphocyte	
DC	 Dendritic	cell	
DNA	 Deoxyribonucleic	acid	
EAE	 Experimental	autoimmune	encephalomyelitis	
EGFR	 Epidermal	growth	factor	receptor	
IFN	 Interferon	
IL	 Interleukin	
KO	 Knock-out	
LCMV	 Lymphocytic	choriomeningitis	
Lm	 Listeria	Monocytogenes	
LPS	 Lipopolysaccharides		
MCA	 3-methylcholanthrene		
MHC	 Major	histocompatibility	complex	
mRNA	 Messenger	RNA	
NK	 Natural	killer	
NSG	 NOD	SCID	gamma	
OXPHOS	 Oxidative	phosphorylation	
PAMPs	 Pathogen-associated	molecular	patterns	
PBMCs	 Peripheral	blood	mononuclear	cells	
pDCs	 Plasmacytoid	dendritic	cell	
PFU	 Plaque-forming	unit	
PRRs	 Pattern-recognition	receptors	
PSMA	 Prostate-specific	membrane	antigen	
RNA	 Ribonucleic	acid	
RT	 Room	temperature	
SOCS-1	 Suppressor	of	cytokine	signaling	1		
TAP	 Transporter	associated	with	antigen	processing	
TCR	 T	cell	receptor	
Th	 T	helper	(cell)	
TLRs	 Toll-like	receptors	
WT	 Wild-type	
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General	introduction:	
1. The	immune	system:	
Since	 the	apparition	of	 life,	organisms	evolved	 from	very	 simple	microorganisms,	 to	more	
and	more	intricate	forms	of	life.	As	the	complexity	of	organisms	increased,	their	cells	started	
specializing	and	were	assigned	more	precise	functions.		
The	 immune	 system	 is	 defined	 as	 the	 combination	 of	 specialized	 tissues	 and	 cells,	which	
defend	an	organism	against	external	enemies.	The	core	 idea	of	 the	 immune	system	 is	 the	
discrimination	between	“self”	and	“non-self”,	and	hence	to	both	protect	the	host	and	fight	
pathogens.	Nonetheless,	during	 its	evolution	the	 immune	system	has	also	become	able	to	
discriminate	and	get	rid	of	“altered	self”,	such	as	malignant	cells.	
The	immune	system	of	mammals	is	divided	in	two	main	parts:	the	innate	immune	system,	
which	 can	 immediately	 respond	 and	 fight	 broad	 classes	 of	 pathogens,	 and	 the	 adaptive	
immune	system,	which	 takes	a	 few	days	 to	be	 ignited,	but	gives	 rise	 to	a	peptide-specific	
response.	 The	 innate	 and	 the	 adaptive	 immune	 system,	 as	 well	 as	 key	 characteristics	
defining	them,	will	be	presented	in	this	chapter.	
1.1. The	innate	immune	system	
The	innate	immune	system	is	the	first	line	of	defence	when	pathogens	manage	to	cross	the	
physical	barriers	protecting	the	 inside	of	the	body	from	the	outside	–	namely	 internal	and	
external	 epithelia.	 To	 prevent	 the	 crossing,	 epithelial	 surfaces	 are	 able	 to	 secrete	mucus,	
that	coats	bacteria	and	interferes	with	their	adhesion	and	invasion,	as	well	as	antimicrobial	
peptides	 that	 can	 directly	 kill	 the	 aforementioned	 pathogens1.	 If	 a	 breach	 in	 the	 barrier	
occurs	and	pathogens	are	able	to	enter,	their	first	encounter	will	be	with	innate	cells	named	
macrophages	that	permanently	reside	in	tissues	throughout	the	body.	These	cells	are	able	
to	 recognize	pathogen-associated	 molecular	 patterns	 (PAMPs),	 via	 receptors	 recognizing	
broad	classes	of	molecules	expressed	at	the	surface	of	microbes.	There	are	several	classes	
of	pattern	recognition	receptors	(PRRs),	and	the	most	extensively	studied	are	the	Toll-Like	
Receptors	 (TLRs).	 Different	 receptors	 will	 bind	 to	 different	 PAMPs	 (see	 Figure	 1).	 For	
example,	 TLR-9	 binds	 in	 the	 endosome	 to	 the	 unmethylated	 deoxycytidylate-phosphate-
deoxyguanylate	(CpG)	DNA,	which	is	found	in	viruses.	TLR-9	is	expressed	in	macrophages	as	
well	as	plasmacytoid	dendritic	cells	(pDCs)	and	B	cells.	Recognition	of	CpG	by	TLR-9	induces	
the	expression	of	 type	 I	 interferon,	and	 inflammation,	which	 is	why	 it	 is	often	used	as	an	
adjuvant	to	start	an	immune	response.	
Upon	 recognition	 of	 a	 PAMP,	 macrophages	 can	 phagocyte	 the	 invader,	 and	 destroy	 it	
internally	via	acidification	and	the	fusion	of	the	phagosome	with	another	vesicle	containing	
lysing	peptides,	proteins	and	enzymes.	Once	activated	in	this	manner,	macrophages	are	able	
to	produce	chemokines,	such	as	CXCL8,	to	recruit	neutrophils2	and	cytokines,	such	as	IL-12	
to	recruit	natural	killer	(NK)	cells.	
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Figure	1:	Toll-like	receptors,	their	 ligands	and	signalling	pathways.	TLR-1,	2,	4,	5,	6	and	11	can	bind	extracellular	PAMPs	
and	induce	signalling.	TLR3,	7,	8,	9	and	13	are	present	in	the	endosome	and	detect	viral	nucleic	acids3	
Neutrophils	 are	 a	 second	 family	 of	 phagocytes	 that	 are	 recruited	 to	 the	 tissue	 upon	
inflammation.	They	can	recognize	and	destroy	microbes	through	the	generation	of	reactive	
oxygen	 species.	 Upon	 activation,	 they	 produce	 inflammatory	 cytokines	 and	 chemokines,	
which	 in	 turn	 recruit	 more	 macrophages	 and	 neutrophils	 to	 the	 inflammation	 site.	
Moreover,	 they	are	able	 to	present	peptides	 to	T	 cells	 via	 the	expression	of	a	membrane	
glycoprotein	named	Major	Histocompatibility	complex	(MHC).		
Immature	 dendritic	 cells	 (DCs)	 are	 a	 third	 class	 of	 cells	 that	 can	 phagocyte	 and	 destroy	
microbes	while	also	acting	as	antigen-presenting	cells	 (APCs).	Their	primary	 function	upon	
engulfment	of	 the	pathogen	 is	 to	 degrade	 it	 into	peptides	 and	present	 it	 to	 the	 adaptive	
immune	cells.	
Lastly,	natural	killer	 (NK)	cells	are	able	to	directly	 lyse	infected	or	malignant	cells.	NK	cells	
are	 activated	 by	 interferon-(IFN-)	 α	 and	 β	 and	 the	 interleukin	 IL-12.	 These	 cytokines	 are	
produced	by	activated	macrophages	and	DCs.	Once	activated,	NK	cells	are	able	to	destroy	
target	cells	through	the	release	of	cytotoxic	granules	containing	the	lytic	enzymes	perforin	
and	granzyme.	NK	cells	do	not	recognize	 ligands	that	derive	directly	 from	a	pathogen,	but	
rather	 react	 to	molecules	 that	 are	 associated	with	 an	 altered	 cellular	 state.	 For	 instance,	
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several	 viruses	 as	 well	 as	 tumours	 have	 evolved	 to	 downregulate	 MHC	 class	 I	 surface	
expression	 in	 order	 to	 escape	 recognition	 from	 the	 adaptive	 immune	 system4.	 In	 this	
context,	NK	cells	 are	useful	 as	 they	are	able	 to	detect	 changes	 in	MHC	class	 I	 expression.	
Indeed,	 a	 low	 level	 or	 complete	 absence	 of	 surface	 MHC-class	 I	 renders	 the	 target	 cell	
susceptible	to	NK	cell	killing	while	normal	levels	of	MHC	class	I	keeps	NK	cells	tolerant5.	 In	
addition	 to	 the	 absence	 of	 MHC	 class	 I,	 an	 inflammatory	 context	 and	 the	 expression	 of	
activatory	 ligands	 are	 also	 required	 to	 trigger	NK	 cell	 cytotoxicity.	 The	ones	 that	 are	best	
characterized	 are	 MICA,	 MICB	 and	 ULBP4,	 which	 can	 bind	 the	 receptor	 NKG2D	 on	 the	
surface	of	the	NK	cell.	These	ligands	are	not	expressed	on	healthy	cells,	but	are	upregulated	
upon	cellular	stress6.	
Cells	 of	 the	 innate	 immune	 system	 have	 the	 ability	 to	 directly	 attack	 microbes,	 and	 to	
produce	 cytokines	 and	 chemokines	 to	 attract	 more	 cells	 to	 the	 site	 of	 inflammation.	
However,	this	is	often	not	sufficient	to	control	an	infection.	Thus,	a	crucial	role	of	the	innate	
immune	 system	 is	 to	 initiate	 the	 adaptive	 immune	 response,	 which	 is	 specific	 and	more	
potent.	A	key	step	in	this	initiation	is	the	presentation	of	specific	peptides,	called	antigens,	
to	the	cells	of	the	adaptive	immune	system.	
1.2. Antigen	presentation	
Antigen	 presentation	 by	 APCs	 to	 lymphocytes	 occurs	 in	 3	 step:	 APC	 activation	 and	
maturation,	processing	of	the	antigen	for	presentation,	and	finally	migration	to	the	 lymph	
node	-	where	APCs	and	naive	lymphocytes	can	meet.	
1.2.1. APCs	maturation	and	activation	
Immature	APCs	have	a	high	 turnover	of	MHC	class	 I	 and	 II	 and	 low	 surface	expression	of	
these	molecules.	Moreover,	they	have	a	high	rate	of	endo-	and	phagocytosis.	Maturation	of	
the	APCs	reduces	their	endocytosis	rate,	and	increases	the	peptide:MHC	half	life	and	surface	
expression.	Upon	recognition	of	PAMPs,	APCs	get	activated.	They	upregulate	costimulatory	
markers,	 such	 as	 CD80	 and	 CD86	 and	 start	 producing	 cytokines.	 This	 costimulation	 and	
inflammatory	 environment	 is	 essential	 to	 the	 ignition	 of	 a	 potent	 immune	 response.	 In	
contrast,	when	antigens	are	presented	by	a	mature	but	non-activated	APC,	 in	the	absence	
of	an	inflammatory	context,	it	creates	tolerogenic	CD4+	or	CD8+	T	cells7.	This	mechanism	is	
called	peripheral	tolerance,	and	ensures	that	T	cells	do	not	react	against	self-antigens	when	
encountered	in	the	periphery.	
1.2.2. Antigen	processing	and	loading	on	the	MHC	
APCs	 can	 present	 peptides	 originating	 from	 either	 their	 cytosol,	 or	 from	 intracellular	
vesicles.	 In	 the	 case	 of	 intracellular	 proteins,	 they	 are	 degraded	 by	 the	 proteasome,	 and	
processed	 into	 peptides.	 These	 peptides	 are	 then	 transported	 into	 the	 endoplasmic	
reticulum	 (ER)	 by	 specialized	 transporters	 called	 TAP1	 and	 TAP2	 (Transporter	 associated	
with	Antigen	Presentation)8.	In	the	ER,	8-10	amino	acid	peptides	can	bind	to	the	MHC	class	I.	
The	MHC:peptide	complex	is	then	exported	on	the	surface	of	the	cell	for	presentation.	The	
pathway	is	different	for	extracellular	pathogens.	Since	they	are	phagocytosed,	they	are	not	
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present	in	the	cytosol	but	in	intracellular	vesicles.	These	vesicles	are	gradually	acidified	until	
the	proteins	are	degraded	into	peptides	by	proteases.	At	this	point,	the	peptide-containing	
vesicle	fuses	with	another	vesicle	containing	the	MHC	class	II.	 In	opposition	to	MHC	class	I	
peptides	 that	 are	 limited	 to	 10	 amino	 acids,	 MHC	 class	 II	 peptides	 are	 of	 more	 variable	
length,	but	usually	13	to	17	amino	acids.	Once	on	the	surface	of	the	APC,	MHC	class	II	binds	
the	TCR	of	CD4+	T	cells	and	can	trigger	T	helper	cell	differentiation,	while	MHC	class	I	binds	
to	the	TCR	of	CD8+	T	cells	to	turn	them	into	cytotoxic	T	cells9.	However,	it	was	shown	that	a	
subtype	of	APCs	is	able	to	cross-present	peptides	originating	from	vesicles	onto	MHC	class	I.	
This	is	useful	when	the	APC	itself	is	not	infected,	but	ingests	debris	of	another	cell	infected	
by	an	 intracellular	pathogen.	This	ability	of	cross-presentation	 is	a	 feature	of	a	subclass	of	
DCs,	CD8+	DCs,	that	are	able	to	engulf	debris	of	infected	cells,	and	cross-present	the	antigen	
coming	 from	 the	 outside	 of	 the	 cell,	 onto	 the	 MHC	 class	 I,	 and	 hence	 to	 trigger	 the	
differentiation	 of	 specialized	 CTLs10,11.	 In	 this	 case,	 proteins	 present	 in	 the	 ER	 can	 be	
transported	into	the	cytoplasm	by	retrograde	translocation.	There	they	can	be	processed	by	
the	proteasome	and	 loaded	onto	MHC	class	 I.	This	only	seems	to	occur	when	CD4+	T	cell	
help	 is	 provided,	 in	 the	 form	of	 the	T	 cell	molecule	CD40L	binding	 to	CD40	on	 the	DCs12.	
Indeed,	CD4	help	could	be	replaced	by	a	CD40-stimulating	monoclonal	antibody	to	 induce	
DCs	cross-presentation	of	an	exogenous	antigen	and	thus	potent	CTL	priming13.	
1.2.3. Migration	to	the	lymph	node	
Maturation	of	 the	APC	drives	a	 reprogramming	of	 the	 cell	 that	 induces	 it	 to	 travel	 to	 the	
nearest	lymph	node	for	antigen	presentation	to	B	and	T	cells.	Upregulation	of	CCR7	on	the	
DC	as	well	as	the	expression	of	its	ligand,	CCL21,	on	lymphatic	endothelial	cells,	was	shown	
to	be	necessary	for	DC	migration	to	the	lymph	node14.	DCs	could	be	detected	in	the	lymph	
node	already	1	day	after	subcutaneous	injection,	and	their	accumulation	reached	a	plateau	
after	3	days.		
1.3. The	adaptive	immune	system	development	
In	 contrast	 to	 the	 innate	 immune	 response,	 which	 is	 immediate	 upon	 encounter	 with	 a	
pathogen,	the	adaptive	immune	response	takes	a	few	days	to	be	launched.	There	are	2	main	
types	of	 adaptive	 immune	cells;	 T	 cells	 and	B	 cells.	Both	are	 created	 in	 the	bone	marrow	
from	 common	 precursors,	 but	 T	 cells	 have	 to	 travel	 to	 the	 thymus	 for	 their	maturation.	
Through	 a	 large	 variety	 of	 T	 cell	 receptors	 (TCRs),	 T	 lymphocytes	 are	 able	 to	 recognize	
specifically	 a	 high	 number	 of	 antigens.	 The	 variety	 in	 the	 T	 cell	 repertoire	 is	 generated	
because	 of	 the	 recombination	 of	 TCR	 genes.	 The	 TCR	 is	 composed	 of	 2	 chains,	 α	 and	 β,	
which	are	comprised	of	1	variable	(V),	1	joining	(J),	and	1	constant	(C)	segment.	These	single	
segments	are	randomly	 joined	through	somatic	recombination	of	 the	 immature	T	cell	TCR	
genes	,	which	originally	comprises	70-80	V	segments	and	61	J	segments	(see	Figure	2).	The	
main	 enzymes	 responsible	 for	 this	 genetic	 rearrangement	 are	 RAG-1	 and	 RAG-215.	 The	
genetic	 recombination	gives	 rise	 to	a	potential	diversity	 that	has	been	estimated	 to	be	of	
1015	 possible	 TCRs,	 which	 can	 each	 recognize	 several	 different	 peptides16.	 However,	 the	
human	body	contains	a	total	of	only	1012	T	cells	at	a	given	time.	Moreover,	the	total	number	
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of	different	TCRs	actually	present	
in	 a	 human	 is	 probably	 less	 than	
108	 17.	 Indeed,	 many	 potential	
TCRs	are	never	expressed	because	
they	 are	 deleted	 in	 the	 thymus	
before	 they	 can	 reach	 the	
periphery	 during	 a	 process	 called	
clonal	 selection,	 which	 occurs	 in	
two	steps.	
Firstly,	 thymic	 positive	 selection	
is	 mediated	 via	 presentation	 of	
self-antigens	 by	 epithelial	 cells	 in	
the	 thymic	 cortex.	 Only	 T	 cells	
that	 are	 able	 to	 bind	 the	 self	
MHC-peptide	 complex	 receive	
survival	 signals	 and	 are	 selected.	
Next,	negative	selection	occurs	in	the	medulla	of	the	thymus,	mainly	via	the	presentation	of	
self-antigens	by	bone	marrow	derived	DCs	and	macrophages.	During	this	step,	T	cells	 that	
possess	a	TCR	of	 too	high	affinity	 to	a	 self-antigen	are	deleted18.	This	ensures	 that	T	cells	
that	 exit	 the	 thymus	 and	 enter	 the	 periphery	 are	 not	 self-reactive	 and	 will	 not	 cause	
autoimmunity.	 If	 T	 cells	 respond	 to	MHC	 class	 II,	 they	 become	 CD4	 positive.	 If	 they	 get	
activated	by	MHC	class	I,	they	become	CD8	positive.	
Single	 positive	 T	 lymphocytes	 reaching	 the	 periphery	 are	 mature	 but	 have	 not	 yet	 been	
activated	via	 the	encounter	of	 their	 specific	 antigen.	Hence,	 they	are	 called	naïve	 T	 cells.	
They	 are	 characterised	 by	 the	 expression	 of	 CD62L	 (or	 L-selectin),	 which	 allows	 them	 to	
adhere	 to	 the	 vascular	 endothelium	 of	
peripheral	lymphoid	organs.		
B	cells	originate	from	the	same	progenitor	
as	 T	 cells	 and	 also	 undergo	 gene	
rearrangement	 to	 produce	 clonal	
diversity.	Unlike	the	T	cell	receptor	that	is	
only	 expressed	 as	 a	 transmembrane	
protein,	 the	 B	 cell	 receptor	 can	 be	
expressed	 either	 as	 a	 transmembrane	
receptor	 (BCR)	or	as	a	 secreted	antibody.	
This	 molecule	 is	 called	 immunoglobulin	
(Figure	 3).	 Immunoglobulins	 are	
composed	of	2	chains,	the	heavy	and	light	
chains.	The	heavy	chain	is	the	first	one	to	
be	rearranged	at	the	pre-B	cell	stage,	and	
its	 successful	 surface	 expression	 induces	
Figure	2:	T	cell	receptor	α-	and	β	-	chain	recombination	and	surface	
expression9	
An#gen-binding	sites	
Figure	3:	Immunoglobulins	are	made	from	a	heavy	and	a	light	
chain	connected	via	disulphide	bonds.	They	can	be	separated	
into	an	Fc	portion	and	two	F(ab)	portions	via	cleavage	with	
the	enzyme	papain.	They	possess	two	antibody-binding	sites.	
Single	chain	antibody	fragments	(scFv)	can	be	made	via	joining	
the	variable	region	from	the	light	chain	(VL)	and	from	the	
heavy	chain	(VH).	Adapted	from	Olafsen	et.	al.	2006	
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cell-survival	signalling	and	the	start	of	the	light	chain	gene	rearrangement.	The	expression	of	
a	 functional	 light	 chain	 produces	 an	 immature	 B	 cell.	 There	 are	 several	 subtypes	 of	
immunoglobulins	 that	 serve	different	 functions.	 Immunoglobulins	M	 (IgM)	 are	 always	 the	
first	 type	 to	 be	 expressed.	 They	 are	 usually	 of	 low	 affinity	 and	 expressed	 in	 their	 soluble	
form	as	a	pentamer.	Affinity	maturation	of	the	immunoglobulin,	as	well	as	isotype	switching	
is	possible	thanks	to	CD4+	T	follicular	helper	cells	(Tfh).	Firstly,	upon	binding	of	the	BCR	to	its	
cognate	 antigen,	 the	 pathogen	 or	 virus	 is	 internalised	 and	 degraded.	 Afterwards,	 the	
peptide	is	presented	in	the	context	of	MHC	class	II	on	the	surface	of	the	B	cell	to	CD4	helper	
T	cells	that	would	have	been	activated	by	the	same	peptide.	The	activated	CD4	T	cell	can	in	
turn	 activate	 the	 B	 cell	 through	 CD40L:CD40	 interaction	 and	 induce	 the	 production	 of	
specific	antibodies	 against	 the	pathogen.	Different	 classes	of	antibodies	are	 specialized	 in	
different	 functions.	 IgMs,	are	produced	before	affinity	maturation	and	hence	are	of	 lower	
affinity.	Nonetheless,	 they	can	 form	pentamers	and	activate	 the	complement	system	very	
efficiently.	IgG	is	the	most	common	class	in	the	blood	and	extracellular	fluid.	IgGs	can	also	
activate	the	complement	system,	but	mainly	act	as	an	inducer	of	antibody-dependant	cell-
mediated	 cytotoxicity	 (ADCC),	 via	 the	binding	of	 Fc	 receptors	on	 innate	 immune	cells.	 IgE	
are	the	mediators	of	allergic	reactions.	Finally,	IgAs	form	dimers	and	can	be	secreted	in	the	
gut	and	the	lungs9.	
1.4. Induction	of	an	adaptive	immune	response	
Naive	 T	 cells	 constantly	 recirculate	 between	 the	 blood	 stream	 and	 peripheral	 lymphoid	
organs,	scanning	for	peptides.	They	access	the	lymph	nodes	by	the	high	endothelial	venule,	
which	 expresses	 CD34,	 the	 ligand	
for	 CD62L.	 Once	 there,	 they	 can	
make	 contact	 with	many	 dendritic	
cells	 and	 other	 antigen	 presenting	
cells.	 If	 none	 of	 the	 presented	
peptide	binds	to	their	TCR,	naive	T	
cells	 exit	 the	 lymph	 node	 via	 the	
efferent	 lymphatic.	 If	 one	 T	 cell	 is	
specific	for	a	peptide	presented	by	
a	 mature	 antigen	 presenting	 cells,	
and	 if	 the	 appropriate	
costimulatory	signals	are	provided,	
T	 cell	 activation	 and	 clonal	
expansion	 will	 start.	 Three	
consecutive	 signals	 are	 necessary	
for	 correct	 and	 functional	 T	 cell	
priming.	
Figure	4:	Scheme	of	known	APCs	ligands	
providing	either	an	activatory	or	an	inhibitory	
second	signal	and	their	respective	receptors	
on	T	cells.	Adapted	from	Pardoll,	2012204	
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the expression of which determines the TReg cell line-
age34,35, and TReg cells therefore express CTLA4 consti-
tutively. Although the mechanism by which CTLA4 
enhances the immunosuppressive function of TReg 
cells is not known, TReg cell-specific CTLA4 knockout 
or blockade significantly inhibits their ability to regu-
late both autoimmunity and antitumour immunity30,31. 
Thus, in considering the mechanism of action for 
CTLA4 blockade, both enhancement of effector CD4+ 
T cell activity and inhibition of TReg cell-dependent 
immunosuppression are probably important factors.
Clinical application of CTLA4-blocking antibodies — 
the long road from mice to FDA approval. Initially, 
the general strategy of blocking CTLA4 was ques-
tioned because there is no tumour specificity to the 
expression of the CTLA4 ligands (other than for some 
myeloid and lymphoid tumours) and because the dra-
matic lethal autoimmune and hyperimmune pheno-
type of Ctla4-knockout mice predicted a high degree of 
immune toxicity associated with blockade of this recep-
tor. However, Allison and colleagues36 used preclinical 
models to demonstrate that a therapeutic window was 
indeed achieved when CTLA4 was partially blocked with 
antibodies. The initial studies demonstrated significant 
antitumour responses without overt immune toxicities 
when mice bearing partially immunogenic tumours were 
treated with CTLA4 antibodies as single agents. Poorly 
immunogenic tumours did not respond to anti-CTLA4 as 
a single agent but did respond when anti-CTLA4 was 
combined with a granulocyte–macrophage colony-
stimulating factor (GM-CSF)-transduced cellular 
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The	first	signal	is	the	binding	of	the	MHC	and	TCR	together.	MHC	class	II	binds	to	the	TCR	of	
CD4+	T	cells,	whereas	the	MHC	class	I	binds	to	the	TCR	of	CD8+	T	cells.	CD4	and	CD8	both	
contribute	 to	 stabilise	 the	 MHC-TCR	 interaction.	 The	 second	 signal	 comes	 from	
costimulatory	 molecules	 expressed	 on	 the	 surface	 of	 the	 APC	 that	 will	 bind	 to	 surface	
receptors	 on	 the	 T	 cell.	 The	 best	 characterized	 costimulatory	molecules	 are	 from	 the	 B7	
family.	These	ligands	can	induce	either	a	stimulatory	or	a	suppressive	signal	2,	as	shown	on	
Figure	4,	 in	red.	The	third	 signal	 is	 the	secretion	of	cytokines	from	the	antigen	presenting	
cell	(APC),	which	can	direct	T	cells	to	differentiate	into	the	appropriate	effector	phenotype.	
Several	 subtypes	 of	 CD4	 T	 cells	 (also	 called	 T	 helper	 cell)	 exist.	 The	main	 ones	 and	 their	
function	are	summarized	in	Table	1.	The	role	of	CD8	T	cells	(also	called	cytotoxic	T	cell,	CTL)	
is	also	summarized.	
Once	activated,	Th1,	Th17,	and	CTL	cells	will	clonally	proliferate	and	migrate	to	the	site	of	
infection	to	respectively	activate	infected	macrophages,	recruit	neutrophils	and	kill	infected	
cells.	 However,	 some	 T	 helper	 cells,	 and	 especially	 Th2	will	 remain	 in	 the	 lymph	 node	 to	
interact	 with	 B	 cells	 and	 induce	 the	 proper	 antibody	 class	 switching.	 T	 regulatory	 cells	
(Tregs)	can	locally	supress	an	immune	response	via	the	expression	of	IL-10	and	TGF-β.	They	
are	important	to	mediate	peripheral	tolerance	and	protect	against	autoimmune	disease.	
An	 additional	 role	 of	 Th1	 cells	 is	 to	 provide	 better	 CD8+	 T	 cell	 priming	when	 interacting	
through	CD40-CD40L	with	the	same	antigen-presenting	cell	in	the	lymph	node.	It	was	shown	
that	 the	 CD4	 T	 cell	 help	 was	 necessary	 for	 CD8+	 T	 cell	 reexpansion	 upon	 a	 second	
stimulation19.	 The	 ability	 of	 the	 immune	 system	 to	 reexpand	 upon	 a	 second	 antigen	
encounter	is	called	immunological	memory.	
	
Name	 Induced	via	 Role	 Production	of	
Th1	 IL-12,	IFN-γ	 • Activation	of	macrophages	
• Stimulation	of	CD8	proliferation	
IFN-γ,	TNFα	
Th2	 IL-4	
	 	
• Promotion	of	antibody	production	by	B	cells	
• Protection	against	extracellular	parasites	
IL-4,	IL-5,	IL-13	
Tfh	 IL-6,	IL-21	 • Antibody	class	switching	 IL-21	
Th17	 TGF-β,	IL-6	 • Recruitement	of	neutrophils	
• Development	of	acute	inflammation	
IL-17,	IL-22	
Treg	 TGF-β	 • Immunosuppression	 IL-10,	TGF-β	
CTL	 -	 • Killing	of	cells	presenting	the	antigen	 IFN-γ,	TNFα	
Table	1:	Induction	and	function	of	CD4	(T	helper	cells)	main	subtypes	and	CD8	(cytotoxic	T	cell)	
1.5. The	immunological	memory	
The	first	observations	of	the	ability	of	the	immune	system	to	“remember”	a	past	 infection	
occurred	 a	 long	 time	 ago,	 precisely	 in	Athens	 in	 430	BC	during	 a	 smallpox	 outbreak.	 It	 is	
then	 that	 the	 Greek	 historian	 Thucydides	 first	 noticed	 that	 it	 “never	 attacked	 the	 same	
person	twice;	so,	at	least,	as	to	be	mortal”20.	However,	in	Europe,	it	is	much	later	that	it	was	
attempted	 to	 use	 this	 characteristic	 for	 protection	 against	 infections.	 In	 1796,	 Edward	
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Jenner	made	 the	observation	 that	people	working	with	cows	were	 less	prone	 to	die	 from	
smallpox.	 He	 then	 assumed	 that	 the	 infection	 with	 the	 non-lethal	 cowpox	 virus	 could	
protect	 the	 individual	 against	 smallpox	 infection.	 To	 test	 his	 hypothesis,	 he	 inoculated	
material	from	a	cowpox	pustule	 into	a	healthy	individual.	He	could	then	demonstrate	that	
this	 method	 was	 indeed	 protective	 against	 smallpox	 infection.	 He	 named	 his	 newfound	
remedy	vaccine21.	
Vaccines	 take	 advantage	 of	 the	 immunological	 memory	 –	 namely,	 the	 aptitude	 of	 the	
immune	 system	 to	 remember	 past	 infections	 and	 to	 provide	 a	 more	 efficient	 immune	
response	 upon	 a	 second	 encounter	 with	 an	 identical	 or	 similar	 pathogen.	 The	
immunological	memory	is	also	a	defining	feature	of	the	adaptive	immune	system,	which	is	
able	 to	give	 rise	 to	 long-lived	memory	cells,	 although	some	 innate	cells	and	especially	NK	
cells	have	been	described	as	having	some	memory	features	as	well22.		One	key	aspect	of	the	
immunological	memory	 is	 that	 it	 occurs	 in	 the	 absence	 of	 the	 “remembered”	 peptide	 or	
pathogen23.		
	
Figure	 5:	 T	 cell	 response	 occurs	 in	 three	 phases:	 expansion,	 contraction,	 memory.	 Short-lived	 effector	 cells	 (SLECs)	
differentiation	 into	 terminal	effectors	and	disappear	after	 the	clearance	of	 the	 infection.	Memory	precursors	effector	
cells	(MPECs)	give	rise	to	the	effector	memory	(TEM)	and	central	memory	(TCM)	T	cells
24	
	
Figure	6:	Memory	CD8+	T	cells	are	generated	after	a	first	infection	and	can	respond	faster	and	with	a	higher	magnitude	
to	a	second	encounter	with	the	pathogen25	
The	 response	 of	 the	 adaptive	 immune	 system	 occurs	 in	 three	 phases:	 expansion,	
contraction	 and	memory	 (see	 Figure	5).	 In	 the	 contraction	phase,	 the	 short-lived	effector	
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cells	 (SLECs)	 start	dying.	 These	 cells	 are	 characterized	by	 the	 surface	expression	KLRG1high	
and	CD127low,	and	the	transcription	factor	T-bet.	The	memory	T	cells	are	the	cells	that	are	
left	after	the	contraction	phase.	They	stem	from	memory	precursor	effector	cells	 (MPECs)	
that	 can	 already	 be	 detected	 in	 the	 effector	 phase	 of	 the	 CD8+	 T	 cell	 response	 via	 their	
surface	expression	of	KLRG1low	and	CD127high,	and	of	the	transcription	factor	eomesodermin	
(EOMES)26.	 Memory	 T	 cells	 undergo	 a	 defined	 reprogramming	 after	 activation	 and	 can	
survive	 for	 long	 periods	 of	 time,	 and	 respond	 rapidly,	 and	 with	 greater	 magnitude,	 to	 a	
second	encounter	with	the	same	microbe	(see	Figure	6).	
Memory	 T	 cells	 have	 characteristics	 that	 differentiate	 them	 from	naïve	 lymphocytes,	 and	
that	allow	them	to	respond	faster	to	the	second	encounter	with	a	germ,	and	hence	mediate	
protection	against	the	pathogenicity.	
Different	surface	markers	and	cytokine	receptors:	
Memory	CD8+	T	cells	express	specific	surface	markers	and	transcription	factors		 	
	
Figure	 7:	 Characteristics	 of	 memory	 CD8+	 T	 cells	 in	 terms	 of	 function,	 surface	 markers,	 and	 the	 expression	 of	 the	
transcription	factor	EOMES	or	T-bet.	Adapted	from	Kaech	et.	al.	201227	
Higher	precursor	numbers	
The	amount	of	antigen-specific	CD8+	T	cells	available	to	respond	to	an	 infection	 is	greater	
after	a	first	encounter.	Indeed,	after	the	initial	clonal	expansion	and	effector	phase,	comes	
the	 contraction	 phase	 in	 which	 most	 of	 the	 effector	 cells	 undergo	 apoptosis,	 after	 the	
infection	 is	 cleared.	 However,	 some	 T	 cells	 are	 able	 to	 survive	 this	 contraction	 step	 and	
remain	 in	the	circulation	of	 long	periods	of	 time.	These	memory	cells	are	more	numerous	
than	 the	 original	 naïve	 precursor,	which	 gives	 a	mathematical	 advantage	 for	 a	 secondary	
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response28.	 For	 example,	 the	 frequency	 of	 antigen	 specific	 CD4+	 T	 cells	 following	 acute	
LCMV	 infection	 was	 increased	 10-fold	 after	 the	 resolution	 of	 the	 infection	 and	 was	
maintained	for	long	periods	of	time	(>300	days)29.	
Lower	activation	threshold	(?)	
Logically,	 it	 was	 firstly	 considered	 that	 memory	 cells	 had	 a	 lower	 threshold	 for	 TCR	
activation	 and	 signalling.	 Indeed,	 it	 was	 shown	 in	 1997	 that	 CD4+	 T	 cells	 that	 had	 been	
activated	 and	 cultured	 for	 12	 days	 could	 respond	 to	 lower	 amounts	 of	 peptide:MHC	
complex	 compared	 to	 naive	 cells30.	 Moreover,	 the	 previously	 activated	 cells	 could	 also	
respond	 to	 peptides	 of	 lower	 affinity	 compared	 to	 naïve	 cells31.	 However,	 some	
contradictory	 data	 have	 been	 produced	 recently,	 which	 show	 that	 memory	 CD8+	 T	 cells	
could	not	 respond	 to	 low	 level	of	 antigen,	 at	which	naive	CD8+	T	 cells	were	able	 to	 start	
proliferation32. 
Metabolic	reprogramming:		
Upon	 activation,	 T	 cells	 switch	 their	 metabolic	 program	 from	 oxidative	 phosphorylation	
(OXPHOS)	 towards	 aerobic	 glycolysis.	 This	 change	 in	 respiration	 is	 not	 necessary	 for	 the	
proliferation	 and	 survival	 of	 T	 cells,	 but	 it	 is	 crucial	 for	 their	 functionality,	 in	 particular	
cytokine	secretion.	Indeed,	it	was	shown	in	CD4+	T	cells	that	the	switch	to	aerobic	glycolysis	
mobilised	the	enzyme	GAPDH	and	allowed	its	release	from	the	IFN-γ	mRNA,	thus	inducing	
the	 cytokine’s	 expression33.	Memory	 CD8+	 T	 cells	were	 also	 shown	 to	 have	 the	 ability	 to	
switch	 from	 oxidative	 phosphorylation	 to	 aerobic	 glycolysis	 when	 OXPHOS	 was	
pharmacologically	 inhibited	 with	 oligomycin.	 Moreover,	 memory	 CD8+	 T	 cells	 could	
upregulate	 their	 glycolytic	 respiration	 at	 higher	 level	 than	 naive	 T	 cells	 upon	 CD3/CD28	
activation.	Similarly	to	CD4+	memory	T	cells,	CD8+	T	cells’	GAPDH’s	activity	was	higher	and	
localised	 in	 the	 cytoplasm,	 which	 would	 increase	 its	 availability	 for	 rapid	 glycolysis	 upon	
activation34.	
In	the	case	of	cancer	or	chronic	infection,	the	antigen	is	never	cleared	from	the	circulation,	
which	prevents	the	normal	contraction	phase	and	memory	differentiation	of	the	T	cells.	In	
that	case,	they	gradually	differentiate	into	a	specific	state	called	exhaustion.	
1.6. T	cell	exhaustion	
Exhausted	 T	 cells	 arise	 upon	 chronic	 stimulation	 with	 a	 specific	 antigen,	 and	 gradually	
become	 functionally	 impaired.	 Exhausted	 T	 cells	 exhibit	 a	 high	 surface	 expression	 of	
inhibitory	 markers	 and	 are	 unable	 to	 adequately	 respond	 to	 stimulation.	 It	 was	 firstly	
described	in	1998	that	CD8+	T	cells,	specific	for	the	antigen	gp33,	could	persist	after	acute	
or	 chronic	 infection	 with	 LCMV.	 But	 the	 cells	 recovered	 from	 the	 chronically	 infected	
animals	were	 not	 able	 to	 produce	 IFN-γ	 upon	 PMA	 ionomycin	 restimulation35.	Moreover,	
this	impairment	was	more	pronounced	in	the	absence	of	CD4	helper	cells,	and	the	duration	
of	 antigen	 exposure	 was	 positively	 correlated	 with	 the	 severity	 of	 the	 exhaustion35.	 The	
usefulness	of	such	an	 inhibitory	mechanism	was	 illustrated	by	the	 intracranial	 infection	of	
mice	with	 the	 LCMV	virus.	Mice	 infected	with	 low	dose	 LCMV	die	of	 immunopathology	9	
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days	after	the	infection.	Mice	receiving	the	high	dose	LCMV,	on	the	other	hand,	develop	a	
chronic	 infection,	but	do	not	succumb	to	the	disease	as	their	CD8+	T	cells	become	rapidly	
inactive	 due	 to	 the	 high	 amount	 of	 antigen	 exposure36.	 It	 is	 in	 fact	 the	 antigen	 exposure	
specifically	 that	 drives	 the	 exhausted	 phenotype.	 Indeed,	 it	was	 shown	 in	 a	 recent	 study	
that	CD8+	T	cells	exposed	to	a	chronic	inflammation	but	low	dose	of	antigen	could	remain	
functional37.	
A	key	aspect	of	 the	exhausted	phenotype	 is	 the	surface	expression	of	 inhibitory	markers.	
PD-1	was	 the	 first	 receptor	 to	be	 linked	to	 the	exhausted	phenotype.	 Indeed,	blockade	of	
PD-L1	during	a	chronic	infection	could	restore	virus-specific	CD8+	T	cells’	persistence,	as	well	
as	ability	 to	proliferate	and	 secrete	TNF-α	and	 IFN-γ.	Moreover,	 infection	of	PD-L1-/-	mice	
with	the	chronic	LCMV	clone	13	strain	 induced	lethal	 immunopathology	between	6-7	days	
after	the	infection38.	
For	a	while	 it	was	thought	that	memory	CD8+	T	cells	could	not	form	in	chronic	 infections.	
However,	 it	 was	 demonstrated	 recently	 that	 a	 subpopulation	 of	 exhausted	 CD8+	 T	 cells,	
characterized	 by	 high	 PD-1	 expression	 and	 low	 production	 of	 IFN-γ	 and	 TNF-α,	 could	
reexpand	after	 transfer	 into	a	naive	host	and	subsequent	 infection.	After	re-infection,	PD-
1high	 CD8+	T	 cells	 from	a	 chronic	 LCMV	 infection	 could	 increase	 their	 numbers	of	 10-fold,	
compared	 to	 100-fold	 for	 PD-1low	 cells	 from	 an	 acute	 LCMV	 infection.	Moreover	 PD-1high	
cells	 expressed	 less	 cytokines37.	 This	 subpopulation	 of	 PD-1high	 cells	 that	 could	 reexpand	
relied	on	the	expression	of	the	transcription	factor	TCF-1.	Indeed,	TCF-1-/-	CD8+	T	cells	from	
chronically	 infected	 animals	 could	 not	 reexpand	 upon	 transfer	 into	 a	 naive	 host	 and	
infection	with	acute	LCMV.	Moreover,	when	CD8+	T	cells	were	extracted	 from	chronically	
infected	mice	and	sorted	according	 to	 their	expression	of	TCF-1,	only	TCF-1+	CD8+	T	cells	
could	reexpand	upon	a	second	infection39.	These	TCF-1+	PD-1high	CD8+	T	cells	had	a	specific	
transcriptional	profile	resembling	CD4+	Tfh	cells	and	CD8+	memory	precursors.	They	could	
be	identified	via	the	surface	expression	of	CXCR5	and	costimulatory	molecules,	such	as	ICOS,	
OX-40	and	CD2840.	 	
Wherry	 et.	 al.	 characterised	 the	 gene	 signature	 of	 exhausted	 CD8+	 T	 cells	 and	 identified	
several	 inhibitory	markers	that	were	upregulated	in	addition	to	PD-1,	such	as	2B4,	CTLA-4,	
NKG2A	and	LAG-341.	Exhausted	T	cells	were	also	observed	 in	human	cancers.	CD8+	T	cells	
extracted	 from	 tumour	 infiltrated	 lymph	 nodes	 of	 melanoma	 patients	 exhibited	 an	
increased	 expression	 of	 the	 inhibitory	 markers	 LAG3,	 2B4	 and	 CTLA-4,	 and	 a	 decreased	
ability	to	secrete	IFN-γ	upon	restimulation42.	
Finally,	 exhausted	 CD8+	 T	 cells	 also	 have	 a	 different	 metabolic	 program	 than	 normal	
memory	 T	 cells	 or	 effector	 cells.	 In	 humans,	 hepatitis	 B	 virus	 (HBV)	 specific	 CD8+	 T	 cells	
expressed	higher	levels	of	the	glucose	receptor	Glut1	and	hence	could	uptake	glucose	more	
efficiently	 than	 the	 cytomegalovirus	 (CMV)	 specific	 CD8+	 T	 cells.	 Glut1	 expression	 was	
positively	correlated	with	PD-1	expression	and	negatively	correlated	with	IFN-γ	secretion43.	
Moreover,	CD8+	T	cells	 that	are	activated	and	 forced	 to	use	OXPHOS	 for	 their	 respiration	
(cultured	in	galactose	instead	of	glucose),	upregulate	PD-1	and	cannot	produce	cytokines,	as	
GAPDH	binds	to	the	IFN-γ	mRNA	and	prevents	its	expression33.	 	
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2. MicroRNAs	
	
MicroRNAs	 are	 small	 RNA	 molecules	 that	 regulate	 gene	 expression	 by	 repressing	 the	
translation	of	mRNAs	or	 inducing	 their	degradation44.	 They	were	 first	 discovered	 in	1993,	
when	it	was	observed	that	C.	Elegans	expresses	a	small	antisense	RNA,	named	lin-4,	that	is	
complementary	to	the	3’UTR	sequence	of	the	lin-14	mRNA,	and	thus	induces	lin-14	protein	
levels	downregulation45.	Since	lin-4	did	not	encode	for	a	protein,	it	was	understood	that	its	
sole	function	was	as	a	non-coding	microRNA.	
Mature	 microRNAs	 are	 single	 strand	 RNAs	 and	 are	 usually	 encoded	 in	 intronic	 regions,	
although	 they	 can	 exceptionally	 be	 encoded	 in	 exonic	 regions	 as	 well.	 They	 are	 often	
transcribed	in	the	form	of	microRNA	clusters.	Transcription	is	classically	carried	out	by	RNA	
pol	II,	but	it	was	shown	by	Chen	et.	al.	and	others,	that	it	is	possible	to	express	miRNAs	using	
RNA	pol	 III	promoters46.	They	are	first	expressed	 in	the	form	of	a	 long	(typically	over	1kb)	
pri-miRNA,	that	contains	the	stem-loop	miRNA	sequence	(see	Figure	8).		
The	enzyme	Drosha	cleaves	 the	pri-miRNA	on	both	ends	of	 the	stemloop	sequence	 in	 the	
nucleus47.	 Then,	 the	 pre-miRNA	 strand,	 of	 approximately	 70	 nucleotides,	 is	 exported	 into	
the	cytoplasm,	where	it	is	processed	by	the	enzyme	Dicer	into	a	20-25	nucleotides	mature	
microRNA48.	The	hairpin	secondary	structure	is	characteristic	of	microRNAs	and	is	necessary	
for	 their	 correct	 processing	 by	 Dicer.	 Indeed,	 it	 was	 shown	 that	 disruption	 of	 the	 base-
pairing	 at	 the	 beginning	 of	 the	 hairpin	 stem	 was	 deleterious	 to	 mature	 microRNA	
expression49.	 Finally,	 it	 is	 incorporated	 into	 the	 miRNA-induced	 silencing	 complex	 (RISC)	
which	can	bind	to	the	3’UTR	of	the	target	mRNAs	and	repress	translation	(Figure	9)50.	This	is	
done	mainly	 via	 a	 6	 nucleotides-long	 seed	 sequence.	 The	 binding	 of	 the	microRNA	 seed	
sequence	 to	 its	 mRNA	 complementary	 sequence	 involves	 imperfect	 base-pairing,	 which	
allows	 one	microRNA	 to	 regulate	 several	mRNAs51.	 The	 highest	 complementarity	 induces	
Figure	8:	Nuclear	processing	of	the	pre-miRNA	by	Drosha.	Cytoplasmic	processing	of	the	pri-miRNA	by	Dicer205	
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the	strongest	translation	inhibition.	Indeed,	it	was	shown	that	a	single	mismatch	in	the	seed	
sequence	could	still	inhibit	the	expression	of	the	mRNA	target,	but	with	a	2-fold	reduction	in	
efficiency49.	Often,	microRNAs	will	affect	protein	production	by	blocking	translation,	without	
actually	affecting	the	levels	of	the	mRNA49,52,53	
Based	 on	 this	 complementarity,	 computational	 approaches	 can	 be	 used	 to	 predict	
microRNA	 targets.	 However,	 such	 targets	 should	 always	 be	 confirmed	 through	 biological	
assays.	 Reporter	 sequences,	 encoding	 for	 the	 GFP	 protein	 or	 the	 luciferase	 enzyme,	 and	
containing	 the	 mRNA	 seed	 sequence	 in	 their	 3’	 UTR,	 can	 be	 used	 to	 confirm	 a	 certain	
microRNA	 is	 indeed	 complementary	 to	 an	 mRNA	 of	 interest54.	 Other	 methods	 exist	 to	
screen	for	new	targets	of	a	microRNA	of	 interest:	for	example	the	immunoprecipitation	of	
proteins	of	the	RISC	complex,	and	identification	of	co-precipitated	mRNAs	by	microarray55.		
The	 vital	 importance	 of	 microRNAs	 was	
highlighted	 by	 experiments	 deleting	 the	
enzyme	Dicer,	which	 is	 responsible	 for	 the	
production	 of	 most	 mature	 microRNAs,	
with	 some	 exceptions56.	 A	 complete	 Dicer	
knock-out	 (KO)	 mouse	 prevented	 the	
formation	 of	 viable	 embryos	 by	 blocking	
the	 differentiation	 of	 embryonic	 stem	
cells57,58.	MicroRNAs	are	also	 important	 for	
the	immune	system.	Conditional	deletion	of	
Dicer	 in	 the	 late	 stage	 of	 the	 lymphocyte	
maturation	 (CD4-CRE	 x	 Dicer	 fl/fl),	
decreased	the	number	of	mature	CD4+	and	
CD8+	 cells	 in	 the	 periphery	 and	 interfered	
with	 their	 ability	 to	 proliferate	 and	 resist	
apoptosis59.	 Moreover,	 CD4-Cre	 Dicer	 deletion	 drove	 T	 helper	 cells	 towards	 the	 Th1	
differentiation	program59,	while	strongly	reducing	the	numbers	of	Tregs,	 inducing	 immune	
pathology	 as	 a	 consequence60.	 Experiments	 knocking-out	 Dicer	 in	 the	 CD8+	 T	 cell	
compartment	specifically,	demonstrated	that	microRNAs	are	crucial	for	lymphocyte	effector	
functions,	migration	and	survival61.	To	identify	which	microRNAs	could	mediate	such	striking	
CD8	effector	defects,	Salaun	et.	al.	performed	microarrays	and	quantitative	PCRs	(qPCR)	on	
human	CD8+	T	cells	and	 identified	a	 few	microRNAs	 that	were	strongly	upregulated	upon	
CD8+	 T	 cell	 activation.	 These	 were	 namely	 miR-155,	 miR-21,	 miR146a,	 miR146b	 and	 the	
miR-17-92	cluster62.	The	functions	of	miR-155	and	miR-17-92	will	be	further	detailed	in	this	
chapter,	as	they	are	the	most	important	microRNAs	in	the	context	of	this	thesis.	
2.1. MiR-155	
MiR-155	 was	 firstly	 discovered	 as	 the	 mediator	 of	 the	 oncogenic	 property	 of	 the	 B	 cell	
Integration	Cluster	 (BIC)	gene.	 Indeed,	chicken	B	cell	 lymphoma	 induced	by	avian	 leukosis	
virus	could	develop	only	with	the	concomitant	insertional	activation	of	c-myc	and	BIC63.	The	
RISC complex 
Figure	9:	miRNA	processing	and	translational	repression206	
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BIC	gene	lacks	an	open	reading	frame,	and	the	complicated	predicted	secondary	structure	
suggested	 an	 oncogenic	 function	 directly	 through	 BIC’s	 RNA	 and	 not	 via	 protein	
translation64.	Moreover,	 BIC	homologs	were	 identified	 in	 the	mouse	and	human	genome,	
which	also	did	not	possess	 an	open	 reading	 frame	and	 in	which	 the	microRNA	 secondary	
structure	was	conserved65.	All	this	evidence	pointed	towards	the	functionality	of	BIC	being	
mediated	via	the	expression,	in	its	third	exon,	of	the	microRNA	miR-155.	
Once	miR-155	was	identified,	its	overexpression	was	associated	with	many	types	of	cancer	
in	 humans,	 such	 as	 B	 cell	 lymphoma66,	 breast,	 lung	 and	 colon	 cancer67.	 In	 breast	 cancer,	
miR-155	 high	 expression	was	 associated	with	 poor	 prognosis	 and	metastasis68,	 as	well	 as	
increased	radioresistance69.	MiR-155	was	shown	to	be	responsible	 for	the	downregulation	
of	the	suppressor	of	cytokine	signalling	1	(SOCS1)70	and	FOXO3a71,	leading	to	increased	cell	
growth	 and	 survival.	 In	 malignant-	 and	 non-malignant	 T	 cell	 lines	 and	 in	 PBMCs,	 it	 was	
shown	 that	 miR-155	 is	 upregulated	 upon	 STAT5	 signalling	 but	 not	 STAT372.	 Finally,	 the	
transcription	factor	IRF4	induced	BIC	expression	in	EBV-transformed	B	cells73.	
But	 miR-155	 is	 not	 only	 expressed	 in	 cancerous	 cells.	 Indeed,	 its	 upregulation	 has	 been	
shown	to	be	very	important	for	the	functionality	of	the	immune	system	as	well.	
MiR-155	 has	 a	 role	 in	 many	 cells	 of	 the	 innate	 immune	 response.	 Indeed,	 in	 human	
monocyte-derived	DCs,	miR-155	 is	 upregulated	 upon	 stimulation	with	 lipopolysaccharides	
(LPS)	 and	 functions	 as	 a	 negative	 feedback	 signal,	 reducing	 the	 production	 of	 the	
inflammatory	 cytokine	 IL-1	after	 the	 initial	 inflammatory	 response,	by	 targeting	TAB2	and	
BACH174.	MiR-155	was	also	upregulated	 in	macrophages	after	TLR2,	3,	4	or	9	signalling	as	
well	as	upon	IFN-β	stimulation75.	In	exhausted	NK	cells,	low	expression	of	miR-155	resulted	
in	 impaired	 IFN-γ	 secretory	 ability,	 as	 well	 as	 high	 levels	 of	 Tim-3	 and	 T-bet.	 Artificial	
reconstitution	of	high	miR-155	levels	could	re-establish	some	IFN-γ	production	and	decrease	
the	Tim-3	levels76.	
MiR-155	also	has	a	crucial	role	 in	the	development	of	the	adaptive	 immunity.	 In	activated	
CD4+	T	cells,	miR-155	is	upregulated	and	induces	the	downregulation	of	IFN-γRα	which	bias	
the	CD4+	differentiation	into	TH1	cells77.	Moreover,	miR-155	is	necessary	for	the	induction	
of	experimental	autoimmune	encephalomyelitis	(EAE),	as	miR-155-/-	CD4+	T	cells	could	not	
differentiate	 into	 Th1778.	 Surprisingly,	 Tregs	 also	 need	 miR-155	 upregulation	 and	
subsequent	 suppressor	 of	 cytokine	 signaling	 1	 (SOCS-1)	 downregulation	 for	 their	 proper	
activation	and	expansion79,	which	might	 indicate	that	there	are	additional	 factors	that	are	
critical	in	the	decision	of	the	CD4	differentiation	route.	
Finally,	miR-155	has	also	proven	to	be	important	for	CD8+	T	cells	effector	functions.	Indeed,	
experiments	 using	 miR-155	 KO	 mice	 and	 adoptive	 transfer	 of	 miR-155	 KO	 CD8+	 T	 cells	
showed	a	strong	impairment	in	clonal	proliferation	upon	antigen	recognition	in	the	absence	
of	 this	microRNA80–82.	On	the	other	hand,	miR-155	did	not	seem	to	be	crucial	 for	 intrinsic	
effector	 functions	per	 se,	 such	as	 cytokine	production,	 killing	and	migration.	 The	miR-155	
enhanced	T-cell	 fitness	 seemed	 to	 result	 from	both	 reduced	stability	of	 the	 suppressor	of	
cytokine	 signaling	1	 (SOCS-1),	as	well	 as	decreased	 responsiveness	 to	 the	antiproliferative	
effect	of	type	I	interferon	signalling81,82.	
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Overexpression	of	miR-155	in	CD8+	T	cells	 increased	the	IFN-g	production82	and	induced	a	
more	 potent	 antitumour	 effect	 of	 CD8+	 T	 cells	 in	 the	 pmel	 model81.	 Moreover,	 mice	
transferred	 with	 pmel	 CD8+	 T	 cells	 overexpressing	 miR-155	 could	 mediate	 B16	 tumour	
rejection	in	the	absence	of	lymphodepletion	or	injection	of	cytokines83.	
2.2. MiR-17-92	
MiR-17-92	is	a	polycistronic	microRNA	cluster	that	contains	6	hairpin	structures,	which	are	
ultimately	 processed	 into	 6	 mature	 microRNAs:	 miR-17,	 miR-18a,	 miR-19a,	 miR-20,	 miR-
19b-1	 and	miR-92-1	 (see	 Figure	 10).	 Based	 on	 their	 seed	 sequence,	 these	microRNAs	 are	
classified	in	4	different	microRNA	families84.	Redundancy	for	these	microRNAs	exists	in	the	
genome,	as	homologues	 to	 these	microRNAs	can	be	 found	on	 the	chromosome	X	both	 in	
mouse	 and	 in	 human.	However,	
miR-17-92	seems	to	mediate	the	
strongest	effect85.	
	
The	differential	expression	of	the	
miR-17-92	 cluster,	or	oncomir-1,	
has	been	associated	with	the	development	of	cancer86.	The	involvement	of	this	cluster	in	B	
cell	 and	 other	 haematological	malignancies	 has	 been	 shown	 in	 human,	 and	miR-17-92	 is	
proposed	as	a	diagnostic	tool	for	large	B	cell	lymphoma87,88.		
In	 mice,	 overexpression	 of	 the	 truncated	 cluster	 miR-17-19b	 synergizes	 with	 the	
overexpression	 of	 c-myc	 to	 induce	 more	 aggressive	 B	 cells	 lymphomas.	 Moreover,	 the	
cancerous	B	cells	were	less	differentiated	when	the	microRNA	cluster	was	overexpressed89.	
Furthermore,	Mu	et	al.,	showed	that	different	members	of	the	17-92	cluster	have	unequal	
oncogenic	 potential,	 as	 the	 reconstitution	 of	 the	 miR-19	 family	 alone	 was	 able	 to	
recapitulate	 the	 effect	 of	 the	whole	 cluster	 in	miR-17-92	KO	 lymphoma	 cells.	 In	 addition,	
they	identified	PTEN	as	a	miR-19	target,	thus	partially	explaining	the	increased	proliferation	
of	 mir-17-92	 overexpressing	 cells90.	 MiR-17-92	 has	 also	 been	 proven	 to	 be	 important	 in	
other	hematopoietic	malignancies	such	as	erythroleukemia91.	
In	addition	to	 its	role	 in	general	development	and	 its	oncogenic	properties,	the	miR-17-92	
cluster	 is	 also	 crucial	 for	 the	 immune	 system	 development,	 response	 to	 infections	 and	
memory	differentiation92.	 In	pre-B	 cells,	 conditional	 knock-out	of	miR-17-92	enhances	 the	
apoptosis	rate	by	the	loss	of	regulation	of	the	pro-apoptotic	gene	Bim85.	In	CD4+	T	cells,	IL-4	
downregulates	the	expression	of	miR-17-92,	and	the	overexpression	of	the	cluster	promotes	
the	Th1	phenotype	in	differentiating	T	cells93.	Furthermore,	Jiang	et	al.	showed	that	miR-17-
92	regulates	the	efficacy	of	the	effector	Th1	cell	response,	by	controlling	 IFN-γ	production	
and	proliferation,	as	well	as	preventing	the	differentiation	into	inducible	regulatory	T	cells.	
In	 consequence,	 mice	 with	 a	 CD4-specific	 deletion	 of	 the	 miR-17-92	 cluster	 are	 more	
susceptible	to	tumour	challenge	with	B16	melanoma	cells94.	Recently,	an	article	from	Wu	et	
al.	showed	that	conditional	granzyme-B-driven	deletion	of	the	miR-17-92	cluster	impairs	the	
CD8+	T	cell	effector	response,	by	reducing	their	proliferative	potential	and	IFN-γ	production.	
Figure	10:	The	human	miR-17-92	cluster84	
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Finally,	 their	 results	 indicate	 that	 the	 overexpression	 of	 the	 cluster	 promotes	 a	 KLRG1high	
CD127low	 terminal	 effector	 phenotype95.	 This	 was	 due	 to	 miR-17-92	 targeting	 and	
downregulation	of	PTEN,	inducing	enhanced	mTOR	signalling	as	a	consequence96.	
Overexpression	 of	miR-17-92	 in	 CD8+	 T	 cells	 bearing	 the	 chimeric	 antigen	 receptor	 (CAR)	
specific	 for	 EGFRvIII	 increased	 their	 ability	 to	 produce	 IFN-γ	 and	 to	 proliferate	 in	 contact	
with	 EGFRvIII+	 U87	 cells.	 CAR+	 CD8+	 T	 cells	 could	 mediate	 tumour	 regression	 in	 vivo	
however	with	no	difference	whether	miR-17-92	was	overexpressed	or	not.	But	miR-17-92	
overexpressing	CAR+	CD8+	T	cells	could	mediate	long	term	protection	against	later	(49	days)	
tumour	challenge97.	
	
These	data	demonstrate	the	importance	of	microRNAs	for	the	functionality	of	all	cells.	More	
specifically,	both	miR-155	and	the	miR-17-92	cluster	have	crucial	functions	for	the	adaptive	
immune	 response,	 which	 explains	 the	 interest	 in	 targeting	 those	 microRNAs	 for	 the	
immunotherapy	of	cancer.	 	
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3. Cancer	development:		
It	is	now	well	understood	that	the	core	characteristic	of	a	cancerous	cell	is	its	mutated	DNA.	
Overexpression	 of	 certain	 pro-tumorigenic	 proteins,	 as	 well	 as	 deletion	 of	 important	
proliferation	checkpoints	 is	sometimes	sufficient	to	start	 tumour	formation.	However,	 it	 is	
usually	not	a	single	mutation	but	 rather	an	accumulation	of	mutations	 that	can	unleash	a	
fully	aggressive	cancer	form.	
Indeed	a	tumoral	lesion	has	to	possess	several	characteristics	in	order	to	be	able	to	develop	
into	a	 full	cancer.	These	characteristics,	which	were	named	hallmarks	of	 cancer,	 firstly	by	
Hanahan	and	Weinberg	in	200098,	encompass	many	aspects	of	the	tumour.	Some	hallmarks	
are	 features	 related	 only	 to	 tumour	 cells	 themselves	 and	 their	 gene	 expression.	 Firstly,	
tumour	 cells	 should	 express	 survival	 and	 proliferation	 signals,	 and	 activate	 pathways	 to	
resist	 apoptosis.	 They	 should	 also	 be	 able	 to	 withstand	 many	 rounds	 of	 replication	 by	
blocking	telomere	shortening.	In	contrast,	there	are	other	hallmarks	that	take	into	account	
the	 relationship	 of	 the	 tumour	 with	 its	 environment,	 such	 as	 its	 ability	 to	 resist	 to	 the	
growth	suppressors	that	might	be	present,	as	well	as	to	 induce	the	creation	of	new	blood	
and	 lymphatic	 vessels.	 Finally,	 another	 hallmark	 of	 cancer	 is	 its	 ability	 to	 go	 through	
epithelial-mesenchymal	transition	(EMT)	and	invade	new	areas	of	the	body.	
Malignant	cells	also	need	to	control	the	emergence	of	an	antitumour	immune	response,	and	
this	 ability	 was	 recently	 added	 to	 the	 list	 of	 characteristics	 as	 an	 “emerging	 hallmark”99.	
Indeed,	although	some	level	of	inflammation	can	be	desirable	for	the	tumour	formation,	a	
strong	 immune	activation	 together	with	 infiltration	of	 immune	cells	 is	usually	 fatal	 to	 the	
tumour.		
	
Figure	11:	The	hallmarks	of	cancer	and	drugs	interfering	with	them99	
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3.1. Immunosurveillance:	
DNA	replication	associated	with	cell	division	brings	the	risk	of	a	potentially	cancer-causing	
mutation.	 Intrinsic	 safety	 mechanisms,	 such	 as	 DNA	 repair	 and	 cell	 apoptosis,	 cause	
abnormal	 cells	 to	 die	 swiftly,	 before	 they	 can	 cause	 any	 harm	 to	 the	 organism.	 But	 the	
immune	 system	 is	 another	 important	 player	 that	 actively	 participates	 in	 patrolling	 the	
human	body	and	eliminating	undesirable	mutant	cells.	This	ability	of	the	immune	system	to	
prevent	 tumour	 formation	 without	 external	 intervention	 is	 known	 as	 cancer	
immunosurveillance.	
The	 first	 attempts	 to	 prove	 this	 hypothesis	 were	 unfruitful,	 as	 athymic	 nude	 mice	 and	
wildtype	 controls	 did	 not	 differ	 in	 their	 tumour	 development	 rate	 upon	 subcutaneous	
injection	of	3-methylcholanthrene	(MCA),	a	highly	carcinogenic	substance100.	Both	wildtype	
and	 nude	MCA-treated	 cohorts	 developed	 subcutaneous	 sarcomas	 at	 similar	 rates	 -	 less	
than	 20%	 -	 120	 days	 after	 treatment.	 Moreover,	 lung	 adenomas	 were	 detected	 in	 all	
cohorts,	with	an	increase	for	mice	that	had	received	MCA	but	no	difference	relative	to	the	
mouse	 strain.	 From	 this	 study,	 Stutman	 and	 colleagues	 concluded	 that	 tumour	
immunosurveillance	 did	 not	 occur	 in	 their	 model.	 However,	 as	 it	 was	 later	 discovered,	
athymic	nude	mice	do	retain	some	immune	cells	and	the	ability	to	mount	limited	but	useful	
immune	 responses101.	 Despite	 their	 lack	 of	 thymus,	 these	 mice	 possess	 some	 residual	
functional	T	cells,	as	well	as	an	intact	repertoire	of	many	innate	immune	players	such	as	NK	
cells.	These	elements	might	have	been	enough	to	compensate	for	the	absence	of	thymus-
maturated	 T	 cells	 and	 mask	 the	 effect	 of	 immunosurveillance	 in	 Stutman’s	 aggressive	
tumour	model.	
Later	 on,	 the	 ability	 of	 the	 immune	 system	 to	 prevent	 tumour	 development	 was	
demonstrated	using	RAG2-/-	mice.	The	recombination-activating	gene-2	(RAG2)	is	necessary	
for	the	rearrangement	of	the	T	and	B	cell	receptor	during	the	lymphocyte	development,	and	
mice	 deficient	 in	 this	 protein	 lack	 T,	 B	 and	NKT	 cells.	 In	 2001,	 Shankaran	 and	 colleagues	
showed	that	RAG2-/-	mice	developed	tumours	earlier	and	with	greater	frequency	than	their	
wildtype	 counterparts.	 They	 also	 tested	 IFN-GR1	 and	 STAT1	 knockout	 (KO)	 mice	 strains,	
which	turned	out	 to	be	more	sensitive	to	MCA	treatment	compared	to	wild	 type	animals.	
Interestingly,	double	KO	 for	RAG2	and	STAT1	did	not	do	worse	 that	 single	KO	 in	 terms	of	
tumour	control,	which	shows	a	high	level	of	overlap	between	the	adaptive	immune	system	
and	the	IFN-γ	response	pathway.	From	this	study,	they	concluded	that	the	immune	system,	
and	 in	 particular	 lymphocytes,	 were	 playing	 an	 important	 role	 in	 the	 control	 of	 tumour	
development102.	
But	 the	 innate	 immune	 system	 and	 innate-like	 T	 lymphocytes	 also	 play	 a	 part	 in	 tumour	
immunosurveillance.	 The	 TCR	 Jα281-deficient	 mice	 (B6.Jα281-/-)	 are	 deficient	 in	 type	 I	
invariant	NKT	cells	(iNKTs).	This	model	was	used	to	assess	the	importance	of	iNKT	cells	in	the	
protection	against	spontaneous	tumour	induction	by	MCA	treatment.	Mice	deficient	in	iNKT	
cells	were	more	prone	 to	 tumour	development	 than	 their	wild	 type	counterpart.	Besides,	
additional	depletion	of	NK	cells	did	not	worsen	the	phenotype,	showing	that	NK	cells	are	not	
able	 to	 compensate	 the	 absence	 of	 NKT	 cells103.	 Finally,	 absence	 of	 NK	 cells	 alone	 was	
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sufficient	to	aggravate	the	tumour	phenotype,	and	abrogate	the	antitumoural	effect	of	IL-12	
injection.	 This	 shows	 that	 NK	 and	 NK	 T	 cells	 collaborate	 in	 the	 protection	 against	 MCA-
induced	tumours,	and	that	NK	cells	are	the	main	mediator	of	the	immune	response	to	the	
cytokine	IL-12104.	
The	cytokine	 IFN-γ	was	shown	multiple	times	to	be	a	very	 important	 immune	mediator	of	
protection	 against	 tumours,	 although	 in	 some	 cases	 it	 can	 contribute	 to	 tumour	
progession105.	Dighe	et	al.	demonstrated	that	the	neutralization	of	IFN-γ	by	the	injection	of	
monoclonal	 antibodies	 completely	 abrogated	 the	 LPS-induced	 rejection	 of	 Meth	 A	
tumours106.	IFN-γ	can	directly	increase	tumour	cells’	immunogenicity.	Indeed,	it	was	shown	
in	1988	by	Weber	and	Rosenberg	 that	surface	expression	of	MHC	class	 I	was	 increased	 in	
tumour	cells	upon	IFN-α	or	IFN-γ	treatment,	both	 in	vitro	and	 in	vivo107.	This	upregulation,	
as	 well	 as	 the	 presence	 of	 a	 functional	 immune	 system	were	 critical	 components	 of	 the	
observed	IFN-γ	-mediated	tumour	rejection106.	To	confirm	these	findings,	it	was	shown	that	
a	 tumour	 cell	 line	 engineered	 to	 express	 an	 MHC	 class	 I	 incompatible	 with	 the	 host’s	
immune	effector	cells	could	hence	not	be	rejected107,102.	 IFN-γ-mediated	tumour	 rejection	
does	 not	 only	 act	 directly	 on	 the	 tumour,	 but	 also	 provides	 an	 appropriate	 inflammatory	
environment	for	the	immune	system	to	be	efficiently	activated.	 Indeed,	 it	was	shown	that	
mice	 lacking	STAT1	signalling,	which	 is	necessary	for	the	 immune	response	to	 IFN-γ,	could	
not	 reject	 highly	 immunogenic	 tumours.	 This	 was	 due	 to	 deficiency	 in	 both	 cytokine	
production	and	cytolytic	activity	of	T	and	NK	cells108.	It	was	later	observed	that	the	absence	
of	STAT1	signalling	was	not	intrinsically	deleterious	to	the	T	cells	effector	functions,	but	was	
necessary	 in	 CD8α+	 dendritic	 cells	 to	 mediate	 efficient	 antigen	 cross-presentation	 and	
priming	of	antitumour	T	cells109.	
However,	 IFN-γ	signalling	can	sometimes	make	the	 tumour	more	resistant	 to	 the	 immune	
system.	 Indeed,	 mouse	 melanoma	 cells	 were	 shown	 to	 upregulate	 PDL-1	 after	 IFN-γ	
treatment,	 inducing	 immunosuppression	 of	 tumour-specific	 CD8+	 T	 cells110.	 In	 humans,	 a	
clinical	 trial	 evaluating	 the	 potential	 of	 IFN-γ	 for	 the	 immunotherapeutic	 treatment	 of	
ovarian	 cancer	 showed	 increased	 mortality	 in	 the	 treated	 group	 and	 had	 to	 be	
interrupted111.	 It	 was	 later	 shown	 that	 human	 ovarian	 cancer	 cells	 expressed	 the	 IFN-γ	
receptor	 and	 could	 upregulate	 PDL-1	 upon	 IFN-γ	 treatment112.	 It	 is	 so	 far	 not	 well	
understood	what	are	the	key	players	determining	the	pro-	or	anti-tumoural	activity	of	IFN-γ.	
The	 existence	 of	 immunosurveillance	 in	 humans	 was	 tricky	 to	 demonstrate	 because	 of	
confounding	 factors,	as	 immunosuppressed	 individuals	are	more	susceptible	 to	 infections.	
However,	 some	 studies	 indicate	 that	 immunosurveillance	 is	 also	 relevant	 for	 humans.	
Indeed,	immunosuppressed	transplant	recipients	generally	display	an	increased	incidence	of	
non-virally	induced	cancers113.	For	example,	patients	were	found	to	have	a	100-fold	increase	
in	the	risk	of	melanoma	after	transplantation	in	Sweden114.	Moreover,	the	incidence	of	both	
virally	 and	 non-virally	 induced	 cancers	 is	 increased	 in	 individuals	 that	 suffer	 from	 genetic	
immunodeficiencies115.	
All	these	data	offer	a	glimpse	of	the	different	interactions	between	the	immune	system	and	
the	 tumour	 and	 show	 the	 importance	 of	 several	 key	 components	 for	 tumour	 protection,	
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mainly	inflammation	via	cytokines	(IFN-γ)	and	the	innate	immune	system	(NK	cells),	efficient	
antigen	 presentation	 (dendritic	 cells)	 and	 a	 competent	 and	 persisting	 adaptive	 immune	
response	(lymphocytes).	
3.2. Immunoediting:	
An	 apparent	 paradox	 in	 the	 immunosurveillance	 hypothesis	 is	 that	 not	 only	
immunocompromised	but	also	immunocompetent	host	develop	tumours.	Why	is	that	so,	if	
the	immune	system	is	so	good	at	preventing	tumour	growth?	To	more	accurately	represent	
the	 complex	 interaction	 between	 tumours	 and	 their	 environment,	 the	 cancer	
immunosurveillance	idea	was	replaced	by	the	more	refined	immunoediting	concept.		
Cancer	 immunoediting	occurs	 in	 three	phases.	First,	arising	mutant	cells	are	detected	and	
removed	 by	 the	 host.	 This	 is	 the	 elimination	 phase.	 Secondly,	 there	 is	 the	 equilibrium	
phase,	 in	which	the	host’s	 immune	system	is	unable	to	completely	get	rid	of	all	malignant	
cells,	but	manages	to	control	their	growth.	During	this	time,	the	immune	system	will	exert	a	
strong	pressure	on	the	tumour	cells	and	only	the	 least	 immunogenic	mutants	will	survive.	
Depending	on	their	tumorigenicity,	these	cells	will	go	on	to	the	third	phase,	the	escape.	In	
that	final	step,	low	immunogenic	and	highly	malignant	tumour	cells	are	no	longer	controlled	
by	the	immune	system	and	develop	into	a	cancer113.	
First	 evidences	 of	 immunoediting	 arose	 from	 mouse	 tumour	 model.	 Indeed,	 tumours	
derived	from	immunocompetent	hosts	grew	more	aggressively	than	from	RAG2-/-	mice	once	
transplanted	 into	wild	 type	mice102.	 This	 demonstrates	 that	 the	 adaptive	 immune	 system	
can	shape	the	immunogenicity	of	escaping	tumour	cells.	Additionally,	it	was	shown	that	the	
innate	immune	system	also	influences	the	immunogenic	phenotype	of	tumour	cells.	Indeed,	
tumours	derived	from	mice	 lacking	both	the	RAG2	protein	and	the	common	gamma	chain	
(RAG2-/-	 x	 γc-/-)	were	more	easily	 rejected	once	 transplanted	 into	WT	mice,	 than	 tumours	
derived	from	RAG2-/-	mice.	This	was	due	to	IFN-γ	produced	by	NK	cells	and	polarisation	of	
tumour	 associated	 macrophages	 into	 the	 antitumoural	 M1	 phenotype116.	 These	
experiments	 show	 that	 tumour	 cells,	 which	 manage	 to	 escape	 the	 immune	 system,	 are	
selected	 for	 specific	 characteristics	 that	 allow	 them	 to	 expand	 better	 upon	 further	
transplant.	
3.3. Tumour	escape	
Some	 elements	 that	 allow	 cancer	 cells	 to	 avoid	 immune	 control	 and	 increase	 their	
malignancy	have	been	recently	identified.	
To	escape	effectors	from	the	adaptive	branch	of	the	immune	system,	tumours	can	mutate	
key	 antigens	 as	 well	 as	 downregulate	 their	 expression	 of	 the	 major	 histocompatibility	
complex	 (MHC).	 Since	 recognition	 from	 T	 lymphocytes	 occurs	 through	 binding	 to	 the	
peptide-MHC,	 cells	 that	 express	 low	 or	 no	 MHC	 will	 be	 poorly	 recognized	 and	 lysed	 by	
cytotoxic	T	 cells.	 In	human	 tumours,	 complete	MHC	class	 I	 loss	 is	 frequent,	 and	occurs	 in	
many	types	of	cancer117.		
One	would	assume	that	the	loss	of	MHC	class	I	would	induce	more	lysing	of	the	tumour	cells	
by	NK	cells	and	γδ	T	cells.	However,	it	does	not	seem	to	be	the	case.	Two	mechanisms	might	
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protect	 the	 malignant	 cells	 from	 NK	 and	 γδ	 T	 cell	 recognition.	 Firstly,	 the	 pro-tumoural	
environment	is	usually	low	on	IL-12	and	immunosuppressive,	which	is	not	adequate	for	the	
proper	activation	of	NK.	Secondly,	NK	cells	also	have	to	bind	to	the	stress-induced	 ligands	
MICA/B	via	their	NKG2D	receptor	for	their	activation.	Consequently,	many	tumours	lose	the	
expression	of	these	ligands,	or	even	shed	them	in	soluble	form	to	induce	a	downregulation	
of	 NKG2D	 at	 the	 surface	 of	 NK	 cells	 before	 they	 reach	 the	 tumour	 cells118,119.	 These	
mechanisms	protect	the	tumour	cells	from	NK	cells	cytotoxicity.	
Another	escape	technique	is	the	secretion	of	immunosuppressive	cytokines	and	factors	to	
deactivate	 the	 immune	 response	 and	 deplete	 the	 tumour	 microenvironment	 of	 crucial	
nutrients.	 For	 example,	 the	 cytokine	 transforming	 growth	 factor	 β	 (TGF-β)	 inhibits	 the	
efficient	activity	of	cytotoxic	T	 lymphocytes	 in	vivo.	Additionally,	TGF-β	can	convert	CD4	T	
cells	into	inducible	T	regulatory	cells	(iTregs),	which	are	in	turn	able	to	suppress	the	activity	
of	 other	 lymphocytes120.	 Moreover,	 this	 cytokine	 was	 also	 shown	 to	 induce	 the	
differentiation	 of	 myeloid	 cells	 into	 terminally	 differentiated	 myeloid	 mononuclear	 cells,	
which	express	CD39	and	CD73.	The	CD39/CD73	enzyme	pair	degrades	ATP	into	adenosine,	
which	has	further	immunosuppressive	effects121.	In	humans,	TGF-β	expression	was	found	in	
several	 types	 of	 cancer	 and	 was	 associated	 with	 disease	 progression	 in	 breast	 cancer	
patients122.		
A	 further	 way	 in	 which	 tumours	 are	 able	 to	 deactivate	 the	 cytotoxic	 response	 is	 by	
catabolising	 the	 crucial	 amino	acid	 tryptophan.	They	do	 so	by	overexpressing	 the	enzyme	
indoleamine-2,3-dioxygenase	 (IDO)	 that	 catalyses	 the	 conversion	 of	 tryptophan	 to	
kynurenine.	 The	 depletion	 of	 tryptophan	 and	 the	 production	 of	 kynurenine	 have	 been	
shown	as	 inducers	of	Th1	cell	 apoptosis123.	Moreover,	 absence	of	 tryptophan	 induces	 the	
activation	of	the	stress-response	kinase	GCN2	in	CD4	T	cells	and	drives	their	differentiation	
into	Tregs124,125.	
Finally,	tumours	are	able	to	recruit	myeloid	cells	that	will	help	create	an	immunosuppressive	
microenvironment	 such	 as	 monocytes,	 which	 are	 transformed	 into	 myeloid-derived	
suppressors	 cells	 (MDSCs).	 Tumour	 cells	 can	 subvert	 myeloid	 cells	 via	 the	 expression	 of	
several	cytokines	and	chemokines	such	as	CSF1,	VEGFA,	SEMA3A,	CCL2	and	CXCL12126.	The	
MDSCs	in	turn	express	inducible	nitric	oxide	synthase	(iNOS)	as	well	as	arginase	1,	that	both	
are	deleterious	to	efficient	T	cell	function	through	the	production	of	reactive	oxygen	species	
and	 depletion	 of	 arginine127.	 Finally,	 tumours	 are	 able	 to	 express	 immunosuppressive	
ligands,	such	as	PDL-1,	which	when	bound	to	their	receptor	on	the	activated	T	cells,	renders	
them	tolerogenic	and	inactive	(see	Figure	4).	
In	addition	of	being	able	to	hide	from	the	immune	system	by	downregulating	MHC	class	I,	
tumours	 can	 directly	 deactivate	 it	 by	 creating	 a	 local	 immunosuppressive	 environment.	
They	do	so	via	the	secretion	of	immunosuppressive	factors,	as	well	as	the	surface	expression	
of	 inhibitory	 receptors	 and	 the	 recruitment	 of	 immunosuppressive	 cells.	 All	 these	
immunosuppressive	mechanisms	have	to	be	carefully	considered	for	the	design	of	efficient	
immunotherapies.	
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4. Immunotherapy	
The	 strong	 evidence	 of	 the	 importance	 of	 the	 immune	 system	 in	 mediating	 tumour	
protection	promoted	the	development	of	antitumour	immunotherapies.	Given	the	fact	that	
lymphocytes	have	the	ability	to	kill	tumour	cells,	and	that	CD8+	T	cells	infiltration	correlates	
with	 good	 prognosis128,	 the	 main	 aims	 of	 immunotherapies	 against	 cancer	 are	 both	 to	
increase	 the	 lymphocytes	 numbers	 on	 site,	 as	 well	 as	 to	 reactivate	 them.	 Indeed,	
lymphocytes	 present	 in	 the	 tumour	 microenvironment	 are	 usually	 of	 the	 exhausted	
phenotype	and	have	lost	most	of	their	effector	functions	and	tumour	lysing	abilities129.	
Different	types	of	immunotherapies	have	been	tested	to	boost	the	immune	system	against	
tumours:	antibodies	can	either	be	used	to	target	tumours	epitopes	and	induce	ADCC,	or	be	
used	to	block	immunosuppressive	pathways.	Treatments	with	cytokines	aim	at	systemically	
boosting	the	immune	system.	Cancer	vaccines	are	made	to	elicit	a	specific	response	against	
one	 or	 several	 relevant	 tumour	 antigen.	 Additionally,	 adoptive	 cell	 transfer	 can	 be	
performed;	 by	 isolating	 and	 expanding	 a	 patient’s	 own	 lymphocytes	 before	 transferring	
them	 back	 into	 the	 circulation.	 Finally,	 checkpoint	 blockade	 inhibitors	 aim	 to	 block	 the	
tumour’s	immunosuppressive	receptors	to	enable	the	immune	system	to	attack	the	tumour	
cells.		
Originally,	 immunotherapies	 were	 classified	 in	 two	 types	 named	 passive	 and	 active	
immunotherapy,	 depending	 on	 whether	 the	 activation	 was	 mainly	 through	 the	 patient’s	
endogenous	 immune	 system	 or	 via	 the	 injection	 of	 a	 foreign	 substance.	 However,	 this	
classification	no	longer	holds	due	to	the	complexity	of	recent	approaches.	While	therapeutic	
vaccines	are	without	question	“active”	immunotherapy,	antitumour	antibody	treatments,	as	
well	 as	 cytokine	 treatments,	which	were	 classically	 designated	 as	 passive,	 do	 rely	 on	 the	
reactivation	 of	 endogenous	 immune	 cells	 for	 their	 functionality.	 Moreover,	 adoptive	 cell	
transfer	 techniques,	 in	which	a	patient’s	own	cells	are	genetically	modified	and	reinjected	
into	 the	 patient,	 also	 rely	 on	 the	 patient’s	 own	 immune	 cells.	 The	 passive	 versus	 active	
definition	of	immunotherapy	therefore	seems	obsolete	and	does	not	reflect	the	complexity	
of	the	interactions	of	the	different	immune	actors.		
4.1. Antibodies	
Using	antibodies	for	tumour	targeting	has	been	of	strong	interest	for	several	decades,	and	
the	 biggest	 hurdle	 has	 been	 to	 find	 antigens	 that	 are	 specific	 to	 the	 tumour	 cells.	 An	
appropriate	 target	 for	 antibody	 immunotherapy	 needs	 to	 be	 expressed	 both	
homogeneously	and	at	a	high	enough	level	on	the	surface	of	the	tumour.	Once	a	target	that	
fulfils	those	criteria	has	been	identified,	antibodies	can	be	produced	against	 it,	and	induce	
three	 types	 of	 response:	 blocking	 a	 receptor	 necessary	 for	 the	 survival	 or	 growth	 of	 the	
tumour,	 inducing	 immune-dependant	 cytotoxicity	 via	 the	 Fc	 portion	 of	 the	 antibody,	 or	
immunomodulating	T	cell	function	(see	Figure	12).			
4.1.1. Monoclonal	antibodies	against	tumour	surface	antigen	
Several	 monoclonal	 antibodies	 targeting	 different	 kind	 of	 tumour	 antigens	 have	 shown	
success	in	clinical	trials.	Consequently,	they	have	become	commercially	available	for	cancer	
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treatment130.	 For	 example,	 Cetuximab	 is	 a	 monoclonal	 antibody	 targeting	 the	 epidermal	
growth	factor	receptor	(EGFR).	It	was	found	to	be	an	efficient	therapy	for	colorectal	cancer	
patients,	 if	 they	 did	 not	 have	 a	 KRAS	 mutation.	 For	 the	 patients	 with	 wild	 type	 KRAS,	
treatment	 with	 Cetuximab	 improved	 the	 overall	 survival	median	 from	 4.8	months	 to	 9.5	
months131.	This	led	in	2012	to	the	approval	of	Cetuximab,	together	with	chemotherapy,	for	
first	line	care	of	EGFR+	KRAS	WT	colorectal	cancer	patients132.	Trastuzumab,	is	another	FDA-
approved	monoclonal	antibody	used	for	the	treatment	of	HER2+	breast	cancer133.	It	showed	
clinical	benefit	 in	48%	of	the	patients	whose	tumours	where	highly	positive	for	HER2.	The	
efficacy	of	both	of	 these	 treatments	were	 linked	 to	 the	 inhibition	of	 signalling,	 as	well	 as	
antibody-dependant	cell-mediated	cytotoxicity.		
	
Figure	12:	Mechanisms	of	tumour	targeting	by	antibodies130	
4.1.2. Bispecific	antibodies	
Bispecific	 antibodies	 have	 the	 advantage	 that	 they	 can	 either	 simultaneously	 target	 2	
antigens	 and	 thus	 increase	 the	 specificity	 of	 the	 antibody	 to	 the	 tumour	 and	 reduce	 the	
non-specific	 toxicity,	or	alternatively	 specifically	attract	 some	 immune	cells	 to	 the	 tumour	
site.	 An	 example	 from	 this	 second	 category	 is	 catumaxomab.	 This	 nonhumanized	mouse	
bispecific	antibody	simultaneously	targets	EPCAM	and	CD3,	and	has	a	functional	Fc	domain	
to	activate	 innate	 immune	cells.	 It	 is	used	for	the	treatment	of	malignant	ascites	together	
with	paracentesis	 (removal	of	 fluid	 from	the	peritoneal	cavity).	Overall	 survival,	as	well	as	
median	 puncture-free	 survival	 was	 significantly	 increased	 for	 patients	 treated	 with	
Catumaxomab134.	Another	bispecific	antibody	used	in	the	clinic	is	blinatumomab.	It	doesn’t	
have	a	functional	Fc	domain	but	it	is	composed	of	2	single	chain	antibody	fragments	(scFv)	
one	targeting	CD19,	and	the	other	one	targeting	CD3.	Blinatumomab	was	approved	by	the	
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FDA	as	treatment	for	refractory	B-ALL,	Philadelphia	chromosome	negative.	Treatment	with	
blinatumomab	 increased	 the	complete	 response	 in	 these	patients	 to	30%	compared	 to	5-
12%	with	previous	chemotherapeutic	regiments135.	
Other	 bispecific	molecules	 have	 been	 investigated,	 such	 as	 ImmTACs,	which	 comprise	 an	
antibody	linked	to	a	T	cell	receptor.	Such	a	molecule,	IMCgp100,	was	made	linking	an	αCD3	
scFv	 to	 a	 TCR	 specific	 for	 the	 gp100	peptide:MHC	complex.	 It	 is	 currently	 in	phase	 II	 trial	
after	 encouraging	 reports	 from	 the	 phase	 I	 trial,	 which	 results	 are	 not	 yet	 published136.	
Similarly	 to	 TCR-transgenic	 T	 cells,	 such	 a	 construct	 creates	 the	 challenge	 of	 having	 HLA-
matching	between	the	patients	and	the	drug,	as	well	as	a	high	enough	MHC	expression	on	
the	surface	of	the	tumour.	
Additional	bispecific	antibodies	have	sought	to	redirect	NK	cells,	for	example	by	linking	the	
Fv	 domains	 of	 an	 αCD16A	 and	 an	 αCD30.	 Such	 a	 molecule	 proved	 efficient	 in	 vitro	 to	
mediate	lysis	of	human	lymphoma	cells137.	Another	investigated	method	to	reactivate	iNKT	
cells	 against	 tumours	was	 to	 take	 advantage	 of	 the	 CD1d	 invariant	molecule	 loaded	with	
alpha-galactosylceramide	(αGC),	which	is	capable	of	strongly	activating	iNKT	cells.	However,	
iNKT	 cells	 become	anergic	 after	 one	 stimulation	with	 this	molecule.	A	new	approach	was	
then	investigated	by	fusing	the	αGC-loaded	CD1d	with	an	scFv	against	the	cancer	antigens	
Her2	 or	 CEA.	 This	 method	 proved	 capable	 of	 initiating	 a	 potent	 and	 specific	 antitumour	
effect	in	a	mouse	model	of	adenocarcinoma138.	
4.1.3. Immunomodulatory	antibodies	
Lastly,	 immunomodulatory	 antibodies	 function	 by	 blocking	 the	 interaction	 of	 important	
immunosuppressive	receptors	with	their	ligands	and	thus	redirecting	the	immune	response	
towards	 inflammation.	 Immunosuppressive	 receptors	 are	 usually	 upregulated	 on	 the	
surface	 of	 activated	 T	 cells	 and	 provide	 a	 negative	 feedback,	 hence	 preventing	 an	
uncontrolled	 immune	 response.	 For	 this	 reason	 they	 have	 been	 named	 immune	
checkpoints.	 The	 absence	 of	 immune	 checkpoints	 can	 drive	 fatal	 immunopathology,	 for	
example	in	CTLA-4-/-	mice139,	or	in	PD-1L-/-	mice	upon	chronic	LCMV	infection38.		
CTLA-4	has	two	immunosuppressive	functions.	On	one	hand	it	binds	to	CD80	and	CD86	and	
prevents	their	binding	to	CD28	for	T	cell	costimulation	(see	Figure	4,	page	19).	On	the	other	
hand	 it	 provides	 immunosuppressive	 signalling	 in	 the	 T	 cell.	 CTLA-4	 is	 constitutively	
expressed	 in	 Tregs,	 and	 blocking	 of	 CTLA-4	 via	 a	 monoclonal	 antibody	 abrogates	 their	
suppressive	function140.	
PD-1	 is	 transiently	 upregulated	 upon	 T	 cell	 activation141	 and	 downregulated	 when	 the	
inflammation	 is	 resolved.	 However,	 PD-1	 expression	 stays	 high	 in	 exhausted	 T	 cells	 upon	
chronic	 infection	 or	 in	 tumour	 infiltrating	 lymphocytes142.	 Several	 tumour	 cell	 lines	 were	
shown	to	either	endogenously	express	the	PD-1	ligand	PD-L1,	or	to	upregulate	it	upon	IFN-γ	
treatment.	Subsequent	binding	of	PD-L1	to	its	receptor	on	T	cells	induced	their	apoptosis143.	
Indeed,	tumours	are	able	to	hijack	mechanisms	designed	to	control	 the	 immune	response	
and	use	them	to	supress	the	function	of	CTLs.	Hence,	researchers	have	sought	to	block	the	
interaction	 of	 those	 immunosuppressive	 receptors	 with	 their	 ligands	 via	 the	 injection	 of	
antagonistic	antibodies.	This	line	of	treatment	is	called	immune	checkpoint	blockade.	
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In	1996,	Leach	et	al.	first	demonstrated	that	αCTLA-4	could	block	the	interaction	of	CTLA-4	
its	 ligand	 and	 hence	 prevents	 immunosuppressive	 signalling	 as	 well	 as	 restores	 the	
availability	 of	 CD80/CD86	 for	 CD28	 costimulation.	 Treatment	 with	 this	 antibody	 induced	
antitumour	immunity	and	protected	the	mice	against	a	further	tumour	challenge144.	A	fully	
humanized	αCTLA-4	called	 ipilimumab	was	subsequently	produced	and	used	 in	a	phase	 III	
trial.	The	trial	demonstrated	that	treatment	with	ipilimumab	improved	both	overall	survival	
and	 progression-free	 survival	 in	 metastatic	 melanoma	 patients.	 Moreover,	 18%	 of	 the	
patients	 treatment	with	 ipilimumab	survived	beyond	2	years,	compared	to	only	5%	of	 the	
patients	 receiving	 the	 vaccine	 alone145.	 Another	 common	 target	 of	 immunomodulatory	
antibodies	is	PD-1.		Nivolumab	and	pembrolizumab	both	target	this	receptor	and	have	been	
found	 to	 have	 an	 antitumour	 effect	 in	 advanced	 melanoma.	 Nivolumab	 improved	 both	
overall	survival	as	well	as	progression-free	survival	in	metastatic	melanoma	without	a	BRAF	
mutation	 compared	 to	 dacarbazine	 chemotherapy.	 Interestingly,	 in	 both	 treatment	 arms,	
the	 expression	 of	 PDL-1	 on	 the	 tumour	 was	 correlated	 with	 better	 overall	 survival146.	
Pembrolizumab	 is	 currently	 used	 in	 16	 phase	 III	 trials	 for	 many	 types	 of	 cancer	 (breast,	
melanoma,	 lymphoma,	 lung	 ect…)147.	 In	 2015,	 pembrolizumab	 was	 proved	 to	 be	 more	
efficient	 than	 ipilimumab	 in	 a	 phase	 III	 clinical	 trial	 for	 the	 treatment	 of	 advanced	
melanoma,	 as	 well	 as	 to	 induce	 less	 high-grade	 adverse	 events148.	 Additionally,	
pembrolizumab	was	 shown	 to	 be	more	 efficient	 than	 chemotherapy	 in	 patients	 that	 had	
ipilimumab-refractory	melanoma149.	 Indeed,	 it	 had	been	 shown	 that	CTLA-4	and	PD-1	are	
not	 redundant	 in	 their	 functionality,	 and	 inhibit	 T	 cell	 function	 by	 distinct	 pathways150.	
Consequently,	combination	therapies	were	experimented,	and	Postow	et.	al.	measured	an	
improved	response	rate	 in	advanced	melanoma	patients	treated	with	both	nivolumab	and	
ipilimumab	compared	to	ipilimumab	administered	as	a	monotherapy151.	
The	unprecedented	efficiency	of	 immune	 checkpoint	blockade	prompted	 FDA-approval	 of	
these	 therapies	 for	 a	 myriad	 of	 cancer	 namely	 non-small-cell	 lung	 cancer152,153,	 kidney	
cancer154,	Hodgkin	 lymphoma155	and	bladder	cancer156,	only	 in	the	 last	year.	One	question	
that	 remains	 unanswered	 is	 which	 biomarkers	 can	 discriminate	 responders	 and	 non-
responders.	
4.2. Cytokine	mediated	immunotherapy	
It	was	in	the	late	seventies	that	the	ability	of	cytokines	to	mediate	lymphocytes	survival	and	
proliferation	was	 discovered.	 This	 new	 development	 allowed	 researchers	 to	 grow	 cells	 in	
culture	 for	 in	 vitro	 studies	 and	 greatly	 improved	 the	 understanding	 of	 lymphocytes	 and	
immune	mechanisms.	 Following	 this	discovery,	and	with	 the	ability	 to	produce	and	purify	
recombinant	cytokines	came	the	interest	to	use	them	in	anti-cancer	treatment.		
Firstly,	IL-2	was	injected	in	patients	with	metastatic	melanoma	and	renal	cell	cancers,	which	
induced	 complete	 and	 durable	 responses	 in	 6.6%	 and	 9.3%	 of	 cases,	 respectively157.	
Systemic	 administration	 of	 IL-2	 is	 a	 non-specific	 treatment,	 aiming	 at	 boosting	 the	
proliferation	of	NK	and	T	cells.	Hence,	adverse	toxicities	were	important	at	first,	with	92%	of	
patients	 experimenting	 grade	 3/4	 diarrhoea,	 and	 81%	 experimenting	 grade	 3/4	
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hypotension158.	 However,	 once	 appropriate	 dosing	 and	 administration	 of	 IL-2	 were	
experimentally	determined,	adverse	events	following	the	treatment	could	be	lowered	from	
2-4%	 fatality	 to	 less	 than	 1%,	 and	 other	 non-fatal	 symptoms	 could	 be	 resolved	 by	
appropriate	additional	care159.		
IL-12,	 on	 the	 other	 hand,	 was	 found	 to	 have	 strong	 adverse	 effects	 that	 could	 not	 be	
controlled.	 IL-12	 has	 the	 ability	 to	 activate	 NK	 cells	 and	 help	 Th1	 cell	 differentiation.	
However,	despite	encouraging	 results	using	 IL-12	 therapies	 in	animals	 (either	via	 systemic	
injection	of	purified	 IL-12	or	via	 local	production	of	 IL-12	 in	 the	 tumour),	 severe	 toxicities	
were	 found	 in	 human	 trials	 using	 IL-12,	 which	 led	 to	 the	 immediate	 halt	 of	 those	 trials.	
However,	more	recent	studies	using	local	IL-12	expression	in	the	tumour	microenvironment,	
in	combination	with	other	therapies,	gave	encouraging	results	and	are	reviving	the	interest	
in	this	cytokine	for	cancer	immunotherapy160.	
4.3. Cancer	Vaccines	
Vaccines	 are	 usually	 developed	 for	 their	 ability	 to	mount	 an	 immune	 response	 against	 a	
known	 pathogen	 and	 prevent	 vaccinated	 individuals	 from	 further	 contracting	 a	 disease.	
Such	prophylactic	vaccines	cannot	be	applied	to	most	cancers,	with	the	exception	of	virally	
induced	 cancers.	 For	 example,	 the	 human	 papilloma	 virus	 (HPV)	 is	 a	 known	 trigger	 for	
cervical	neoplasia.	Vaccines	against	the	human	papilloma	virus	(HPV)	have	been	developed	
and	could	successfully	prevent	HPV	infection	as	well	as	neoplasia	development161.	
For	most	cancers	however,	research	has	focused	on	designing	vaccines,	which	aim	to	set	off	
an	 effective	 antitumour	 immune	 response	 once	 the	 cancer	 is	 already	 established.	 Such	
therapeutic	 vaccines	 can	 be	 formulated	 in	 many	 ways,	 which	 will	 affect	 the	 type	 of	 the	
response,	whether	the	 inflammation	 is	more	 local	or	systemic,	or	 if	 the	cells	are	activated	
against	only	one	epitope	or	several.	
4.3.1. Peptide-based	cancer	vaccines	
Peptide	and	adjuvant-based	vaccines	aim	at	igniting	an	adaptive	immune	response	against	a	
chosen	target.	However,	most	antigens	expressed	by	the	tumour	are	of	low	affinity	and	are	
subject	to	peripheral	tolerance	since	the	body	recognizes	them	as	“self”.	Consequently,	the	
antigen	 of	 choice	 for	 a	 therapeutic	 vaccine	 has	 to	 be	 carefully	 considered.	 Antigens	 of	
highest	 interest	 for	 therapeutic	 vaccines	 include	 mutated	 antigens	 (neoantigens),	 cancer	
testis	antigens	-	which	are	expressed	only	in	male	germ	cells	but	not	adult	somatic	tissues	
with	 the	 exception	 of	 tumours	 -	 and	 antigens	 that	 are	 overexpressed	 in	 the	 tumour	
compared	 to	 normal	 tissue.	 Finally,	 tissue-specific	 antigens	 can	 be	 considered	 when	 the	
tissue	happens	 to	be	dispensable	 for	 the	survival	of	 the	patient,	 for	example	 the	prostate	
specific	membrane	antigen	PSMA,	or	the	B	cell	antigen	CD19162.	
It	was	found	that	it	is	best	to	use	long	peptides	in	adjuvant	based	vaccines,	as	they	are	able	
to	mediate	both	CD4+	as	well	as	CD8+	T	cell	response,	in	opposition	to	short	peptides	which	
can	 only	 bind	 to	 MHC-class	 I	 and	 thus	 induce	 CD8+	 T	 cell	 response	 only.	 When	 not	
accompanied	by	the	presence	of	appropriate	CD4+	T	helper	cells,	 the	 induced	CD8+	T	cell	
response	is	much	less	efficient	and	shorter-lived163.	But	even	undertaking	this	approach,	the	
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clinical	benefits	of	peptide	vaccines	as	monotherapies	were	limited.	
4.3.2. DNA	vaccines:	
The	 delivery	 of	 tumour	 antigen	 via	 its	 genetic	 sequence	 has	 also	 been	 studied.	 Bacterial	
plasmids	modified	to	include	the	gene	of	the	antigen	of	interest	can	be	directly	injected	into	
the	muscles	of	patients,	and	some	cells,	such	as	APCs,	will	uptake	the	genetic	material	and	
start	expressing	the	protein.	It	can	then	be	presented	to	T	cells	via	the	classical	MHC	class	I	
pathway	 of	 antigen	 processing	 and	 presentation.	 To	 optimize	 this	 approach,	 packaging	
vectors	for	DNA	delivery	have	been	engineered.	For	example	bacterial	or	viral	vector	can	be	
used.	 They	 possess	 the	 advantage	 of	 infecting	 the	 target	 cells	 and	 delivering	 the	 gene	 of	
interest	 more	 effectively.	 An	 additional	 advantage	 of	 this	 approach	 is	 the	 fact	 that	
pathogens	 carry	 PAMPs,	 which	 trigger	 an	 inflammatory	 immune	 response.	 In	 a	 recent	
clinical	 trial	 for	 the	 treatment	 of	 prostate	 cancer,	 Kantoff	 and	 colleagues	 administered	
subcutaneously	a	recombinant	vaccinia	virus	expressing	the	prostate	antigen	PSA	and	three	
immune	 costimulatory	 molecules,	 namely	 B7.1,	 ICAM-1,	 and	 LFA3,	 together	 with	
recombinant	GM-CSF.	The	development	of	autologous	immunity,	in	the	form	of	antibodies	
to	 the	 vaccinia	 virus,	 prevented	 boosting	 with	 the	 same	 vector.	 Hence,	 a	 recombinant	
fowlpox	virus,	expressing	the	same	set	of	antigen	and	costimulants,	was	used	in	subsequent	
boosting	vaccinations.	At	three	years	post-treatment,	30.5%	of	the	vaccinated	patients	were	
still	alive,	compared	to	17.5%	in	the	control	arm	164.	It	should	be	mentioned	that	the	control	
arm	did	not	 receive	 recombinant	GM-CSF	but	only	 the	empty	 vectors	 alone,	which	might	
also	have	influenced	the	results.		
Of	note,	oncolytic	viral	vectors	have	also	been	used.	Their	advantage	is	that	they	are	both	
directly	harmful	to	the	tumour,	and	at	the	same	time	inducing	tumour	antigen	presentation	
in	 an	 inflammatory	 context,	 which	 improves	 the	 quality	 of	 the	 subsequent	 immune	
response.	A	recent	clinical	trial	using	a	herpes	simplex	oncolytic	virus	expressing	GM-CSF	(T-
VEC)	 to	 attract	 antigen-presenting	 cells	 to	 the	 tumour	 site	 showed	 encouraging	 results.	
Specifically,	patients	treated	with	T-VEC	had	an	overall	survival	of	23.3	months	compared	to	
18.9	months	in	the	GM-CSF	control	arm165.	
4.3.3. Whole	tumour	cell	vaccines	
To	 circumvent	 the	 hurdle	 of	 the	 antigen’s	 identification	 and	 selection,	 researchers	 have	
attempted	 using	 whole	 cell	 vaccines.	 Autologous	 tumour	 lysates	 incorporate	 the	 whole	
spectrum	 of	 tumour	 antigen	 and	 neoepitopes	 without	 the	 need	 to	 individually	 identify	
them.	However,	the	success	of	this	approach	in	clinical	trials	was	limited,	although	slightly	
higher	 than	 for	 single	 peptide.	 A	 review	 compared	 the	 objective	 clinical	 response	 in	 173	
trials	 using	 either	 whole	 cell	 based	 approach	 or	 peptide-based	 approach	 as	
immunotherapies	 for	 a	wide	 range	of	 cancers.	Whole	 cell	 vaccines	had	an	8.1%	objective	
clinical	 response,	compared	to	3.6%	for	molecularly	defined	antigens.	A	similar	 result	was	
found	when	the	analysis	was	restricted	to	advanced	metastatic	melanoma	(12.7%	for	whole	
cell	versus	6.7%	for	peptides).	Interestingly,	according	to	their	analysis	the	use	of	allogeneic	
tumour	cell	lines	had	a	similar	efficiency	than	autologous	tumour	lysates166.	This	would	be	a	
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good	way	to	avoid	the	logistic	difficulty	and	the	high	cost	of	using	the	patients	own	tumour	
lysates.	Moreover,	an	advantage	of	tumour	cell	lines	is	that	they	can	be	modified	to	express	
additional	 immunoattractant,	such	as	GM-CSF,	which	would	increase	further	the	efficiency	
of	 the	vaccine.	Unfortunately,	most	 clinical	 trials	using	 this	 technique	so	 far	did	not	 show	
clinical	benefits167.		
4.3.4. DCs	vaccines	
A	more	controlled	way	of	 inducing	antigen	presentation	by	professional	APCs	 is	 to	extract	
them	from	the	patient	and	pulse	them	with	the	peptide	or	peptides	of	choice.	Indeed,	after	
maturation,	DCs	are	the	most	potent	APCs,	capable	of	triggering	robust	 immune	response	
and	 to	 provide	 all	 the	 signals	 to	 T	 cells	 for	 their	 expansion	 and	 activation.	 DCs	 can	 be	
purified	 from	 the	 blood	 of	 cancer	 patients,	maturated	 and	 pulsed	with	 antigen	 or	whole	
tumour	 lysate	 in	 vitro.	 Several	 clinical	 trial	 have	 been	 kicked	 off,	 and	 showed	 marginal	
improvement	 in	 terms	of	 tumour	 responses168.	 A	 2010	phase	 III	 clinical	 trial	 showed	 that	
Sipuleutel	T,	a	vaccine	comprising	activated	DCs	pulsed	with	a	prostate	antigen,	 improved	
overall	 survival	of	4	months	 in	castration-resistant	prostate	cancer	patients.	Following	 the	
publication	of	these	results,	the	FDA	approved	Sipuleutel	T	for	clinical	use169.	
4.4. Adoptive	cell	transfer	
Adoptive	cell	transfer	consists	in	the	reinfusion	of	autologous	immune	cells,	after	expansion,	
treatment	or	genetic	modification,	into	the	cancer	patient	to	mediate	antitumour	immunity.	
Some	 preclinical	 study	 show	 that	 the	 combination	 of	 radiation	 therapy	 and	 transfer	 of	
preactivated	 NK	 cells	 could	 mediate	 tumour	 rejection	 in	 mice170.	 Additionally,	 several	
studies	 have	 been	 published	 showing	 CAR-modified	 NK	 cells	 for	 the	 immunotherapy	 of	
cancer171,172.	 However,	 the	 vast	 majority	 of	 the	 research	 has	 focused	 on	 expanding	 or	
genetically	modifying	T	lymphocytes,	which	is	what	we	detail	in	this	chapter.	
4.4.1. Tumour	infiltrating	lymphocytes	
As	it	was	previously	mentioned,	tumours	are	usually	infiltrated	with	tumour-specific	CD8+	T	
lymphocytes	 (TILs).	 However,	 due	 to	 the	 chronic	 exposure	 as	 well	 as	 the	
immunosuppressive	 environment,	 these	 T	 cells	 are	 exhausted	 and	 hence	 functionally	
impaired.	 Researchers	 sought	 to	 isolate	 those	 TILs	 and	 expand	 them	 in	 vitro,	 aiming	 to	
artificially	 increase	 their	 total	 number,	 and	 to	 reactivate	 them	away	 from	 the	deleterious	
cancer	environment.	This	allows	the	T	cells	to	retrieve	their	functionality	by	providing	them	
with	the	appropriate	inflammatory	signals.	After	in	vitro	expansion,	the	lymphocytes	can	be	
re-infused	 into	 the	 circulation	 via	 an	 intravenous	 injection,	 usually	 after	 the	 patient	 has	
been	 pre-treated	 with	 chemotherapy	 or	 irradiation	 to	 induce	 lymphodepletion.	 This	
technique	proved	very	successful	for	metastatic	melanoma,	where	22%	of	patients	receiving	
TILs	 after	 ex	 vivo	 expansion,	 in	 combination	 with	 lymphodepletion,	 reached	 complete	
response173.	
Unfortunately,	this	method	can	only	be	applied	for	the	kind	of	tumours	that	are	reasonably	
well	 infiltrated	 by	 TILs.	 Additionally,	 some	 tumours	 are	 simply	 not	 accessible	 to	 surgical	
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resection.	Moreover,	as	previously	discussed,	tumours	have	been	edited	to	express	antigen	
of	 low	 immunogenicity,	 which	 means	 that	 the	 retrieved	 TILs	 might	 not	 have	 an	 optimal	
affinity	 to	 the	 tumour	antigens.	Hence,	 researchers	aimed	 to	genetically	modify	T	 cells	 to	
redirect	them	against	the	tumour	with	high	affinity.	
4.4.2. TCR-transgenic	T	cells	
It	was	sought	to	use	lymphocytes	from	peripheral	blood,	as	they	are	more	easily	accessible.	
These	cells	can	be	genetically	modified	to	enforce	the	expression	of	a	tumour	T	cell	receptor	
(TCR)	 specific	 for	 a	 tumour	antigen.	 Such	 receptors	 are	 isolated	either	 from	patients	who	
happen	 to	 have	 a	 high	 affinity	 CD8+	 T	 cell	 clone	 against	 a	 shared	 antigen,	 or	 sometimes	
from	mouse	model.	Retro-	or	lentiviruses	are	often	used	as	a	way	to	insert	genetic	material	
into	the	cells	and	induce	the	expression	of	the	new	receptor174.	There	are	drawbacks	in	this	
method.	 Firstly	 different	 human	 leukocyte	 antigen	 (HLA)	 types	 exist	 amongst	 the	
population,	 and	 each	 TCR	 is	 compatible	 only	with	 a	 certain	HLA	 type.	 Secondly,	 TCRs	 are	
composed	 of	 2	 chains,	 and	 hence	 mispairing	 between	 one	 of	 the	 newly	 introduced	 TCR	
chains	 and	 the	 complementary	 endogenous	 TCR	 chain	 can	occur	 and	prevent	 the	 correct	
expression	 of	 the	 tumour-specific	 TCR.	 Thirdly,	 like	 naturally	 occurring	 T	 cells,	 TCR-	
engineered	T	cells	depend	on	the	expression	of	the	peptide-MHC	complex	at	the	surface	of	
the	tumour	for	their	activity.	
4.4.3. Chimeric	antigen	receptors	
To	 solve	 these	 issues,	 chimeric	 antigen	 receptors	 were	 created.	 These	 receptors	 do	 not	
occur	naturally	and	are	composed	of	two	parts.	The	extracellular	domain	comprises	the	scFv	
of	 an	 antibody	 specific	 for	 an	 extracellular	 tumour	 antigen	 and	 is	 fused	 the	 intracellular	
CD3ζ	 signalling	 domain,	 as	well	 as	 one	or	more	 costimulatory	 domains	 depending	 on	 the	
CAR	 generation	 (see	 Figure	 13).	 It	 was	 observed	 that	 the	 addition	 of	 the	 costimulatory	
domain	could	efficiently	compensate	the	fact	that	tumour	cells	generally	do	not	express	the	
appropriate	 costimulatory	 ligands175.	 The	 expression	 of	 a	 CAR	 on	 the	 surface	 of	 a	
lymphocyte	allows	for	direct	recognition	of	a	non-processed	antigen	on	the	surface	of	the	
tumour,	 thus	 avoiding	 the	 issue	of	MHC	 class	 I	 expression.	Moreover,	 proteins	 as	well	 as	
carbohydrates	and	glycolipids	can	be	recognized	by	CARs,	which	expands	the	list	of	possible	
targets176.		
The	excitement	around	CARs	grew	strong	when	the	results	of	a	pilot	clinical	trial	conducted	
by	 Carl	 June	 were	 published	 in	 2011.	 Out	 of	 three	 advanced	 leukemia	 patients,	 2	 had	 a	
complete	response	and	the	last	one	a	partial	response177.		Since	then,	more	than	20	clinical	
trials	have	been	 launched	and	published,	and	 showed	great	promise	 for	 the	 treatment	of	
leukemia	 and	 other	 haematologic	 malignancies178.	 The	 adoptively	 transferred	 cells	 were	
targeting	the	antigen	CD19,	which	is	expressed	by	leukemic	cells	but	also	by	normal	B	cells.	
A	 successful	 anti-CD19	 CAR	 treatment	 is	 thus	 always	 accompanied	 by	 a	 long	 term	 B	 cell	
aplasia.	 Targeting	 solid	 tumours	 via	 CAR	 therapy	 proved	more	 challenging	 and	 didn’t	 yet	
yield	 such	 outstanding	 results	 as	 for	 leukemias178.	 A	 hurdle	 in	 the	 development	 of	 CAR	 T	
cells	against	solid	tumours	was	the	selection	of	the	appropriate	antigen	to	avoid	on-target	
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off-tumour	toxicity.	A	publication	from	2010	reported	that	a	metastatic	colon	cancer	patient	
succumbed	after	treatment	with	CAR	T	cells	redirected	against	HER2	using	the	scFv	of	the	
monoclonal	 antibody	 trastuzumab.	 CAR	T	 cells	were	 able	 to	 recognize	HER2	expressed	 at	
low	levels	in	the	lung	and	induced	a	lethal	pulmonary	oedema179.	A	way	to	better	manage	
the	sensitivity	of	CAR	T	cells	to	tumour	antigens,	and	avoid	the	recognition	of	 low	antigen	
expression	might	 be	 to	modulate	 and	 lower	 the	 affinity	 of	 the	 scFv	 to	 its	 ligand.	 In	 their	
recent	 publication,	 Liu	et.	 al.	 showed	 that	 reducing	 the	 anti-HER2	 scFv	 affinity	 prevented	
recognition	 of	 tumours	 expressing	 physiologic	 levels	 of	 the	 target	 without	 affecting	 the	
ability	of	CAR	T	cells	to	lyse	tumours	overexpressing	HER2180.	
4.5. Combination	therapy:	
All	the	previously	mentioned	approaches	function	via	different	pathways	and	effector	cells	
to	 redirect	 the	 immune	 system	 against	 the	 tumour.	 To	 increase	 further	 the	 efficiency	 of	
treatments,	 current	 approaches	 are	 seeking	 to	 combine	 different	 treatments	 and	 hence	
augment	the	overall	efficiency.	For	example,	the	efficiency	of	a	whole	cell	cancer	vaccine	in	
preclinical	model	of	melanoma	was	 improved	to	50%	rejection	using	co-inhibition	of	both	
aCTLA-4	 and	 aPD-1,	 compared	 to	 10%	 and	 25%	 when	 immune	 checkpoints	 were	
administered	 individually.	 In	 a	 similar	 manner,	 combining	 a	 vaccine	 comprising	 GM-CSF	
transduced	 whole	 tumour	 cells	 with	 co-blockade	 of	 CTLA-4	 and	 PD-1	 proved	 the	 most	
efficient	for	two	different	mouse	tumour	models181.	Similarly,	combining	immunotherapies	
and	tumour-targeted	drugs	is	an	approach	that	shows	great	promises,	as	both	methods	can	
synergistically	improve	the	efficiency	of	each	other182.	
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Figure	13:	First,	second	and	third	CAR	generations	incorporate	respectively	none,	one	or	
two	co-stimulatory	domains	in	their	intracellular	moiety	
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Overall,	many	different	 cancer	 immunotherapies	exist	 and	have	 shown	promise	 in	 clinical	
trials.	Although	 this	 field	 is	 relatively	new,	 there	 is	 a	 strong	 interest	 in	 further	developing	
existing	therapies,	and	hopefully	increasing	the	life	expectancy,	as	well	as	quality	of	life,	of	
cancer	patients.		
The	work	 presented	 in	 this	 thesis	 aims	 to	 improve	 the	 understanding	 of	 the	 role	 of	 two	
microRNAs,	 miR-17-92	 and	 miR-155	 in	 the	 functionality	 of	 CD8+	 T	 cells.	 Moreover,	 we	
sought	to	harness	miR-155	overexpression	to	improve	adoptive	cell	transfer	of	CD8+	T	cells	
for	cancer	treatment.	
	 	
	45	
General	aims:	
Immunotherapies	 have	been	named	 “breakthrough	of	 the	 year”	 by	 the	 journal	 science	 in	
2013,	in	particular	because	of	the	successes	of	checkpoint	blockade	inhibitors	and	adoptive	
transfer	 of	 T	 lymphocytes.	 The	 second	 method	 consists	 in	 reinfusing	 a	 patient’s	 own	
immune	cell,	after	expansion	and	sometimes	genetic	modification.	Although	this	technique	
is	very	potent	in	the	case	of	melanoma	and	hematologic	cancers,	it	has	been	less	successful	
for	solid	tumours.	
It	is	known	that	CD8+	T	cells	are	important	for	tumour	regression,	as	their	infiltration	in	solid	
tumours	 can	 generally	 predict	 a	 better	 outcome	 for	 the	 patient.	 However,	 it	 is	 not	 fully	
understood	what	 are	 the	 factors,	 in	 addition	 to	 quantity,	which	 can	 drive	 a	more	 potent	
CD8+	T	cell	anti-cancer	response.	Understanding	which	genes	should	be	expressed	to	turn	T	
cells	into	potent	anti-tumour	agent,	is	critical.	Indeed,	once	the	genetic	profile	of	the	perfect	
antitumour	 effector	 T	 cell	 is	 known,	 it	 would	 be	 possible	with	 the	 current	 technology	 to	
force	the	expression	of	said	genes	and	consequently	to	harness	the	power	of	T	cells	and	use	
it	in	the	immunotherapy	of	cancer.	
MicroRNAs	are	attractive	candidates	for	genetic	modification	and	modulation,	as	they	can	
rapidly	 downregulate	 the	 expression	 of	 several	 proteins.	 This	 allows	 one	 microRNA	 to	
simultaneously	 target	 different	 pathways.	 Since	 it	 might	 be	 necessary	 to	 change	 the	
expression	 of	 several	 genes	 in	 order	 to	 turn	 T	 cells	 into	 strong	 effectors,	modulating	 the	
expression	of	microRNAs	has	recently	attracted	a	lot	of	attention.	
In	 our	 research,	 we	 focused	 on	 the	 function	 of	 one	 microRNA	 cluster	 and	 one	 single	
microRNA,	 miR-17-92	 and	 miR-155.	 Both	 of	 them	 are	 upregulated	 upon	 CD8+	 T	 cells	
activation,	which	could	indicate	an	important	role	for	CD8+	T	cells	effector	functions.	
Our	 aim	 is	 to	 study	 and	 understand	 the	 role	 of	 both	 of	 these	microRNAs	 in	 the	 CD8+	 T	
effector	response.	Moreover,	to	demonstrate	the	potency	of	modulating	the	expression	of	
these	 microRNAs	 in	 CD8+	 T	 cells	 to	 improve	 antitumour	 efficiency.	 Finally,	 we	 will	
investigate	 the	possibility	of	 combining	 the	expression	of	a	chimeric	antigen	 receptor	and	
the	overexpressionf	of	a	microRNA.	
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Thesis	work:	
• Chapter	I:	The	miR-17-92	cluster	regulates	naïve	T	cell	
homeostasis	as	well	as	effector	and	memory	differentiation	
• Chapter	II:	Overexpression	of	miR-155	in	OT-1	cells	enhances	
their	responsiveness	to	low	affinity	antigen	
• Chapter	III:	Overexpression	of	miR-155	in	anti-PSMA	CAR+	
CD8+	T	cells	
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Chapter	 I:	 The	 miR-17-92	 cluster	 regulates	
naïve	 T	 cell	 homeostasis	 as	 well	 as	 effector	
and	memory	differentiation	
1. Aim:		
This	project	was	 initiated	when	 the	 information	on	 the	 role	of	 the	miR-17-92	 cluster	was	
limited	in	CD8+	T	cells.	At	the	time,	miR-17-92	was	found	to	be	upregulated	in	effector	CD8+	
T	cells,	and	downregulated	in	memory	CD8+	T	cells62,	but	its	role	was	still	undetermined.	
The	aim	of	 this	project	was	to	dissect	 the	roles	of	 the	miR-17-92	cluster,	 in	 terms	of	both	
regulation	of	the	antigen-driven	CD8+	T	cell	response,	and	CD8+	T	cells	homeostasis.	
2. Results:	
MiR-17-92	is	important	for	CD8+	T	cell	homeostatic	survival	and	expansion	
Mice	expressing	 the	CD4-CRE	 transgene	were	crossed	 to	mice	bearing	a	 floxed	miR-17-92	
allele.	The	resulting	homozygous	fl/fl	animals	expressing	the	CRE	transgene	(17-92-/-)	were	
used	 to	 study	 the	 effect	 of	 the	 absence	 of	 miR-17-92	 in	 CD8+	 T	 cells.	 This	 strained	 was	
crossed	to	the	OT-1	strain,	to	study	the	antigen-specific	effect	of	the	absence	of	miR-17-92.	
Animals	 from	both	17-92-/-	 and	OT-1	 x	17-92-/-	 strains	were	apparently	healthy	and	had	a	
normal	life	expectancy.	However,	when	the	numbers	and	percentages	of	peripheral	CD8+	T	
cells	 were	 assessed,	 a	 significant	 decrease	 was	 measured	 compared	 to	 the	 WT	 controls	
(Figure	14A).	To	confirm	that	this	decrease	was	intrinsic	to	the	CD8+	T	cells,	and	that	there	
was	no	bias	of	other	CD4-expressing	cell	types,	bone	marrow	chimera	mice	were	generated.	
CD45.1	wildtype	mice	were	lethally	irradiated	and	their	immune	system	was	reconstructed	
with	a	1:1	mix	of	WT	CD45.1/2	and	17-92-/-	CD45.2	bone	marrow	(Figure	14B).	The	ratio	of	
KO/WT	 cells	 was	 then	 assessed	 in	 blood	 and	 lymphoid	 organs	 2	 months	 post	 transfer.	
Firstly,	to	verify	that	the	graft	efficiency	was	similar	for	cells	from	the	CD45.1/2	or	CD45.2	
hosts,	the	ratio	of	B220+	cells	from	both	congenic	markers	was	measured.	Since	B	cells	do	
not	express	CD4,	miR-17-92	should	not	be	deleted	in	this	subtype	and	they	should	behave	
as	wildtype	CD45.1/2	B	cells.	Indeed,	the	ratio	of	B220	cells	from	both	hosts	was	1,	showing	
that	 the	 engraftement	 efficiency	 of	 lymphocyte	 precursors	 was	 similar	 (Figure	 14C).	 We	
then	 measured	 the	 ratio	 of	 cells	 expressing	 CD45.2:CD45.1/2	 in	 the	 CD4	 and	 CD8	
compartment,	in	which	miR-17-92	should	be	deleted.	The	amount	of	CD45.2+	cells	in	these	
2	compartments	was	strongly	decreased	in	the	blood,	as	well	as	in	the	inguinal	lymph	nodes	
and	the	spleen	(Figure	14C).	This	result	shows	that	the	reduced	homeostatic	levels	of	CD8+	
T	 cells	were	an	 intrinsic	effect	of	 the	absence	of	miR-17-92.	 Finally,	 to	assess	 the	 survival	
potential	 of	 CD8+	 miR-17-92-/-	 T	 cells,	 we	 collected	 splenocytes	 of	 the	 bone	 marrow	
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chimeras	mice,	and	cultured	them	in	vitro.	When	cultured	with	IL-7,	these	cells	did	as	well	
as	their	wildtype	counterparts	–	the	ratio	stayed	stable	at	1:5.	However,	 in	the	absence	of	
IL-7	miR-17-92-/-	 T	 cells	were	not	able	 to	 survive	 like	 the	WT	T	cells	and	 the	 ratio	 sank	 to	
1:100	(Figure	14D).	This	suggests	that	miR-17-92-/-	T	cells	are	impaired	in	their	resistance	to	
cytokine	depletion.	
	
Figure	14:	 (A)	The	number	and	percentages	of	CD8+	positive	T	cells	was	measured	by	 flow	cytometry	 in	 the	blood	of	
miR-17-92-/-	(KO)	mice	compared	to	age	and	sex-matched	wildtype	(WT)	mice.	(B)	Bone	marrow	chimeras	were	made,	by	
reconstituting	irradiated	CD45.1	mice	with	a	1:1	mix	of	WT	CD45.1/2	and	KO	CD45.2	bone	marrow.	(C)	2	months	after	
reconstitution,	percentages	of	B220+,	CD4+	and	CD8+	cells	in	the	blood,	spleen	and	lymph	nodes	were	assessed	via	flow	
cytometry.	 The	 ratio	 of	 CD45.1/2:CD45.2	 percentages	were	 plotted	 for	 each	 organ	 and	 cell	 subtype.	 (D)	 Splenocytes	
from	2-3	months	old	bone	marrow	chimera	mice	were	plated	with	IL-2,	supplemented	or	not	with	IL-7.	The	ratio	of	miR-
17-92-/-	KO:WT	was	measured	by	flow	cytometry	3,	5	and	7	days	after	the	start	of	the	culture.	Data	presented	are	from	
one	representative	experiment	out	of	2	or	3	independent	experiments.	 
To	understand	if	the	difference	in	the	amount	of	CD8+	T	cells	in	the	periphery	was	due	to	a	
defect	at	the	thymus	level	(development	and/or	egress),	or	in	the	homeostatic	persistence,	
splenocytes	were	isolated	and	injected	into	RAG2-/-	recipients	(Figure	15A).	Since	these	mice	
do	not	have	any	mature	T	cells,	transferred	T	cells	will	undergo	homeostatic	proliferation	to	
fill	 the	 T	 cell	 compartment.	 A	 mixture	 of	 WT	 and	 17-92-/-	 splenocytes	 were	 injected	
intravenously	at	a	1:1	ratio.	After	one	week,	the	ratio	had	decreased	to	1:5	KO:WT	CD8+	T	
cells	 in	the	blood	of	the	RAG-/-	mice	(Figure	15B).	This	demonstrates	that	the	ability	of	the	
17-92-/-	 to	 undergo	 homeostatic	 proliferation	 is	 decreased.	 However,	 although	 the	 ratio	
decreased	a	bit	more	in	the	following	weeks,	miR-17-92	KO	CD8+	T	cells	were	able	to	survive	
for	 long	periods	of	 time,	as	 they	were	 still	present	52	days	after	 transfer.	These	 surviving	
cells	 had	 a	more	 naive	 phenotype	 (CD62Lhigh	 CD44low)	 compared	 to	WT	CD8+	 T	 cells	 that	
were	more	effector	like	(CD62Llow	CD44high)	(Figure	15C).	
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Absence	of	miR-17-92	impairs	CD8+	T	cells	proliferation	upon	stimulation	
To	confirm	the	reduced	ability	of	miR-17-92-/-	CD8+	T	cells	to	get	activated	and	proliferate,	
we	 CFSE-labelled	 T	 cells	 and	 cultured	 them	 with	 5µg/ml	 plate-bound	 CD3	 and	 2µg/ml	
soluble	 CD28.	 After	 48	 hours,	 the	 WT	 CD8+	 T	 cells	 had	 undergone	 2	 to	 3	 rounds	 of	
proliferation,	while	the	miR-17-92-/-	CD8+	T	cells	had	barely	started	replicating	(Figure	16A).	
Moreover,	the	accumulation	of	miR-17-92-/-	CD8+	T	cells	upon	viral	 infection	was	impaired	
as	well.	MiR-17-92-/-	and	WT	mice	were	infected	with	200	plaque	forming	unit	(PFU)	LCMV	
and	the	percentage	of	blood	CD8+	T	cells	was	measured	before	the	 infection,	as	well	as	6	
and	8	days	 after	 (Figure	16B).	Both	 the	percentage	and	absolute	numbers	of	miR-17-92-/-	
CD8+	T	cells	were	diminished	at	the	peak	of	the	infection	(day	8,	Figure	16C).		Although	miR-
17-92-/-	CD8+	T	cells	were	not	able	to	expand	to	the	same	levels	as	WT,	they	did	manage	to	
control	the	viral	load,	as	shown	by	similar	numbers	of	PFU/spleen	between	KO	and	WT	mice	
at	day	8	of	infection	(Figure	16D).	
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Figure	 15:	 (A)	 Splenocytes	 from	 the	 miR-17-92-/-	 mice	 or	 WT	 controls	 were	 mixed	 at	 a	 1:1	 ratio	 and	 transferred	
intravenously	 into	 RAG2	 KO	 hosts.	 (B)	 The	 ratio	 of	 KO:WT	 cells	 in	 the	 CD8	 compartement	 was	 assessed	 via	 flow	
cytometry	7,	13,	28	and	52	days	after	the	transfer	in	the	blood	of	the	RAG2	KO	mice.	(C)	4	weeks	after	the	transfer,	the	
phenotype	of	the	CD8+	T	cells	WT	or	miR-17-92-/-	was	measured	by	flow	cytometry	via	the	surface	exrpression	of	CD62L	
and	CD44	on	 the	 surface	 of	 the	 cells.	 Data	presented	 are	 from	one	 representative	 experiment	out	of	 2	 independent	
experiments.	
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Figure	16:	(A)	CFSE-labelled	CD8+	T	cells	were	stimulated	with	αCD3/αCD28	in	vitro	and	CFSE	dilution	was	measured	by	
FACS	2	days	after	stimulation.	(B)	Percentages	of	CD8+	T	cells	were	assessed	in	the	blood	of	WT	and	miR-17-92-/-	mice	
before	and	6	and	8	days	after	LCMV	infection.	(C)	Numbers	of	CD8+	T	cells	at	day	8	of	LCMV	infection	were	measured	in	
the	 blood	 of	WT	 and	miR-17-92-/-	mice.	 (D)	 Plaque	 forming	 assay	 allowed	 to	 determine	 the	 viral	 load	 per	 spleen	 of	
infected	mice	7	days	after	infection.	Data	presented	are	from	one	representative	experiment	out	of	2	or	3	independent	
experiments.	
Absence	of	miR-17-92	impairs	effector	functions	of	CD8+	T	cells	
Three	months	after	LCMV	infection,	the	mice	were	sacrificed,	and	splenocytes	were	isolated	
to	 assess	 the	 functionality	 of	 memory	 CD8+	 T	 cells.	 Splenocytes	 were	 restimulated	 with	
either	plastic-coated	αCD3	and	soluble	αCD28	or	a	mix	of	LCMV-specific	peptides.	After	5	
hours	of	 co-incubation,	 cytokines	were	 stained	 for	 intracellular	 cytokines	and	analysed	by	
flow	 cytometry.	 The	 percentages	 of	 IFN-γ-producing	 cells	 amongst	 the	 total	 CD8+	 T	 cells	
population	 was	 decreased	 in	 miR-17-92-/-	 mice	 compared	 to	 WT,	 in	 both	 antibody-	 or	
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Figure	17:	After	5	hours	of	stimulation	with	either	αCD3	and	αCD28	antibody	or	LCMV-specific	peptides,	IFN-γ	
and	TNFα	were	stained	intracellularly	in	either	WT	or	miR-17-92-/-	(KO)	CD8+	T	cells.	The	percentages	of	IFN-γ+	
(left	 panel)	 and	 IFN-γ	 and	TNFα	double	positive	 cells	 (right	panel)	were	measured	 by	 flow	 cytometry.	Data	
presented	are	from	one	representative	experiment	out	of	2	independent	experiments.	
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peptide-mediated	 stimulation	 (Figure	 17	 left	 panel).	 Moreover,	 the	 percentages	 of	
polyfunctional	T	cells	(producing	both	IFN-γ	and	TNFα),	was	also	decreased	(Figure	17	right	
panel).	 	 This	 demonstrated	 impaired	 effector	 functions	 in	 CD8+	 T	 cells	 in	 the	 absence	 of	
miR-17-92.	
Absence	of	miR-17-92	intrinsically	prevents	CD8+	T	cells	accumulation	upon	listeria	
infection	and	promotes	a	central	memory	phenotype	
Since	 the	 promoter	 driving	 CRE	 expression	 and	 miR-17-92	 deletion	 is	 CD4,	 all	 cells	 that	
express	CD4	will	become	knock-out	for	the	miR-17-92	cluster.	This	includes	T	cells	but	also	
some	DCs,	B	cells	and	granulocytes.	To	confirm	that	the	decreased	cell	expansion	was	CD8+	
T	 cell	 intrinsic,	 and	 to	 compare	 WT	 and	 KO	 cells	 in	 a	 competitive	 environment,	 we	 co-
transferred	OT-1	miR-17-92-/-	and	WT	CD8+	T	cells	into	congenically	different	WT	hosts.	OT-
1	CD8+	T	cells	are	transgenic	for	the	Vα2	and	Vβ5	TCR	chains	which	makes	them	specific	for	
the	 SIINFEKL,	 a	 peptide	derived	 from	 the	ovalbumin	protein	 (OVA).	After	 the	 intravenous	
transfer	of	50’000	WT	and	KO	OT-1	CD8+	T	cells	at	a	1:1	 ratio,	mice	were	 infected	with	a	
1’000CFU	dose	of	a	strain	of	L.	monocytogenes	expressing	the	OVA	protein	(Lm-OVA).	The	
transferred	cells	could	be	discriminated	thanks	to	the	CD45.1	and	CD45.2	congenic	marker.	
The	ratio	between	KO	and	WT	cells	was	measured	7,	13	and	28	days	after	listeria	infection.	
Although	the	initial	ratio	was	1:1,	 it	subsequently	dropped	to	1:10	miR-17-92-/-:WT	CD8+	T	
cells,	showing	that	the	ability	of	miR-17-92-/-	CD8+	T	cells	to	accumulate	in	response	to	an	
infection	was	indeed	reduced	compared	to	WT	OT-1	cells	(Figure	18	A).		However,	the	ratio	Phenotype of OT-1 cells 4 weeks
after listeria challenge
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Figure	18:	(A)	WT	or	miR-17-92-/-	(KO)	cells	were	cotransferred	into	WT	animals	at	a	1:1	ratio.	Mice	
were	subsequently	infected	with	OVA-expressing	L.monocytogenes	(listeria-OVA).	The	ratio	of	
transferred	WT	was	measured	7,	13	and	28	days	after	infection.	(B)	The	phenotype	of	the	
transferred	OT-1	cells	was	evaluated	in	terms	of	CD127	and	KLRG1	expression	4	weeks	after	listeria	
infection.	(C)	Representative	FACS	plot	of	CD127	and	KLRG1	of	OT-1	cells	(left	panel)	WT	or	(right	
panel)	miR-17-92	KO	4	weeks	after	listeria	infection.	Data	presented	are	from	one	representative	
experiment	out	of	2	independent	experiments.	
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was	 stably	 maintained	 until	 28	 days	 after,	 which	 indicated	 that	 KO	 cells	 are	 capable	 of	
forming	 long-lived	memory	cells.	As	a	confirmation,	 the	phenotype	of	miR-17-92-/-	CD8+	T	
cells	was	skewed	towards	a	more	central	memory	phenotype	as	compared	to	WT	cells	four	
weeks	after	infection	(Figure	18	B	and	C).	
3. Discussion:	
In	this	first	chapter,	we	set	out	to	understand	the	importance	of	the	miR-17-92	cluster	for	
CD8+	T	cells	homeostasis	and	response	to	infection.	
A	publication	from	Salaun	et.	al.	firstly	identified	the	microRNAs	from	the	miR-17-92	cluster	
as	some	of	the	highest	expressed	in	CD8+	T	cells62.	Moreover,	the	dynamic	regulation	of	this	
microRNA	cluster	was	found	to	be	upregulated	at	the	effector	function,	and	downregulated	
during	the	memory	phase95,96.	Interestingly,	different	microRNAs	in	the	cluster	did	not	have	
exactly	 the	same	 levels	of	expression	at	 the	mature	microRNA	 level,	 showing	 intra-cluster	
differences	in	the	processing	efficiency,	and/or	half-life96.	
To	understand	the	importance	of	this	cluster	for	the	functionality	of	CD8+	T	cells,	we	used	a	
CD4-CRE	x	miR17-92	LoxP	mouse	model,	to	delete	miR-17-92	specifically.	We	found	that	the	
absence	 of	 miR-17-92	 hindered	 the	 homeostatic	 persistence	 and	 proliferation	 of	 CD8+	 T	
cells.	Moreover,	upon	activation,	their	ability	to	proliferate	as	well	as	to	produce	cytokines	
was	impaired.	Finally,	miR-17-92-/-	CD8+	T	cells	had	a	more	central	memory	phenotype	than	
their	wild	type	counterparts	and	could	persist	for	long	periods	of	time.	
We	 firstly	observed	 that	 there	was	a	decrease	 in	 the	percentage	and	numbers	of	CD8+	T	
cells	in	the	periphery	of	miR-17-92-/-	mice,	compared	to	WT	B6	mice.	We	also	showed	that	
this	difference	was	 intrinsic	by	creating	bone	marrow	chimera	mice.	 Indeed,	although	 the	
miR-17-92	was	CD4-specific,	several	subsets	of	cells	express	CD4	and	would	become	miR-17-
92	 knock-out.	 This	 is	 true	 for	 CD4+	 and	 CD8+	 T	 cells,	 which	 become	 KO	 at	 the	 double	
positive	 stage	 but	 also	 other	 cell	 types	 such	 as	 dendritic	 cells	 and	monocytes.	 The	 bone	
marrow	chimera	allowed	showing	that	in	a	wild	type	environment,	the	amount	of	miR-17-
92-/-	CD4+	and	CD8+	cells	was	decreased	at	homeostasis.	
Another	group	using	the	same	model	of	CD4-CRE,	miR-17-92	LoxP	to	study	the	deletion	of	
miR-17-92	in	CD4	T	cells	did	not	report	such	a	decrease,	whether	in	CD4	or	in	CD8.	However,	
they	did	not	explicitly	show	equal	numbers	at	homeostasis183.	Moreover,	in	another	study,	
mice	reconstituted	with	miR-17-92-/-	bone	marrow	were	shown	to	have	decreased	numbers	
of	B	cells	in	the	periphery,	but	no	difference	in	the	numbers	of	lymphocytes85.	These	results	
contrast	with	our	findings.	To	confirm	that	the	effect	we	saw	was	indeed	due	to	the	deletion	
of	the	miR-17-92	cluster	and	not	to	our	model,	it	would	be	best	to	repeat	the	experiments	
using	different	controls.	Firstly,	amounts	of	single	positive	CD8+	T	cells	in	the	periphery,	in	
terms	of	numbers	and	percentages,	can	vary	from	one	strain	to	another.	Hence,	it	would	be	
preferable	 to	 use	 CRE-	 littermate	 as	 WT	 controls	 instead	 of	 WT	 mice	 from	 a	 different	
breeding.	 However,	 this	 was	 not	 possible	 as	 the	 strain	 we	 used	 was	 CRE	 homozygous.	
Secondly,	 a	 study	 published	 in	 2012	 demonstrated	 that	 using	 the	 CD4	 promoter	 for	 CRE	
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expression	 induces	 satisfying	 levels	 of	 gene	 deletion	 and	 marginal	 toxicity	 when	
hemizigously	expressed.	However,	 possessing	2	 copies	of	 the	CD4-CRE	 transgene	 reduced	
the	 amount	 of	 thymic	 cellularity	 by	 20%184.	 Unfortunately,	 there	 is	 a	 possibility	 that	 the	
expression	 of	 the	 CRE	 transgene	 would	 have	 affected	 the	 outcome	 of	 our	 experiments,	
which	is	why	a	confirmation	using	a	different	model,	such	as	CD4-CRE	hemizigous	and	CRE+	
LoxP-	controls	would	be	desirable.	
We	observed	that	miR-17-92-/-	were	impaired	in	their	ability	to	proliferate	in	the	absence	of	
stimulation,	 in	 RAG2	 KO	 mice.	 This	 might	 be	 due	 to	 an	 impairment	 of	 the	 cells	 to	
differentiate	 into	 effector/effector-memory	 cells.	 Indeed,	 it	 was	 shown	 that	 CD4	 T	 cells	
undergoing	homeostatic	proliferation	upregulate	 the	CD44	marker	and	adopt	an	effector-
memory-like	phenotype185.	In	our	model,	we	observed	that	miR-17-92-/-	CD8+	T	cells	did	not	
upregulate	 CD44	 and	 kept	 a	 high	 expression	 of	 CD62L,	 which	 is	 a	 naïve	 phenotype.	
Moreover,	 it	 was	 shown	 that	 overexpression	 of	 miR-17-92	 skews	 CD8+	 T	 cells	 towards	
terminal	effectors95.	Hence,	upregulation	of	the	miR-17-92	cluster	during	the	effector	phase	
might	be	necessary	for	the	differentiation	of	CD8+	T	cells.	
We	saw	that	miR-17-92-/-	CD8+	T	cells	were	 impaired	 in	 their	ability	 to	proliferate	 in	vitro	
and	 in	 vivo	 upon	 infection	with	 LCMV	or	 Lm-OVA.	 This	 reflects	 the	 findings	 of	 two	 other	
groups	which	used	the	granzymeB-CRE	miR-17-92	LoxP	model	and	observed	a	decrease	 in	
the	 accumulation	 of	miR-17-92-/-	 CD8+	 T	 cells	 upon	 LCMV	 infection95,96.	 In	 contrast,	 they	
showed	 that	 overexpression	 of	miR-17-92	 in	 CD8+	 T	 cells	 increased	 the	 proliferation	 and	
accumulation	 at	 the	 peak	 of	 the	 infection	 and	 induced	 terminal	 differentiation,	 hence	
impairing	the	formation	of	memory	cells95.	In	CD4+	T	cells,	deletion	of	the	miR-17-92	cluster	
increased	 the	sensitivity	of	 the	cells	 to	activation-induced	cell	death183.	 In	our	 in	vivo	 two	
models	 of	 infection,	 it	 would	 be	 interesting	 to	 better	 discriminate	 between	 impaired	
proliferation	 or	 reduced	 survival	 by	 performing	 a	 BrdU	 incorporation	 experiment	 and	 by	
assessing	apoptosis	regulators	such	as	BCL-2	and	Bim.	
Although	the	accumulation	of	miR-17-92-/-	CD8+	T	cells	was	decreased,	some	cells	were	able	
to	 persist	 for	 long	 periods	 of	 time	 as	we	 could	 detect	 CD8+	 T	 cells	 4	weeks	 after	 listeria	
infection	 and	 3	 months	 after	 LCMV	 infection.	 These	 cells	 were	 mostly	 of	 the	 memory	
phenotype	CD127high	KLRG1low.	However,	they	did	not	respond	efficiently	to	restimulation.	
Indeed,	 there	 was	 a	 2-fold	 decrease	 in	 the	 percentage	 of	 miR-17-92-/-	 CD8+	 T	 cells	
expressing	 IFN-γ.	 This	 corresponds	 to	 previous	 finding,	 as	 Wu	 et.	 al.	 also	 observed	 a	
decrease	in	cytokine	production	upon	miR-17-92	deletion	in	CD8+	T	cells95.	
One	possible	way	in	which	the	absence	of	miR-17-92	might	increase	the	differentiation	into	
memory	 cells,	 is	 by	 its	 targeting	 of	 the	 protein	 PTEN.	 Indeed,	 PTEN	mRNA	 contains	 sites	
complementary	 to	 the	 seed	 sequence	 of	 5	 of	 the	 cluster’s	 microRNAs95.	 PTEN	 is	 a	
suppressor	of	 the	mTOR	pathway,	and	 it	was	shown	that	 interfering	with	mTOR	signalling	
via	Rapamycin	treatment	 induced	a	stronger	CD8+	T	cell	memory	differentiation186.	 In	 the	
absence	of	miR-17-92,	 the	mTOR	pathway	might	be	decreased.	To	confirm	 this,	we	could	
quantify	the	amount	of	phosphorylated	S6,	a	ribosomal	protein	phosphorylated	upon	mTOR	
signalling.	
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Overall,	 we	 show	 that	 miR-17-92	 is	 a	 crucial	 microRNA	 cluster	 for	 the	 differentiation	 of	
CD8+	T	 cells	 into	effector	 cells,	 and	 their	 clonal	expansion.	The	absence	of	 this	microRNA	
induced	CD8+	T	cells	to	adopt	a	more	memory	phenotype,	but	decreased	their	functionality.	
Although	overexpression	of	this	microRNA	was	proven	to	drive	CD8+	T	cells	towards	a	more	
terminal	effector	phenotype,	and	prevented	their	 long	term	survival95,	 the	combination	of	
miR-17-92	overexpression	and	CAR	transduction	 in	a	human	xenograft	mouse	model	gave	
promising	 antitumour	 results97.	 Hence	 miR-17-92	 seems	 to	 be	 a	 promising	 target	 for	
immunotherapy.	
Overexpression	 of	 miR-17-92	 has	 to	 this	 date	 not	 been	 implemented	 in	 an	 autologous	
tumour	 graft	model.	 It	would	 be	 interesting	 to	 test	 the	 antitumour	 efficiency	 of	 tumour-
specific	 mouse	 CD8+	 T	 cells	 overexpressing	 miR-17-92.	 Moreover,	 since	 miR-17-92	
modulates	 the	 memory	 phenotype	 of	 CD8+	 T	 cells,	 it	 might	 be	 interesting	 to	 try	 to	
downregulate	its	expression	with	an	antagomiRs,	at	different	timepoints	after	activation.	It	
has	been	shown	that	different	microRNAs	in	the	cluster	are	differentially	regulated	and	have	
sometimes	 opposing	 functions90.	 Hence,	 it	 might	 be	 interesting	 to	 try	 to	 target	 or	
overexpress	individual	microRNAs,	to	fine-tune	the	cluster’s	function.	
While	 researching	 this	 subject,	we	were	simultaneously	working	on	a	project	on	miR-155,	
which	gave	promising	results.	The	miR-17-92	was	subsequently	dropped	which	explains	why	
some	important	experiments	have	to	this	day	not	been	performed.		
4. Methods:	
4.1. Mouse	strains	
MiR-17-92fl/fl	mice	from	the	C57BL/6J	strain	were	purchased	from	Jackson	Laboratory,	and	
crossed	 to	 a	 CD4-CRE	 C57BL/6J	 strain,	 to	 make	 a	 mouse	 model	 miR-17-92fl/fl	 and	
homozygous	 for	 the	 CD4-CRE	 allele.	 It	will	 be	 referred	 to	 as	 17-92-/-	 in	 this	 report.	Other	
models	 were	 used	 such	 as	 OT-1	 x	 17-92fl/fl	 x	 CD4-Cre,	 where	 the	 mice	 express	 an	 OVA-
specific	transgenic	TCR	on	the	surface	of	the	CD8+	T	cells.	This	second	model	will	be	referred	
to	as	OT-1	x	17-92-/-.	RAG2	KO	mice	and	the	congenic	CD45.1	C57BL/6J	mice	were	supplied	
by	our	local	animal	facility.	The	latter	were	crossed	with	CD45.2	C57BL/6J	mice	to	generate	
CD45.1/2	mice.	
4.2. Genotyping:	
DNA	was	extracted	 from	ear	punches	using	 the	Kapa	Mouse	genotyping	kit	and	 following	
the	instruction	of	the	manufacturer	(Kapabiosystems	KK7352).	Primers	sequences	and	PCR	
programs	are	described	in	the	Appendix	page	88.	
4.3. Infection	models:	
LCMV:	Mice	were	infected	intraveneously	with	200PFU	of	LCMV	of	the	WE	strain,	provided	
by	Dietmar	Zehn’s	laboratory	at	the	CHUV.	The	immune	response	was	assessed	at	the	peak	
of	infection	7-8	days	after	infection,	usually	by	bleeding.		
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Viral	 titers	 were	 determined	 at	 day	 7	 by	 an	 LCMV	 focus-forming	 assay	 from	 splenocyte	
suspension	(Experiment	performed	by	D.	Utzschneider)	
Listeria	 Monocytogenes:	 Mice	 were	 infected	 intravenously	 with	 1’000-2’000	 CFU	 of	 L.	
monocytogenes.	 The	 immune	 response	 was	 assessed	 at	 day	 6	 or	 day	 7	 in	 the	 blood	 or	
spleen	of	the	mice.	
4.4. Bone	marrow	chimeras	
CD45.1	 C57BL/6J	 mice	 were	 lethally	 irradiated	 with	 a	 dose	 of	 900rad	 in	 a	 Caesium-137	
irradiator.	Bone	marrow	cells	 from	miR-17-92fl/fl	CD45.2	or	WT	CD45.1/2	donor	mice	were	
isolated	 from	 femur	 and	 tibia	 bones	with	 PBS	 flushing.	 Cells	 were	 subsequently	 washed,	
counted,	and	mixed	at	1:1	ratio.	A	 few	hours	after	 irradiation,	hosts’	 immune	system	was	
reconstituted	 by	 intravenous	 injection	 of	 a	 total	 of	 4	 million	 mixed	 bone	 marrow	 cells.	
Analyses	of	the	homeostatic	reconstitution	of	the	host’s	immune	system	were	performed	2	
to	3	months	later.	
4.5. RAG2	KO	homeostatic	proliferation	assays	
Spleens	of	CD45.1/2	C57BL/6J	mice	and	CD45.2	miR-17-92fl/fl	CD4-CRE	mice	were	sampled	
and	 processed	 in	 a	 sterile	 manner.	 The	 percentage	 of	 CD8+	 T	 cells	 in	 each	 sample	 was	
measured	and	1mio	of	CD8+	T	cells	from	each	strain	was	injected	i.v.	in	RAG2	KO	mice.	
4.6. Flow	cytometry	
Surface	staining:	Blood	samples	were	directly	stained	in	FACS	buffer	at	4°C	for	30	minutes,	
before	lysis	of	red	blood	cells	and	fixation	with	BD	buffer	(BD	349202)	during	10	minutes	at	
room	 temperature.	 Blood	 samples	 were	 subsequently	 washed	 twice	 and	 resuspended	 in	
FACS	buffer	(PBS	2%FCS	2mM	EDTA).	
Spleens	were	processed	through	nylon	filters	(100μM)	in	FACS	buffer.	Cells	were	pelleted	in	
50ml	falcon	tubes	by	centrifugation	at	400xrcf	for	5	minutes.	Cell	pellet	was	resuspended	in	
5ml	RBC	lysis	solution	(Qiagen	158904)	for	10	minutes	at	room	temperature,	then	washed	
twice.	1	 to	4	mio	cells	were	 then	stained	 in	FACS	buffer,	washed,	and	then	acquired	on	a	
LSR-II	FACS.	Lymph	nodes	and	thymus	were	processed	and	stained	in	a	similar	way.	
Intracellular	cytokine	staining:	To	assess	the	cytokine	production	of	lymphocytes,	1-4	million	
splenocytes	were	plated	 in	 a	 96-well	 plate	with	 either	 10um	of	 a	 LCMV	peptide	mix	 (see	
supplemental	 methods	 page	 89),	 or	 10ng/ml	 final	 concentration	 PMA	 and	 500ng/ml	
ionomycin,	 or	 5µg/ml	 plate-bound	 CD3	 and	 2µg/ml	 soluble	 CD28	 and	 placed	 in	 the	
incubator	 at	 37°C.	 After	 30	minutes,	 Golgistop	 (monensin,	 BD	 554724)	was	 added	 to	 the	
wells	at	a	1/1’500	dilution.	The	cells	were	placed	back	in	the	incubator	for	an	additional	4	
hours	 before	 surface	 staining	 and	 intracellular	 staining.	 Fixation	 and	 permeabilization	 for	
the	intracellular	detection	of	cytokines	was	performed	with	the	BD	kit	(554714)	according	to	
the	manufacturer’s	instruction.	
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4.7. Statistical	analysis	
When	two	groups	were	compared,	the	t	test	with	a	two-sided	P	value	and	a	95%	confidence	
interval	was	performed.	When	more	than	two	groups	over	time	were	compared,	a	two-way	
ANOVA	 test	 was	 performed.	 Figures	 show	 one	 representative	 experiment	 out	 of	 2	 or	 3	
independent	 experiments.	 The	 individual	 dots	 always	 represent	 biological	 replicates	
(number	of	mice	or	independent	wells).	When	technical	replicates	were	performed	(usually	
in	duplicates),	the	average	of	the	replicates	was	plotted.	All	statistical	tests	were	performed	
using	the	Prism	version	6	software	(NS,	not	significant;	*P	<	0.05;	**P	<	0.01;	***P	<	0.001;	
****P	<	0.0001.)	
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Chapter	 II:	Overexpression	of	miR-155	 in	
OT-1	cells	enhances	 their	 responsiveness	
to	low	affinity	antigen	
1. Aim:	
In	2013,	our	group	published	an	article	in	the	journal	immunity	about	the	role	of	miR-155	in	
CD8+	 T	 cells.	 In	 this	 publication,	 we	 demonstrated	 that	 the	 deletion	 of	 miR-155	 was	
intrinsically	detrimental	to	the	correct	proliferation	and	survival	of	CD8+	T	cells	in	vivo	upon	
infection.	Moreover,	 we	 could	 show	 that	 OT-1	miR-155-/-	 cells	 could	 not	mediate	 potent	
antitumour	 response	 in	 the	 B16	model,	 upon	 vaccination	with	 CpG-OVA.	 Using	 the	 pmel	
model,	 our	 collaborators	 demonstrated	 that	 the	 overexpression	 of	 miR-155	 induced	 an	
ameliorated	 antitumour	 response	 upon	 vaccinia	 virus	 –	 hgp100	 infection	 and	 systemic	
injection	 of	 the	 cytokines	 IL-281.	 The	 aim	 of	 this	 project	 was	 firstly	 to	 characterize	 the	
overexpression	 of	miR-155	 in	 the	OT-1	model	 and	 its	 ability	 to	 ameliorate	 the	OT-1	 cells	
antitumour	 response	 upon	 vaccination	 with	 CpG-OVA.	 The	 second	 aim	 was	 to	 take	
advantage	of	the	existing	pre-defined	high	and	low	affinity	OVA	ligands,	SIINFEKL	(N4)	and	
SIITFEKL	 (T4)	 respectively,	 to	 study	 the	 implication	 of	 miR-155	 overexpression	 for	 the	
modulation	of	the	T	cell	response	according	the	TCR	ligand’s	affinity.	
2. Results	
OT-1	 cells	 were	 efficiently	 transduced	 and	 could	 stably	 overexpress	 miR-155	 in	
vitro	
OT-1	T	cells	were	purified	from	the	spleens	of	OT-1	CD45.1	mice	and	transduced	with	either	
the	 GFP_SCR	 (SCR)	 or	 the	 GFP_miR-155	 (miR-155)	 construct.	 These	 retroviral	 expression	
plasmids,	can	co-express	the	GFP	protein	and	a	microRNA	under	the	same	promoter	called	
PGK.	Two	days	after	transduction,	the	percentage	of	transduced	cells	was	assessed	via	flow	
cytometry	 by	 measurement	 of	 GFP+	 cells.	 It	 was	 on	 average	 90%	 (Figure	 19A).	 After	
transduction	 (day	4-day	10),	miR-155	 levels	were	measured	by	qPCR.	The	amount	of	miR-
155	 expressed	 in	 resting	 OT-1	 cells	 transduced	 with	 miR-155	 was	 increased	 30-50	 fold	
compared	to	the	levels	in	SCR	transduced	cells	(Figure	19B).	To	assess	the	influence	of	the	
endogenous	 upregulation	 of	 miR-155	 upon	 activation,	 total	 levels	 of	 miR-155	 were	
measured	 in	 OT-1	 SCR	 or	 miR-155	 cells	 after	 activation	 with	 either	 a	 1:1	 ratio	 of	
αCD3/αCD28-coated	magnetic	beads	or	the	B16-OVA	cell	line	at	a	1:5	target:effector	ratio.	
The	levels	of	miR-155	were	indeed	increased	upon	activation	in	both	the	OT-1	SCR	and	the	
OT-1	miR-155,	which	 is	not	 surprising	 since	 the	endogenous	miR-155	 is	upregulated	upon	
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activation.	However,	1	day	after	activation,	the	level	of	miR-155	in	the	miR-155	transduced	
cells	was	only	2-fold	higher	 compared	 to	 the	SCR-transduced	cells.	 This	 indicates	 that	 the	
transgene	 expression	 does	 not	 increase	 with	 activation,	 and	 that	 when	 the	 endogenous	
levels	of	miR-155	are	high,	 the	overexpression	of	miR-155	only	minimally	affects	 the	total	
amount	of	microRNA.	This	is	true	for	both	non-specific	activation	(Figure	19C)	and	activation	
with	a	cell	line	expressing	the	high	affinity	target	OVA	(Figure	19D).	
	
	
MiR-155	overexpression	increases	the	proliferation	and	accumulation	of	OT-1	cells	
in	vivo	in	the	blood	and	spleen	of	infected	and	vaccinated	mice	
In	 vivo,	 miR-155	 overexpression	 allowed	 OT-1	 cells	 to	 respond	 more	 efficiently	 to	 an	
infection	with	Listeria	monocytogenes	expressing	the	ovalbumin	protein	(Lm-OVA).	Indeed,	
OT-1	cells	percentages,	measured	as	the	percentage	of	CD45.1+	GFP+	double	positive	cells	
in	the	CD8+	gate,	were	increased	at	the	peak	of	the	infection	in	the	spleen	(Figure	20A).	The	
overexpression	of	miR-155	had	an	 impact	only	during	 the	 late	phase	of	 the	expansion,	as	
there	 was	 no	 difference	 either	 in	 percentage	 or	 numbers	 of	 OT-1	 miR-155	 4	 days	 after	
infection.	However,	6	days	after	Lm-OVA	 infection,	both	numbers	and	percentage	of	OT-1	
miR-155	were	increased	compared	to	OT-1	SCR.	This	was	due	to	an	increased	proliferative	
ability.	Indeed,	at	day	6	post	infection,	13%	of	OT-1	miR-155	cells	had	proliferated	2.5	hours	
after	BrdU	injection,	whereas	only	4%	of	OT-1	SCR	had	proliferated	in	the	same	time	(Figure	
20B).	OT-1	miR-155	cells	could	respond	more	efficiently	to	vaccination	with	CpG	and	OVA.	
Indeed,	both	the	percentages	(Figure	20C)	and	numbers	(Figure	20D)	of	OT-1	miR-155	cells	
were	 increased	 in	 the	 blood	 of	 vaccinated	 animals	 compared	 to	 OT-1	 SCR.	 This	
OT-1	cells	could	be	transduced	eﬃciently	with	a	retroviral	construct	
co-expressing	GFP	and	miR-155.	Higher	expression	was	maintained	at	
the	resEng	state	and	throughout	immune	acEvaEon	in	vitro	
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Figure	19:	(A)	1	representative	FACS	plot	showing	GFP	expression	in	OT-1	cells	2	days	after	transduction	(B)	
qPCR	measurement	of	miR-155	levels	in	SCR	or	miR-155	resting	cells.		(N=3)	(C)	qPCR	of	miR-155	levels	
before	and	1,	2	and	4	days	following	coculture	with	αCD3/αCD28	coated	beads	or	(D)	B16-OVA.	Experiment	
representative	of	2	independent	experiments.	
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demonstrates	 the	miR-155-mediated	 increased	 ability	 to	 accumulate	 is	 independent	 of	 a	
systemic	infection	(Figure	20	C	and	D).	
	
Figure	20:	(A)	Percentages	of	GFP+	OT-1	cells	amongst	total	CD8	were	measured	in	the	spleen	of	Lm-OVA	infected	mice	
4,	6	and	7	days	after	infection.	(N=6)	(B)	The	proliferation	of	OT-1	SCR	and	OT-1	miR-155	was	assessed	by	intracellular	
staining	 of	 BrdU	 positive	 cells	 2.5	 hours	 after	 peritoneal	 BrdU	 injection,	 4	 and	 6	 days	 after	 Lm-OVA	 infection.	 (C)	
Percentages	of	OT-1	cells	amongst	CD8+	T	cells	were	measured	in	the	blood	of	mice	7	days	after	vaccination	with	CpG-
OVA	or	 infection	with	Lm-OVA.	 (D)	Absolute	numbers	of	OT-1	SCR	and	OT-1	miR-155	were	calculated	 in	 the	blood	of	
mice	 7	 days	 after	 listeria	 infection	 using	 trucount	 FACS	 tube.	 Experiment	 representative	 of	 two	 independent	
experiments.	
MiR-155	overexpression	 in	OT-1	 cells	marginally	 improves	 their	 ability	 to	 control	
tumour	growth	
WT	CD45.2	mice	were	engrafted	subcutaneously	in	the	flank	with	0.1	million	(mio)	B16-OVA	
cells	in	suspension	in	PBS.	Three	days	later,	T	cells	were	purified	from	the	spleen	of	a	CD45.1	
OT-1	mouse	and	activated	in	vitro	with	αCD3/αCD28	beads.	The	next	day,	the	T	cells	were	
transduced	either	with	the	pMGP-SCR	or	pMGP-miR155	plasmid.	Six	days	after	the	tumour	
graft,	mice	received	an	intravenous	injection	of	0.1	mio	OT-1	SCR	or	OT-1	miR-155.	The	next	
day,	 mice	 either	 received	 an	 intravenous	 injection	 of	 2’000	 cfu	 of	 Lm-OVA,	 or	 a	
subcutaneous	 injection,	 at	 the	 base	 of	 the	 tail,	 of	 CpG	 and	 OVA.	 The	 timecourse	 of	 the	
experiment	 is	 summarised	 in	Figure	21A.	Although,	as	 shown	previously,	 the	proliferation	
and	accumulation	of	cells	was	increased	at	the	peak	of	the	response	(Figure	20),	the	tumour	
protection	was	only	mildly	 improved	when	mice	were	 transferred	with	OT-1	miR-155	and	
infected	 with	 Lm-OVA	 (Figure	 21B).	 Furthermore,	 there	 was	 no	 improvement	 upon	 cell	
transfer	and	vaccination	(Figure	21C).	Indeed,	although	the	accumulation	of	OT-1	miR-155	in	
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the	periphery	was	increased	compared	to	OT-1	SCR,	the	percentage	of	OT-1	miR-155	in	the	
TILs	was	similar	as	the	one	from	OT-1	SCR	(data	not	shown).	
	
Figure	21:	(A)	B6	mice	were	engrafted	subcutaneously	at	day	0	with	1x105	B16-OVA	(n=5-6).	At	day	6,	1x105	OT-1	T	cells	
were	transferred	intravenously.	At	day	7,	mice	were	either	infected	with	Lm-OVA	or	vaccinated	with	CpG	OVA.	Tumour	
volumes	were	measured	with	a	caliper	every	other	day	from	day	7-post	engraftement	until	the	end	of	the	experiment	
for	(B)	mice	infected	with	Lm-OVA	or	(C)	mice	vaccinated	with	CpG	OVA.	The	graphs	are	one	experiment	representative	
of	two	independent	experiments.	
Upon	cotransfer,	OT-1	miR-155	cells	preferentially	accumulate	in	the	tumour	when	
compared	to	OT-1	SCR		
As	variation	within	animals	or	differences	in	tumour	sizes	could	affect	the	ability	of	the	CD8+	
T	cells	to	 infiltrate	tumours,	 independently	of	their	phenotype,	we	sought	to	compare	the	
OT-1	SCR	and	OT-1	miR-155	cells	directly	in	the	same	host.	In	this	situation,	the	OVA-specific	
CD8+	T	cells	will	have	to	compete	with	one	another	for	space	and	survival	signals,	making	
the	conditions	more	stringent.	In	this	purpose,	we	cotransferred	OT-1	CD45.1/2	SCR	and	OT-
1	 CD45.1	 miR-155	 cells	 intravenously	 in	 CD45.2	 tumour-bearing	 mice.	 The	 mice	 were	
subsequently	either	treated	with	PBS,	or	vaccinated	with	CpG	+	OVA,	or	 infected	with	Lm-
OVA(Figure	22).	7	days	after	the	vaccination	or	infection,	the	mice	were	sacrificed	and	the	
percentages	 of	OT-1	 SCR	 and	OT-1	miR-155	were	measured	 in	 the	 blood	 and	 tumour	 via	
FACS	staining.	In	this	setting,	the	ability	of	OT-1	miR-155	CD8+	T	cells	to	accumulate	in	the	
blood	 (Figure	 22	 left	 panel)	 or	 in	 the	 tumour	 (Figure	 22	 right	 panel)	 7	 days	 after	 either	
vaccination	or	infection	significantly	surpassed	that	of	the	OT-1	SCR	cells.	This	contrasts	with	
the	previous	observation	that	the	tumour	invasion	was	similar	in	a	non-competitive	setting,	
showing	that	the	OT-1	miR-155	cells	performed	better	under	the	competitive	pressure.	
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Figure	22:	(A)	CD45.2	OT-1	cells	were	transduced	with	miR-155	and	CD45.1/2	OT-1	cells	were	transduced	with	SCR	and	
cotransferred	in	CD45.1	tumour	bearing	mice.	(B)	7	days	after	vaccination	or	 infection,	mice	were	sacrificed	and	GFP+	
OT-1	cells	were	quantified	 in	the	blood.	(C)	Tumour	 infiltrating	 lymphocytes	were	purified	and	stained	and	GFP+	OT-1	
cells	were	quantified.	Graphs	representative	of	one	experiment.	
We	then	assessed	 the	effector	 functions	of	 the	OT-1	cells	by	 restimulating	 them	with	 the	
high	affinity	SIINFEKL	(OVA	N4)	peptide	for	4	hours	and	subsequently	staining	intracellularly	
for	 IFN-γ	 and	 TNF-α.	 At	 the	 peak	 of	 the	 infection,	 both	OT-1	miR-155	 and	 SCR	 extracted	
from	the	tumour	could	respond	to	restimulation	and	express	IFN-γ	efficiently	(Figure	23A).	
Moreover,	 OT-1	 miR-155	 cells	 were	 more	 polyfunctional	 than	 the	 controls,	 as	 a	 higher	
percentage	 could	 also	 express	 TNF-α	 (Figure	 23B).	 Finally,	 we	 stained	 for	 the	 surface	
markers	 PD-1,	 CD62L	 and	 CD44	 and	 could	 not	 see	 striking	 differences	 in	 the	 tumour,	
whereas	 in	 the	 blood	 miR-155	 had	 an	 increased	 expression	 of	 CD44	 and	 decreased	
expression	 of	 CD62L	 (data	 not	 shown).	 The	 expression	 of	 CD8α	 (Figure	 23C)	 and	 CD8β	
(Figure	 23D)	 were	 both	 systematically	 increased	 in	 the	 tumour-infiltrating	 OT-1	 miR-155	
cells,	 both	 in	 the	 vaccination	 and	 in	 the	 infection	 setting.	 This	 was	 also	 the	 case	 for	
circulating	cells	(data	not	shown).	
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Figure	23:	(A)-(B)	OT-1	SCR	and	OT-1	miR-155	were	extracted	from	the	tumours	7	days	after	vaccination	or	infection	and	
restimulated	with	the	N4	peptide	before	intracellular	cytokine	staining.	(C)	Expression	of	CD8α	on	the	surface	of	OT-1	
cells	was	quantified	by	the	FACS	staining	and	measure	of	the	median	fluorescence	via	flow	cytometry.	(D)	Expression	of	
CD8β	on	the	surface	of	OT-1	cells	was	quantified	by	the	FACS	staining	and	measure	of	the	median	fluorescence	via	flow	
cytometry.	Graphs	representative	of	one	experiment.	
Cells	 overexpressing	 miR-155	 have	 an	 increased	 glycolytic	 capacity	 and	 non-
glycolytic	acidification	rate	
We	then	sought	to	characterize	the	metabolic	capacities	of	the	OT-1	miR-155	cells	and	see	if	
they	differed	 from	the	OT-1	SCR.	To	do	so	we	performed	seahorse	assays	 to	evaluate	 the	
OT-1	cells	capacity	to	perform	glycolytic	respiration	from	a	glucose	supplemented	medium,	
and	 to	 upregulate	 their	 glycolytic	 respiration	 upon	 stimulation	 with	 αCD3/αCD28	
stimulation	 with	 beads	 (Figure	 24A).	 We	 also	 tested	 CD8+	 T	 cells	 from	 a	 miR-155	 KO	
breeding,	 either	 homozygous	 for	 the	 miR-155	 deletion	 (miR-155-/-)	 or	 possessing	 both	
wildtype	 alleles	 (miR-155+/+).	 To	measure	 the	 ability	 of	 the	 CD8+	 T	 cells	 to	 perform	 non-
glycolytic	 acidification,	 and	 to	 respond	 to	 stimulation	 in	 the	 absence	 of	 glucose,	 we	
performed	a	glycolysis	 stress	assay.	The	cells	were	plated	 in	medium	depleted	of	glucose,	
but	 containing	 glutamine.	 They	 were	 subsequently	 activated	 with	 αCD3/αCD28-coated	
beads.	 Afterwards,	 glucose,	 oligomycin	 and	 2DG	 were	 added	 to	 the	 wells	 and	 the	
extracellular	 acifification	 rate	 (ECAR)	 was	 measured	 at	 least	 3	 times	 (Figure	 24B).	 Upon	
activation,	 all	 cell	 subtypes	 could	 increase	 their	 glycolytic	 metabolism.	 This	 increase	 was	
more	 marked	 in	 the	 presence	 of	 glucose	 in	 the	 medium	 (Figure	 24A).	 The	 addition	 of	
oligomycin	 blocks	 oxidative	 phosphorylation	 and	 reveals	 the	 glycolytic	 capacity.	 It	 was	
increased	 in	OT-1	miR-155	 cells,	 especially	 in	 the	 glycolysis	 stress	 assay	 (Figure	 24B).	 The	
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basal	glycolysis,	before	activation,	was	augmented	in	OT-1	miR-155	cells	in	the	presence	of	
glucose	 (Figure	24C)	 and	also	 in	 its	 absence	 (Figure	24D),	 showing	 that	 the	OT-1	miR-155	
cells	were	more	efficient	at	non-glycolytic	acidification.	To	assess	the	activity	of	the	mTOR	
pathway	in	those	cells,	we	measured	the	amount	of	phosphorylated	ribosomal	protein	S6,	
which	 is	 downstream	 of	 the	 mTORC1.	 OT-1	 SCR	 and	 OT-1	 miR-155	 cells	 were	 fixed	 and	
intracellularly	stained	1	hour	and	15	minutes	after	coculture	with	αCD3/αCD28.	The	amount	
of	phosphorylated	S6	was	increased	in	OT-1	miR-155	upon	activation	(Figure	24E).	
	
Figure	24:	(A)	Extracellular	acidification	rate	(ECAR)	was	measured	every	7	minutes	in	a	96-well	plate	using	a	seahorse	
machine.	αCD3/αCD28	beads,	oligomycin,	 FCCP	and	2DG	were	 sequentially	 added	 to	 the	wells	 and	 subsequent	 ECAR	
was	 measured	 at	 least	 3	 times.	 The	 starting	 medium	 contained	 10mM	 glucose	 and	 2mM	 glutamine	 (B)	 ECAR	 was	
measured	using	a	seahorse	machine	before	and	after	the	addition	of	αCD3/αCD28	beads,	glucose,	oligomycin	and	FCCP.	
(C)	 The	 average	 ECAR	 of	 the	 three	 measured	 basal	 values	 was	 plotted	 for	 each	 well	 for	 the	 glucose-supplemented	
medium	 (D)	The	average	ECAR	of	 the	 three	measured	basal	 value	was	plotted	 for	each	well	 for	 the	medium	without	
glucose.	(E)	The	phosphorylation	of	the	ribosomal	protein	S6	was	assessed	by	phosphostaining	and	measured	by	FACS	
1h15	after	OT-1	SCR	and	OT-1	miR155	activation	with	αCD3/αCD28	beads.	Graphs	of	one	experiment	representative	of	
three	independent	experiments.	
Overexpression	 of	 miR-155	 in	 OT-1	 cells	 improves	 their	 ability	 to	 mediate	
protection	against	tumours	expressing	a	low	affinity	antigen	
We	were	surprised	to	observe	that	the	OT-1	miR-155	cells	did	not	significantly	improve	the	
tumour	protection	against	the	B16-OVA	antigen	upon	priming	through	a	systemic	infection	
with	 Lm-OVA,	 or	 through	 vaccination	with	 CpG	OVA.	 Indeed,	 previously	 published	 results	
with	the	demonstrated	a	dramatic	 improvement	of	 the	CD8+	T	cells-mediated	antitumour	
response	upon	miR-155	overexpression81.	However,	that	study	was	not	using	OT-1	cells	but	
pmel	cells.	The	pmel	model	takes	advantage	of	self-tolerant	mgp100-specific	CD8+	T	cells,	
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which	do	not	protect	 against	 the	mouse	 gp100	 (mgp100)-expressing	B16	 tumours,	 unless	
stimulated	by	an	 infection	with	a	vaccinia	virus	expressing	 the	human	gp100187.	Once	 the	
tolerance	 is	 broken	 thanks	 to	 the	 infection	 and	 the	 higher	 affinity	 hgp100	 antigen,	 pmel	
CD8+	 T	 cells	 can	 recognize	 and	 destroy	 tumour	 cells	 expressing	 the	 mgp100.	 Our	 high	
affinity	 OT-1	 model	 was	 thus	 different	 compared	 to	 the	 original	 study.	 Moreover,	 the	
upregulation	of	the	endogenous	miR-155	has	been	shown	to	be	correlated	with	the	strength	
of	the	affinity	of	the	TCR	to	the	peptide:MHC	complex81.	In	our	hands,	we	could	confirm	via	
the	transfection	of	OT-3	cells,	which	have	a	low	affinity	to	OVA,	that	the	endogenous	miR-
155	 was	 less	 upregulated	 upon	 activation	 with	 the	 peptide.	 Hence,	 the	 difference	 after	
activation	between	the	OT-3	cells	overexpressing	miR-155	or	the	ones	transduced	with	the	
SCR	 was	 greater	 compared	 to	 OT-1	 SCR	 and	 miR-155	 activated	 with	 B16-OVA	
(Supplementary	 Figure	 34).	 To	 understand	 if	 the	 affinity	 to	 the	 target	 antigen	 was	 a	
determining	factor	in	the	improved	CD8+	T	cell	function	upon	miR-155	overexpression,	we	
took	 advantage	 of	 the	 SIINFEKL	 (N4)	 and	 SIITFEKL	 (T4)	 peptides.	 The	 SIINFEKL	 is	 the	
endogenous	ovalbumin	peptide,	and	 is	of	high	affinity	to	the	OT-1	TCR.	The	SIITFEKL	 is	an	
altered	 peptide	 ligand	 that	 has	 a	 much	 decreased	 affinity	 to	 the	 OT-1	 TCR,	 at	 the	 limit	
between	 negative	 selection	 and	 self-tolerance18.	 We	 subcutaneously	 engrafted	 C57BL/6J	
mice	with	1x105	B16	 tumour	 cells	 expressing	 the	endogenous	ovalbumin	 (B16-N4)	on	 the	
right	flank,	and	1x105	B16	tumour	cells	expressing	the	altered	low	affinity	ovalbumin	(B16-
T4)	on	the	left	flank.	As	usual,	OT-1	cells	were	either	transduced	with	SCR	or	miR-155	and	
were	 injected	 intravenously	6	days	post	graft.	Then,	vaccination	was	performed	with	CpG	
and	N4	the	following	day	(Figure	25A).	As	previously	observed,	the	overexpression	of	miR-
155	did	not	improve	the	protection	against	B16-N4	tumours	(Figure	25B).	However,	21	days	
after	engraftement,	 the	B16-T4	 treated	with	OT-1	miR-155	CD8+	T	cells	were	 significantly	
smaller	than	the	ones	treated	with	the	OT-1	SCR	cells	(Figure	25C).	As	a	conclusion,	in	this	
model,	the	overexpression	of	miR-155	could	improvethe	antitumour	efficiency	of	OT-1	cells	
only	in	the	context	of	tumours	expressing	a	low	affinity	antigen.	
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	Figure	25:	(A)	B6	mice	were	engrafted	subcutaneously	on	the	left	flank	with	B16-T4	and	on	the	right	flank	with	B16-N4.	
6	 days	 after	 the	 graft,	 the	mice	were	 injected	 intravenously	with	 1x105	OT-1	 SCR	 or	OT-1	miR-155	 cells,	 or	 PBS.	 The	
following	 day,	 they	were	 vaccinated	with	 CpG	 and	 the	 high	 affinity	 OVA	 peptide,	 SIINFEKL	 (N4).	 (B)	 B16-N4	 tumour	
growth	in	the	different	treatment	groups	was	measured	every	2	days	with	a	manual	caliper.	(C)	B16-T4	tumour	growth	
was	 also	 measured	 every	 2	 days.	 2-way	 ANOVA	 and	 tukey’s	 multiple	 comparison	 test	 was	 used	 to	 compute	 the	
statistical	 significance	 at	 day	 21	 post	 graft	 for	 the	 different	 treatment	 groups	 (N=6).	 Graphs	 of	 one	 experiment	
representative	of	2	independent	experiments.	
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We	 also	 measured	 the	 percentage	 of	 OT-1	 miR-155	 in	 T4	 tumour	 at	 the	 end	 of	 the	
experiment	 (22	 days	 after	 engraftement),	 and	 we	 could	 observe	 that	 it	 was	 higher	
compared	to	OT-1	SCR.	In	the	spleen	and	N4	tumours	of	the	same	mice,	however,	there	was	
no	difference	between	 the	amount	of	OT-1	 SCR	and	OT-1	miR-155	 cells	 (Figure	26A).	We	
repeated	the	experiment	but	sacrificed	the	animals	7	days	after	vaccination,	at	the	peak	of	
the	immune	response	to	assess	the	OT-1	cells	distribution	and	functionality	in	the	different	
organs.	 As	 expected,	 the	OT-1	miR-155	 cells	 were	 strongly	 enriched	 in	 the	 spleen	 of	 the	
vaccinated	animals,	compared	to	the	OT-1	SCR,	showing	an	increase	of	the	circulating	OT-1	
miR155	cells	(Figure	26B).	Moreover,	this	increase	was	also	reflected	in	the	tumour	draining	
lymph	nodes	(dLNs),	on	both	flanks	of	the	mice,	although	the	T4	dLNs	(Figure	26E)	seemed	
to	be	attracting	less	cells	that	the	N4	dLNs	(Figure	26C).		
Figure	26:	(A)	percentages	of	OT-1	cells	amongst	CD8+	gate	22	days	after	engraftment.	The	differences	in	population	are	
non	significant.	Percentages	of	OT-1	in	the	CD8	gate	7	days	after	CpG	and	N4	vaccination	in	the	(B)	spleen,	(C)	N4	tumour	
axillary	and	inguinal	draining	lymph	nodes,	(D)	N4	tumour,	(E)	T4	tumour	axillary	and	inguinal	draining	lymph	nodes,	(F)	
T4	tumour.	Graphs	of	one	experiment	representative	of	2	independent	experiments.	
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Most	interestingly,	although	the	N4	dLNs	were	enriched	in	OT-1	miR-155	cells	compared	to	
the	 OT-1	 SCR	 controls,	 the	 N4	 tumours	 contained	 similar	 numbers	 of	 OT-1	 miR-155	
compared	to	OT-1	SCR	(Figure	26D).	 In	the	B16-T4	tumours	however,	 the	amount	of	OT-1	
miR-155	was	increased	compared	to	the	controls,	showing	a	local	effect,	specific	of	the	low-
affinity	antigen,	in	the	ability	of	miR-155	overexpressing	T	cells	to	either	survive	or	expand	
better	(Figure	26D).		
miR-155	overexpression	increases	the	tumour	infiltration	and	functionality	of	OT-1	
cells	upon	low	affinity	vaccination	
Finally,	we	looked	at	the	ability	of	the	overexpression	of	miR-155	to	increase	the	response	
to	 a	 low	affinity	priming,	 by	 vaccinating	 the	mice	bearing	N4	and	T4	 tumours	with	either	
CpG	and	the	T4	peptide	or	CpG	and	the	N4	peptide.	As	a	result,	the	tumour	invasion	of	OT-1	
miR-155	 T	 cells	 was	 increased	 in	 both	 the	 N4	 and	 T4	 tumours.	 Showing	 that	 upon	 low	
affinity	 antigen	 priming,	 OT-1	 overexpressing	miR-155	 are	 advantaged	 compared	 to	OT-1	
SCR	for	the	invasion	of	both	high	and	low	affinity	tumours	7	days	after	vaccination	(Figure	
27A).	 Moreover,	 the	 functionality	 of	 the	 OT-1	 miR-155	 cells	 was	 augmented	 in	 the	 N4	
tumours,	at	the	peak	of	the	response	following	both	N4	and	T4	vaccination.	The	percentage	
of	cells	producing	IFN-γ	was	higher	in	the	OT-1	cells	transduced	with	miR-155	(Figure	27B),	
and	there	was	a	tendency	for	more	polyfunctionality	as	well	as	the	percentage	of	IFN-γ	and	
TNF-α	double	positive	cells	was	augmented	(Figure	27C).	This	demonstrates	the	potential	of	
miR-155	to	rescue	low	affinity	T	cells,	not	only	in	their	effector	functions	but	also	during	the	
priming	 of	 the	 response.	 These	 findings	 confirm	miR-155	 as	 an	 interesting	 candidate	 for	
immunotherapy,	 as	 circulating	 T	 cells	 are	 usually	 of	 low	 affinity	 to	 tumour	 associated	
antigens	 because	 of	 central	 tolerance.	 Overexpressing	 miR-155	 could	 potentially	 rescue	
those	low	affinity	T	cells	and	make	them	more	efficient	in	controlling	tumour	growth.	
	
Figure	 27:	 (A)	 Percentages	 of	 OT-1	 cells	 in	 the	 CD8	 gate	 7	 days	 after	 CpG	 +	 T4	 vaccination	measured	 in	 N4	 and	 T4	
tumours.	Percentages	of	OT-1	 cells	 in	 the	N4	 tumours	producing	 (B)	 IFN-γ	and	 (C)	both	 IFN-γ	and	TNF-α,	assessed	by	
intracellular	cytokine	staining.	Graphs	representative	of	1	experiment.	
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3. Discussion:	
We	have	shown	that	the	overexpression	of	miR-155	in	OT-1	T	cells	improves	their	ability	to	
respond	 to	 antigen	 stimulation	 upon	 vaccination	 and	 infection,	 both	 in	 terms	 of	
proliferation	 and	 cytokine	 production.	 Moreover,	 the	 ability	 of	 OT-1	 miR-155	 cells	 to	
infiltrate	tumours	was	ameliorated	in	the	context	of	either	competition	via	the	co-injection	
of	OT-1	SCR	cells,	or	upon	low	affinity	vaccination	with	the	SIITFEKL	(T4)	peptide	and	CpG.	
Finally,	OT-1	miR-155	T	cells	were	capable	to	infiltrate	B16	tumours	expressing	the	T4	ligand	
more	efficiently,	and	could	consequently	mediate	a	better	tumour	control	in	this	model.	In	
contrast,	when	OT-1	cells	were	optimally	activated	by	a	high	affinity	peptide,	overexpressing	
miR-155	was	unhelpful	 in	 terms	of	 antitumour	effect	 against	 the	B16	 tumours	expressing	
the	high	affinity	SIINFEKL	(N4)	ligand.		
We	and	others	have	shown	that	the	upregulation	of	miR-155	is	proportional	to	the	affinity	
of	the	TCR	to	the	peptide:MHC	ligand,	as	OT-1	T	cells	express	miR-155	at	higher	levels	when	
stimulated	with	the	N4	ligand	in	vitro	compared	to	the	T4	ligand81.	Additionally,	stimulation	
with	A2/NY-ESO-1157–165	multimers	induced	a	higher	miR-155	upregulation	in	human	CD8+	T	
cells	transduced	with	TCRs	of	stronger	affinity	to	the	NY-ESO	peptide188.	Moreover,	miR-155	
is	upregulated	dynamically	in	vivo	during	the	course	of	an	infection.	For	example	in	effector	
cells	sorted	from	LCMV	infected	mice,	miR-155	expression	peaked	at	day	6	post	 infection,	
and	was	subsequently	downregulated81.	In	our	OT-1	model,	we	observed	a	reduction	in	the	
difference	 in	miR-155	 levels	 between	miR-155	 and	 SCR	OT-1	 cells	 when	 the	 endogenous	
miR-155	was	upregulated	after	in	vitro	stimulation.	The	50-fold	difference	in	miR-155	levels	
in	resting	cells	became	a	2-fold	difference	after	one	day	of	stimulation	with	αCD3/αCD28-
coated	 beads	 or	 B16-OVA.	Hence,	 adding	more	miR-155	might	 be	 less	 useful	 to	 the	 cells	
during	the	peak	of	endogenous	miR-155	expression.	We	did	not	yet	measure	the	expression	
of	 miR-155	 in	 SCR	 and	 miR-155	 transduced	 OT-1	 T	 cells	 in	 vivo	 upon	 listeria	 infection.	
However,	 we	 did	 observe	 that	 transduction	 with	 miR-155	 induced	 an	 advantage	 in	 the	
proliferation	 and	 accumulation	 of	 OT-1	 cells	 at	 the	 peak	 of	 the	 in	 vivo	 response	 to	
vaccination	and	infection,	but	not	in	the	early	time	point,	4	days	after	infection.	This	might	
be	because	the	endogenous	miR-155	 is	downregulated	 in	the	SCR	cells	6	and	7	days	after	
infection,	but	not	in	the	miR-155	transduced	cells,	which	continuously	overexpress	miR-155.	
To	confirm	this	hypothesis,	it	would	be	interesting	to	extract	RNA	from	SCR	or	miR-155	OT-1	
cells	sorted	from	the	spleen	of	infected	mice,	and	measure	the	dynamic	regulation	of	miR-
155	upon	listeria	infection	in	vivo.	
MiR-155	 expression	 has	 been	 previously	 shown	 to	 have	 an	 effect	 on	 the	 metabolism	 of	
tumour	cells.	For	example,	high	expression	of	either	miR-155	or	mTORC1	is	associated	the	
aggressive	 ERα	negative	 tumour	phenotype	 in	 breast	 cancer	 patients189.	Moreover,	 it	was	
shown	 that	 miR-155	 could	 modulate	 mTOR	 signaling	 in	 breast	 cancer	 cells.	 Indeed,	
overexpression	of	miR-155	in	MCF-7,	an	ER+	tumour	cell	line	with	low	basal	miR-155	levels,	
downregulated	 the	Rictor	 protein	 levels	 and	hence	both	 increased	mTORC1	 signaling	 and	
blocked	the	mTORC2189.	The	involvement	of	miR-155	in	the	modulation	of	mTOR	signalling	
in	CD8+	T	 cells	 is	not	yet	published.	Here,	we	demonstrated	 that	miR-155	overexpression	
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could	 enhance	 mTOR	 signalling	 upon	 stimulation.	 Indeed,	 phosophorylation	 of	 the	
ribosomal	protein	S6,	which	is	a	downstream	marker	of	mTOR	activity,	was	increased	upon	
OT-1	 miR-155	 cells	 activation.	 It	 would	 be	 interesting	 to	 confirm	 if	 in	 our	 model	 the	
increased	mTOR	pathway	was	also	due	to	a	decrease	 in	 the	rictor	protein	expression.	We	
know	 that	mTOR	 signalling	 is	 associated	 with	 a	more	 effector	 phenotype,	 as	 blocking	 of	
mTORC1	via	rapamycin	increased	the	amount	of	memory	T	cells	in	mice	upon	vaccinia	virus	
infection186.	In	line	with	this	observation,	the	OT-1	miR-155	T	cells	had	lower	expression	of	
the	marker	CD62L	compared	to	the	OT-1	SCR	in	the	periphery	at	the	peak	of	the	infection	
(data	not	shown).	
The	metabolic	switch	from	oxidative	phosphorylation	towards	glycolysis	upon	activation	of	
the	CD8+	T	cells	has	been	shown	to	be	crucial	for	their	functionality34.	A	recent	publication	
indicated	that	miR-155	might	be	important	in	the	regulation	of	cell	metabolism.	Researchers	
showed	that	in	the	MCF-7	breast	cancer	cell	line,	the	expression	of	miR-155	was	associated	
with	 a	 higher	 aerobic	 glycolytic	 activity	 and	 an	 increase	 in	 expression	 of	 the	 glucose	
transporter	GLUT1.	Interestingly,	 in	the	same	study	the	high	miR-155	cells	were	also	more	
resistant	to	the	glycolysis	inhibitor	2-DG,	demonstrating	that	they	possessed	a	better	ability	
of	 to	 perform	 metabolic	 switch	 between	 glycolysis	 and	 oxidative	 phosphorylation.	
Consequently,	 inhibition	of	miR-155	sensitized	 the	cells	 to	2-DG	 treatment190.	 In	our	OT-1	
cell	model	we	observed	an	increase	in	the	basal	glycolysis	of	OT-1	miR-155	cells	both	in	the	
presence	 and	 absence	 of	 glucose,	 indicating	 an	 increased	 ability	 for	 non-glycolytic	
acidification,	 potentially	 via	 the	 conversion	 of	 the	 glutamine	 present	 in	 the	 media	 into	
lactate.	Moreover,	 the	OT-1	miR-155	also	demonstrated	a	higher	 glycolytic	 capacity	upon	
activation.	It	would	be	interesting	to	investigate	more	precisely	which	metabolic	pathways	
are	involved	in	these	changes.	
Both	numbers	and	percentages	of	OT-1	miR-155	T	cells	were	increased	in	vivo	at	the	peak	of	
vaccination	with	OVA	CpG	and	infection	with	Lm-OVA.	We	showed	in	a	previous	publication	
that	 miR-155	 could	 downregulate	 the	 expression	 of	 the	 protein	 Suppressor	 of	 cytokine	
signalling	1	 (SOCS-1).	 This	downregulation	was	advantageous	both	 for	 the	proliferation	of	
the	CD8+	T	cells	and	for	their	ability	to	mediate	tumour	control.	Indeed,	pmel	CD8+	T	cells	
transduced	with	 a	 shRNA	 targeting	 SOCS-1	 had	 an	 increased	 accumulation	 at	 day	 4	 post	
hgp100	vaccinia	virus	infection	and	could	subsequently	decrease	the	growth	of	melanoma.	
It	is	likely	that	the	difference	observed	in	our	model	is	also	linked	to	the	downregulation	of	
SOCS-1.	 Hence,	 it	 would	 be	 interesting	 to	 confirm	 by	measuring	 SOCS-1	mRNA	 levels	 by	
qPCR,	or	protein	levels	by	western	blot.	
Although	 OT-1	 miR-155	 cells	 were	 increased	 in	 numbers	 and	 percentages	 in	 spleen	 and	
draining	 lymph	 nodes	 of	 both	 tumours,	 overexpression	 of	 miR-155	 lead	 to	 a	 higher	
accumulation	of	cells	only	 in	 the	 low-affinity	 tumours.	One	explanation	might	be	that	 in	a	
high	 affinity	 setting,	 the	 OT-1	 SCR	 cells	 are	 already	 being	 highly	 stimulated	 and	 are	
producing	high	level	of	miR-155	as	a	consequence.	Hence,	they	are	already	making	the	best	
of	the	limited	amount	of	survival	signals	in	the	immunosuppressive	tumour	environment.	In	
this	context,	miR-155	constitutive	expression	likely	did	not	confer	an	improved	capacity	to	
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OT-1	 T	 cells	 to	 infiltrate	 tumours.	 Moreover,	 OT-1	 miR-155	 cells	 only	 mediated	 a	 better	
protection	 against	 tumour	 expressing	 the	 low	 affinity	 ligand	 T4,	 and	 not	 the	 high	 affinity	
ligand.	This	is	somewhat	surprising	since	we	and	others	showed	that	stimulated	OT-1	miR-
155	are	capable	of	producing	more	IFN-γ	and	TNF-α	as	compared	to	OT-1	SCR	cells82,83.	One	
would	 expect	 higher	 cytokine	 production	 to	 be	 helpful	 for	 the	 OT-1	 cells	 tumour-lysing	
ability,	even	without	an	increase	in	accumulation.	However,	we	confirmed	in	vitro	that	the	
cytotoxic	abilities	of	OT-1	SCR	and	OT-1	miR-155	cells	did	not	differ,	which	means	that	this	
increase	 of	 cytokine	 production	 was	 either	 compensated	 by	 another	 mechanism	 (higher	
rate	of	activation	 induced	cell	death)	or	was	not	useful	 in	this	context.	As	we	discussed	 in	
the	 introduction,	 IFN-γ	signalling	 is	known	to	mediate	PDL-1	upregulation	 in	some	tumour	
cell	 lines.	We	did	not	observe	a	change	in	the	PD-1	expression	levels	on	the	surface	of	the	
tumour	 infiltrating	OT-1	miR-155	 cells	 compared	 to	OT-1	 SCR	 cells.	 However,	we	 did	 not	
measure	 if	 PDL-1	 expression	 increased	 on	 tumour	 cells	 in	 vivo	 upon	 OT-1	 miR-155	 cell	
transfer.	If	it	is	the	case,	it	could	explain	why	the	higher	IFN-γ	production	by	miR-155	CD8+	T	
cells	 did	 not	 result	 in	 a	 better	 tumour	 protection.	Additionally,	 it	would	be	 interesting	 to	
measure	the	proliferative	ability	of	OT-1	cells	within	the	tumour	tissue,	to	see	if	the	tumour	
environment	 would	 specifically	 prevent	 the	 OT-1	 miR-155	 cells	 from	 proliferating,	 as	
compared	to	lymphoid	organs.	
In	 contrast,	 there	 were	 more	 OT-1	 miR-155	 cells	 than	 OT-1	 SCR	 cells	 infiltrating	 OVA-
expressing	 tumours	 in	 the	 cotransfer	 setting.	 This	might	 be	 due	 to	 proliferation	 kinetics,	
with	miR-155	proliferating	faster	and	reaching	the	tumour	earlier.	Once	in	competition	with	
SCR	OT-1	cells	for	cytokines	and	survival	signal,	miR-155	cells	are	likely	to	do	better	due	to	
their	better	ability	to	respond	to	low	levels	of	IL-2	via	the	downregulation	of	SOCS-1	and	the	
phosphorylation	of	STAT581.	 	We	already	observed	that,	 in	optimal	culture	conditions	with	
high	 levels	 of	 cytokines,	OT-1	miR-155	 cells	 did	 not	 differ	 significantly	 in	 their	 survival	 or	
proliferative	 ability	 compared	 to	 OT-1	 SCR.	 To	 confirm	 that	miR-155	OT-1	 cells	 are	more	
successful	in	a	competition	setting,	we	plan	to	co-culture	OT-1	SCR	and	OT-1	miR-155	in	the	
presence	of	limiting	amounts	of	cytokines.		
Importantly,	while	miR-155	overexpression	in	OT-1	T	cells	did	not	improve	their	antitumour	
activity	 against	 tumours	 expressing	 the	 bona	 fide	 OVA	 epitope	 N4	 (SIINFEKL),	 it	 did	 so	
against	 tumours	 expressing	 the	 low-affinity	 antigen	 T4	 (SIITFEKL).	 This	 might	 explain	 the	
discrepancy	we	observe	between	our	results,	which	show	close	to	no	tumour	protection	in	
the	B16-N4	model,	 and	 the	 results	of	 Ji	et.	al.	which	 show	a	dramatic	 increase	 in	 tumour	
protection	in	the	pmel	model	upon	miR-155	transduction83.	Indeed,	pmel	T	cells	are	tolerant	
to	the	mouse	gp100	antigen	(mgp100),	and	do	not	respond	to	either	endogenous	mgp100	
expression,	 or	 vaccination	 with	 a	 mgp100	 expressing	 virus187.	 However,	 infection	 with	
vaccinia	virus	expressing	the	human	gp100	 induces	a	potent	response	of	the	pmel	CD8+	T	
cells,	 which	 are	 then	 able	 to	 destroy	 tumours	 expressing	 the	 mgp100	 antigen.	 The	 low	
affinity	SIITFEKL	(T4)	antigen	that	we	used	in	our	OT-1	model	is	of	comparable	affinity	to	the	
mgp100	 in	 the	 pmel	 model.	 Indeed,	 it	 was	 shown	 that	 expression	 of	 SIITFEKL	 in	 foetal	
thymic	 organ	 culture	 did	 not	 induce	 the	 negative	 selection	 of	 single	 positive	 OT-1	
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thymocytes,	 when	 expressed	 at	 low	 doses18.	 Hence,	 overexpression	 of	 miR-155	 might	
ameliorate	the	antitumour	response	only	in	a	low	affinity	setting,	both	for	the	pmel	and	the	
OT-1	model.	However,	in	the	pmel	model	of	Ji	et.	al.,	transfer	of	genetically	modified	CD8+	T	
cells	 was	 accompanied	 with	 infection	 with	 a	 vaccinia	 virus	 and,	 in	 some	 experiments,	
systemic	 injections	of	 IL-281.	We	plan	to	 investigate	 if	we	obtain	similar	 results	as	 Ji	et.	al.	
when	we	overexpress	miR-155	in	pmel	cells	and	vaccinate	the	mice	with	CpG	and	hgp100,	
instead	of	 infecting	 them	with	 the	vaccinia	 virus.	 This	would	allow	us	 to	 confirm	 that	 the	
discrepancies	we	observe	in	our	respective	results	are	due	to	the	affinity	of	the	model	TCR	
used,	and	not	to	the	difference	of	the	in	vivo	T	cell	priming.	
Interestingly,	we	could	observe	in	our	system	that	overexpression	of	miR-155	did	not	only	
allow	a	better	response	to	a	target	cell	expressing	a	low-affinity	antigen,	but	also	improved	
the	response	when	the	OT-1	miR-155	cells	were	primed	with	CpG	and	the	T4	peptide.		
There	might	be	two	explanations	for	the	miR-155	mediated	improvement	of	the	low	affinity	
response.	Firstly,	as	we	previously	mentioned,	low	affinity	interaction	between	the	TCR	and	
the	peptide:MHC	complex	 induces	 lower	 levels	of	the	endogenous	miR-155.	This	might	be	
due	 to	 the	 IRF4	 binding	 to	 the	 BIC	 promoter191,	 as	 it	 has	 been	 shown	 that	 IRF4	 is	 a	 key	
element	 in	 the	 affinity-mediated	 regulation	 of	 CD8+	 T	 cells	 responses192.	 In	 that	 context	
overexpressing	 miR-155	 might	 be	 more	 useful	 and	 rescue	 the	 cells	 that	 have	 been	 sub-
optimally	activated	via	a	low-affinity	ligand.		
Additionally,	 we	 observed	 downstream	 effects	 of	 miR-155	 overexpression,	 which	 might	
have	 an	 effect	 on	 the	 TCR:MHC	 functional	 avidity.	 Indeed,	 we	 measured	 an	 increased	
surface	expression	of	both	CD8α	and	CD8β	at	resting	phase.	This	might	have	an	effect,	not	
on	the	TCR	affinity	for	the	peptide:MHC,	as	the	cells	have	an	identical	transgenic	TCR,	but	on	
the	 functional	 avidity	 of	 the	 TCR	 to	 the	 peptide:MHC	 complex.	 Indeed	 blocking	 the	
interaction	between	CD8α	and	the	MHC	abrogated	the	ability	of	CD8+	T	cells	to	kill	target	
cells	 expressing	 a	 low	 affinity	 ligand,	 but	 had	 no	 effect	 on	 their	 ability	 to	 kill	 target	 cells	
expressing	 a	 high	 affinity	 antigen193.	 Hence,	 although	 CD8-binding	 to	 the	 MHC	 molecule	
seems	to	be	dispensable	for	high	affinity	ligands,	it	 is	necessary	to	stabilize	the	interaction	
between	 the	 TCR	 and	 a	 low	 affinity	 ligand.	 A	 higher	 surface	 expression	 of	 these	 two	
molecules	might	improve	the	OT-1	cells	avidity	to	low	affinity	ligand.	To	test	this	hypothesis,	
we	are	planning	 to	measure	 the	upregulation	of	miR-155	 in	CD8+	T	 cells	upon	binding	 to	
different	 concentration	of	either	N4	or	T4	peptides,	and	 to	assess	 if	CD8-blockade	affects	
the	outcome.	Moreover,	we	would	like	to	take	advantage	of	CD8β	KO	T	cells,	and	transduce	
them	with	our	miR-155	construct,	in	order	to	determine	their	ability	to	improve	low-affinity	
antitumour	effect	in	vivo.	
Overall,	our	results	demonstrate	that	overexpression	of	miR-155	in	tumour-specific	CD8+	T	
cells	is	a	promising	approach	for	cancer	immunotherapy.	Indeed,	a	better	ability	of	CD8+	T	
cells	to	expand	in	a	competition	setting	might	be	useful	in	human	patients	to	circumvent	the	
need	for	lymphodepleting	treatments	before	adoptive	cell	transfer.	This	would	improve	the	
safety	of	the	procedure.	Moreover,	endogenous	tumour	antigens	are	often	of	 low	affinity.	
Hence,	overexpressing	miR-155	would	help	naturally-occurring	tumour-specific	CD8+	T	cells	
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respond	better,	even	 in	the	absence	of	genetic	modification	to	 improve	the	TCR’s	affinity.	
This	would	prove	useful	in	therapies	using	the	culture	and	reinjection	of	tumour	infiltrating	
lymphocytes,	by	rescuing	those	of	low	affinity.	In	our	hands	and	in	the	hand	of	others,	mir-
155	overexpression	in	CD8+	T	cells	did	not	 induce	the	occurrence	of	a	 lymphoproliferative	
disease	 in	the	short	term83.	This	 is	an	encouraging	sign	for	the	safety	of	the	procedure,	as	
miR-155	overexpression	has	been	associated	with	several	malignancies.	However,	the	long-
term	safety	of	miR-155	overexpression	for	a	clinical	use	would	have	to	be	further	validated	
before	its	implementation.	
4. Methods:	
4.1. Mouse	strains:	
OT-1	 mice	 transgenic	 and	 H-2Kb/OVA-specific	 TCR	 and	 pmel	 mice	 transgenic	 for	 the	 H-
2Kb/pmel	17/gp100	epitope	were	bred	in	house	until	6-15	weeks	of	age	and	used	to	obtain	
OT-1	and	pmel	CD8+	T	cells.	OT-3	mice	of	low	affinity	OVA-specific	TCR,	were	obtained	from	
Dietmar	Zehn’s	laboratory.	Pmel	mice	producing	CD8+	T	cells	specific	for	the	mouse	gp100	
protein	 were	 bred	 in	 house.	 C57BL/6J	 mice	 were	 purchased	 from	 Harlan.	 C57BL/6J	
expressing	the	CD45.1	or	CD45.1/2	congenic	markers	were	bred	in	house.	
4.2. 	Cell	lines	
B16-F10	mouse	melanoma	cell	 line	was	used	either	 as	 such	or	 transduced	 to	express	 the	
SIINFEKL	 (N4)	 or	 SIITFEKL	 (T4)	 OVA	 protein.	 B16-OVA	 implicitly	 refers	 to	 the	 high	 affinity	
SIINFEKL	ovalbumin	protein.	
4.3. Production	of	retroviral	particules	
107	 phoenix-ECO	 cells	 were	 plated	 in	 a	 T150	 flask	 the	 day	 before	 the	 transfection.	
Transfection	with	a	mix	of	15μg	of	either	pMGP-SCR	or	p-MGP-M155	(Addgene	26527)	and	
15μg	 of	 the	 pCL-ECO	 packaging	 plasmid	 was	 performed	 with	 the	 JetPEI	 kit	 (Chemie	
Brunschwig	 101-10)	 following	 manufacturer’s	 instruction.	 Phoenix-ECO	 media	 was	
discarded	and	replaced	with	19ml	of	fresh	media	24	hours	after	transfection.	The	media	was	
collected	48-	and	72	hours	after	transfection	and	concentrated	via	ultracentrifugation	for	2	
hours	 at	 11’000xrcf.	 Retroviral	 particules	were	 carefully	 resuspended	 in	mouse	RPMI	 and	
snap-frozen	in	dry	ice	to	be	subsequently	stored	at	-80°C	until	use.	
4.4. Transduction	of	mouse	T	cells	and	maintenance	in	culture	
Spleens	of	OT-1	mice	were	dissociated,	and	T	cells	isolated	using	the	mouse	T	cell	isolation	
kit	 (stemcell	 19851).	 T	 cells	 were	 subsequently	 activated	 by	 co-culturing	 them	 with	
αCD3/αCD28-coated	magnetic	beads	 (Lifetechnologies	11452D)	at	a	2:1	beads:T	cell	 ratio.	
Usually,	0.5x106	T	cells	were	plated	 in	a	48-well	plate	 in	mouse	RPMI	 (see	supplementary	
methods	 page	 89)	 supplemented	 with	 50IU	 IL-2.	 On	 the	 same	 day,	 non-treated	 48-wells	
plate	were	 coated	with	 retronectin	 at	 a	 20μg/ml	 concentration	 and	 left	 overnight	 at	 4°C.	
20h	after	T	cell	activation,	the	retronectin-coated	plates	were	washed	with	PBS	and	blocked	
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for	30min	at	RT	with	PBS	2%BSA.	The	plates	were	washed	again	before	the	addition	of	the	
concentrated	 virus.	 If	 the	 volume	 of	 virus	 added	 on	 the	 plate	 (determined	 by	 prior	 virus	
titration)	was	 inferior	 to	250μl,	 the	 final	volume	was	adjusted	to	250μl	with	medium.	The	
retronectin-coated	 plates	 containing	 the	 virus	 were	 then	 centrifugated	 for	 90minutes	 at	
32°C	at	2’000xg.	At	 the	end	of	 the	 centrifugation,	 the	activated	T	 cells	 from	each	48-well	
were	resuspended	and	were	directly	added	on	top	of	 the	corresponding	well	 in	 the	virus-
coated	plate.	 The	 cells	 +	 virus	were	 centrifugated	 for	10min	at	25°C	at	200x	 rcf	 and	 then	
directly	placed	in	the	incubator	at	37°C.	The	next	day,	500μl	of	mouse	RPMI	supplemented	
with	50IU/ml	IL-2	was	added	on	top	of	the	transduced	cells.	The	percentage	of	transduced	
cells	was	assessed	2	days	after	transduction	via	flow	cytometry	detection	of	GFP	expression.	
At	this	time,	the	cells	were	either	used	for	in	vivo	tumour	challenge,	or	kept	in	culture.	The	
cells	in	vitro	were	switched	to	mouse	RPMI	+	10IU	IL-2/ml	+	10ng/ml	IL-7	+	10ng/ml	IL-15	at	
day	2	post	transduction,	and	to	mouse	RPMI	+	10ng/ml	IL-7	+	10ng/ml	IL-15	at	day	4	post	
transduction.	Transduced	mouse	CD8+	T	cells	could	be	kept	in	culture	in	IL-7	and	IL-15	and	
used	for	in	vitro	assays	for	2-3	weeks	after	transduction.	
4.5. Tumour	challenge	
C57BL/6J	mice	 6-10	weeks	 old	were	 subcutaneously	 engrafted	with	 105	 B16-OVA	 (N4)	 or	
B16-T4	tumour	cells	 in	100	or	200	μl	PBS.	6	days	 later,	105	mio	OT-1	cells	 (usually	around	
90%	SCR	or	miR-155	transduced)	were	transferred	intravenously	in	the	tail	vein.	7	days	after	
the	 tumour	graft,	mice	were	either	 infected	or	 vaccinated.	 Infections	were	performed	via	
the	intravenous	injection	of	2’000	PFU	L.	monocytogenes	genetically	modified	to	express	the	
OVA	 protein	 either	 in	 the	 high	 affinity	 natural	 N4	 epitope	 or	 the	 low	 affinity	 T4	 variant.	
Vaccination	 was	 performed	 as	 a	 subcutaneous	 injection	 at	 the	 base	 of	 the	 tail.	 The	
vaccination	mix	incorporated	10μg	N4	or	T4	peptide	with	50μg	CpG	in	PBS.	Tumour	growth	
was	measured	 using	 a	manual	 caliper	 from	 day	 6-post	 engraftement	 and	 every	 2-3	 days	
after	 that	 until	 the	 end	 of	 the	 experiment.	 Tumour	 sizes	 were	 calculated	 in	mm3	 as	 the	
product	of	length,	width	and	height,	divided	by	2.	
4.6. Organ	processing	for	in	vitro	analysis	
Spleens	were	mashed	through	a	100μm	filter,	and	treated	with	red	blood	cell	lysis	buffer	for	
5minutes	 before	 staining.	 Lymph	 nodes	 were	mashed	 through	 a	 40μm	 filter	 and	 stained	
directly.	Tumours	were	cut	 in	small	pieces	with	scissors,	and	put	 into	a	MACS	c-tube	with	
2.5ml	of	plain	DMEM	containing	enzymes	 from	the	MACS	130-096-730	kit.	Tumours	were	
then	 mechanically	 processed	 using	 the	 gentleMACS	 Dissociator	 (#	 130-093-235)	 and	 the	
m_impTumor_02	programm.	Afterwards,	tumours	were	 incubated	at	37°C	for	20	minutes,	
rolling	 constantly.	 Finally,	 tumours	were	 again	mechanically	 processed	using	 the	 program	
m_impTumor_03.	 Resuspended	 tumours	were	 filtered	 through	 40μm,	 before	 pelleting	 by	
centrifugation.	 Debris	 were	 removed	 by	 percoll	 purification.	 The	 tumour	 cell	 pellet	 was	
firstly	resuspended	in	a	15ml	falcon	in	40%percoll	in	PBS	at	37°C.	Then	4ml	of	70%	percoll	in	
PBS	 was	 carefully	 layered	 on	 top	 of	 the	 40%	 percoll.	 The	 tubes	 were	 subsequently	
centrifuged	at	975x	rcf	for	20	minutes,	without	brake	and	with	level	6	acceleration.	Tumour	
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infiltrating	 lymphocytes	were	 isolated	 from	the	middle	phase	of	 the	density	gradient,	and	
washed	2x	before	staining	or	 restimulation	 for	 the	detection	of	cytokine	production.	Both	
the	axillary	and	inguinal	 lymph	nodes	on	the	same	flank	as	the	tumour	were	sampled	and	
defined	as	tumour	draining	lymph	nodes	(dLNs)	in	the	results.		
4.7. Functional	assays	
Detection	 of	 proliferation	 in	 vivo	 via	 bromodeoxyuridine	 (BrdU)	 incorporation:	Mice	 were	
injected	with	1.8mg	BrdU	diluted	in	PBS	intraperitoneally	2.5	hours	before	organ	collection	
and	 analysis.	 Organs	 were	 processed	 as	 described	 previously.	 After	 staining	 for	 surface	
markers,	cells	were	fixed	and	firstly	the	cell	membrane	was	permeabilized,	then	the	nuclear	
membrane	 was	 permeabilized	 using	 the	 Cytoperm	 Plus	 (BD	 561651).	 Add	 DNAse	 at	 a	
concentration	 of	 0.3μg/μl	 and	 incubate	 for	 1	 hour	 at	 37°C.	 Then	 add	 the	 anti-BrdU	 PE	
antibody	 in	 diluted	 in	 Perm/Wash	 buffer	 and	 incubate	 xx	minutes	 at	 room	 temperature.	
Wash	2x	before	resuspension	and	acquisition	via	flow	cytometry.	
4.8. FACS		
Trucount	beads	quantification	of	absolute	number	of	cells/ml	of	blood:	Absolute	numbers	of	
cells	in	the	blood	were	quantified	thanks	to	Trucount	beads	(BD	340334).	50μl	of	blood	was	
added	 to	 the	 Trucount	 tubes	 containing	 a	 defined	 number	 of	 beads.	 50μl	 of	 FACS	 buffer	
containing	 a	 2x	 concentrated	 amount	 of	 antibodies	was	 added	 directly	 to	 the	 blood	 and	
beads	mix	and	incubated	at	4°C	for	20	minutes.	400μl	of	1x	FACS	lysing	buffer	(BD	349202)	
was	then	added	to	the	stained	blood.	No	wash	was	performed	before	acquisition,	in	accord	
with	the	manufacturer’s	instruction,	to	maximize	the	measurement	accuracy.		
After	 acquisition	 the	 total	 number	 of	 cells/ml	 of	 blood	 was	 calculated	 as	 such:	=  𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑏𝑒𝑎𝑑𝑠 ∗ 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑖𝑛 𝑡𝑢𝑏𝑒 ∗ 200	
Intracellular	 cytokine	 staining:	 To	 assess	 intracellular	 cytokine	 production,	 10ng/ml	 final	
concentration	PMA	and	500ng/ml	 ionomycin,	or	10μM	of	SIINFEKL	peptide	were	added	to	
plated	splenocytes	or	 tumour	 infiltrating	 lymphocytes	 in	a	96-well	plate	and	placed	 in	 the	
incubator	 at	 37°C.	 After	 30	minutes,	 Golgistop	 (monensin,	 BD	 554724)	was	 added	 to	 the	
wells	at	a	1/1’500	dilution.	The	cells	were	placed	back	in	the	incubator	for	an	additional	4	
hours	 before	 surface	 staining	 and	 intracellular	 staining.	 Fixation	 and	 permeabilization	 for	
the	intracellular	detection	of	cytokines	was	performed	with	the	BD	kit	(554714)	according	to	
the	manufacturer’s	instruction.	
CFSE	labelling:	Count	cells	in	suspension	and	transfer	desired	number	to	a	15ml	falcon	tube.	
Pellet	 cells	 by	 centrifugation,	 discard	 supernatant	 and	 resuspend	 thoroughly	 in	 1ml/mio	
cells	pre-warmed	37°C	PBS	solution	containing	CFSE	diluted	to	a	working	concentration	of	
1μM.	 Incubate	 the	 cells	 for	 20	minutes	 at	 37°C,	 under	 constant	 rolling	motion,	 protected	
from	light.	Add	1volume	of	ice-cold	FCS,	and	incubate	cells	on	ice	for	at	least	5	minutes.	Fill	
the	 rest	 of	 the	 tube	 with	 complete	 medium,	 14	 ml	 final.	 Centrifuge	 cells,	 discard	
supernatant	and	resuspend	cells	in	fresh	complete	medium.	The	cells	can	now	be	counted,	
used	for	flow	cytometry	and	cocultures.	
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4.9. qPCR	
Cells	were	 collected,	 resuspended	 in	 RNAlater	 (Ambion	 AM7020)	 and	 stored	 at	 -20°C	 for	
further	 RNA	 isolation.	 Subsequently,	 RNA	 was	 purified	 in	 40μl	 H2O	 using	 the	 miRVana	
(Ambion	 AM1561)	 kit	 and	 following	 manufacturer	 instructions.	 MiR-specific	 reverse	
transcription	was	performed	on	5μl	 of	 the	extracted	RNA	and	using	Taqman	primer	pairs	
(Taqman	 SnoRNA202	 1232,	 Taqman	 mmu-miR155	 2571)	 and	 the	 Taqman	 reverse	
transcription	 kit	 (Lifetechnologies	 4366597)	 following	 manufacturer	 instructions.	 Finally,	
qPCR	was	 run	using	96-well	optical	plates	 (Lifetechnologies	4346906)	 in	a	7500	Fast	Real-
Time	 PCR	machine	 (Thermofisher	 4351106).	 The	 qPCR	mix	 volume	was	 of	 10μl/well	 and	
comprised	2μl	of	the	RT	reaction	mixed	with	the	primers	and	Taqman	Fast	Universal	Master	
Mix	(Lifetechnologies	4352042).	All	qPCR	reactions	were	performed	in	2	technical	replicates,	
and	the	values	were	excluded	if	the	difference	in	CT	was	higher	than	0.2	or	if	one	of	the	CT	
value	was	higher	than	33.	The	mean	of	the	technical	replicates	of	the	control	gene	(Sno202)	
was	substracted	to	the	mean	of	the	technical	replicates	of	the	gene	of	interest	(miR-155)	to	
calculate	the	ΔCT.	Fold	changes	in	expression	where	then	calculated	using	a	control	sample	
for	normalization	as	such:	𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑜𝑓 𝑚𝑖𝑅155 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑖𝑛 (𝑥) = 2!"# !"#$%"& !"#$%& !!"#(!"#$%& !)	
4.10. Statistical	analysis	
	
Experiments	 showed	 are	 representative	 experiments	 of	 usually	 2	 replicates.	
Statistical	 tests	 performed	 were	 2-way	 ANOVAs	 followed	 by	 a	 Tukey’s	 multiple	
comparison	test	to	compare	the	different	groups	between	them.	
When	two	groups	were	compared,	the	t	test	with	a	two-sided	P	value	and	a	95%	confidence	
interval	was	performed.	When	more	than	two	groups	over	time	were	compared,	a	two-way	
ANOVA	test	was	performed,	followed	by	a	Tukey’s	multiple	comparison	test.	Figures	show	
one	representative	experiment	out	of	2	or	3	independent	experiments.	The	individual	dots	
always	 represent	 biological	 replicates	 (number	 of	 mice	 or	 independent	 wells).	 When	
technical	 replicates	 were	 performed	 (usually	 in	 duplicates),	 the	 average	 of	 the	 replicates	
was	plotted.	All	statistical	tests	were	performed	using	the	Prism	version	6	software	(NS,	not	
significant;	*P	<	0.05;	**P	<	0.01;	***P	<	0.001;	****P	<	0.0001.)	
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Chapter	III:	Overexpression	of	miR-155	in	
anti-PSMA	CAR+	CD8+	T	cells	
1. Aim:	
Recent	studies	have	shown	the	potential	of	chimeric	antigen	receptor	(CAR)	therapy	for	the	
treatment	of	 various	 cancers,	 especially	 haematological	malignancies.	However,	 designing	
effective	CAR	treatments	against	solid	tumours	has	proven	difficult	to	achieve.	Indeed,	solid	
tumours	 induce	 a	 strongly	 immunosuppressive	 microenvironment	 that	 infiltrating	 T	 cells	
need	to	overcome	in	order	to	perform	their	cytolytic	activity.	
Our	aim	is	to	improve	the	antitumour	efficiency	of	an	existing	CAR	against	a	solid	tumour	by	
overexpressing	 miR-155.	 We	 used	 a	 CAR	 targeting	 the	 prostate	 specific	 marker	 antigen	
(PSMA)	as	our	model	CAR	to	test	our	hypothesis.	PSMA	is	a	protein	that	is	overexpressed	in	
the	endothelium	of	advanced	prostate	cancer,	as	well	 as	 in	 the	neovasculature	of	 several	
other	 cancers,	 but	 not	 in	 normal	 endothelium194.	 It	 was	 previously	 shown	 that	 the	 anti-
PSMA	 chimeric	 antigen	 receptor	 can	 specifically	 lyse	 PSMA+	 cells,	 and	 induce	 tumour	
regression	 in	 vivo	 in	 xenograft	mouse	models195–197.	 The	 results	 of	 a	 Phase	 I	 clinical	 trial	
showed	that	T	cells	transduced	with	an	anti-PSMA	CAR	could	engraft	efficiently	in	prostate	
cancer	 patients,	 and	 mediate	 some	 partial	 responses198.	 We	 sought	 to	 ameliorate	 the	
antitumour	efficiency	of	CAR	T	cells	redirected	against	PSMA	by	overexpressing	miR-155,	as	
a	 proof	 of	 concept	 of	 the	 potential	 of	 combining	 miR-155	 overexpression	 with	 CAR	
transduction.	
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2. Results:	
Efficient	and	stable	transduction	of	CD8+	T	cells	 from	peripheral	blood	of	healthy	
donor	with	the	PSMA-CAR-miR-155	or	-SCR	construct	
We	 obtained	 the	 lentiviral	 construct	 expressing	 the	 anti-PSMA	 CAR	 of	 the	 second	
generation	 from	the	 laboratory	of	Prof.	Coukos	 in	U-Penn.	We	subsequently	modified	 the	
plasmid	to	incorporate	the	miR-155	and	SCR	sequence	after	the	CAR	sequence,	so	that	both	
the	 CAR	 and	 miR-155	 would	 be	 co-expressed	 in	 the	 transduced	 cells	 (see	 page	 90	 for	
microRNAs	sequence	and	Figure	28A	for	a	schematic	view).		
Peripheral	blood	 from	healthy	donors	was	 collected	 from	 the	 Lausanne	 transfusion	blood	
center	 and	 CD8+	 T	 cells	 were	 purified	 (see	 Methods	 4.3,	 page	 83).	 CD8+	 T	 cells	 were	
transduced	with	either	the	SCR-	or	the	miR-155	CAR	construct	and	CAR	expression	on	the	
surface	of	 the	 cells	was	measured	5-7	days	 after	 transduction	by	 flow	 cytometry.	Usually	
CAR+	CD8+	T	cells	comprised	30-50%	of	the	total	population.	These	cells	were	subsequently	
expanded	 by	 coculture	 with	 the	 MS1_PSMA	 cell	 line.	 After	 re-expansion,	 the	 CAR+	
population	usually	amounted	to	80-90%	of	the	whole	population	(Figure	28B).	Transduced	
cells	 could	 be	 restimulated	 with	 irradiated	 MS1_PSMA	 or	 irradiated	 PBMCs	 and	 kept	 in	
culture	for	up	to	3	weeks.	CAR	expression	at	the	surface	of	the	cells	was	stable	during	this	
time	lapse.	
	
Figure	 28:	 (A)	 Scheme	 of	 the	 three	 lentiviral	 plasmids	 incorporating	 both	 the	 αPSMA	 CAR	 and	 either	 the	 green	
fluorescent	 protein	 (GFP)	 or	 the	 microRNA	 miR-155	 or	 the	 scrambled	 control	 (SCR)	 under	 the	 control	 of	 the	 EF1α	
promoter.	(B)	Human	CD8+	T	cells	were	transduced	with	the	lentiviral	constructs	and	surface	expression	of	the	αPSMA	
CAR	was	detected	by	flow	cytometry	using	an	APC-conjugated	anti-mouse	F(ab)2	antibody.	
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MiR-155	 was	 augmented	 at	 baseline	 in	 cells	 transduced	 with	 the	 miR-155_CAR	
construct	
After	transduction	and	restimulation,	CD8+	T	cells	were	left	in	culture	with	150IU	IL/2	for	13	
days	 and	 restimulated	 with	 either	 MS1_PSMA	 	 at	 a	 5:1	 T	 cells:MS1_PSMA	 ratio,	 or	
αCD3/αCD28	 beads	 at	 a	 1:1	 ratio.	 Before	 restimulation,	 the	 difference	 in	 miR-155	
expression	 between	 CAR_SCR	 and	 CAR_miR-155	 cells	 was	 of	 3-fold.	 Upon	 activation,	 the	
endogenous	 miR-155	 was	 highly	 upregulated	 and	 masked	 the	 effect	 of	 constitutive	
overexpression.	1	day	after	activation,	the	difference	was	only	1.5-fold,	and	even	less	later	
in	the	response	(Figure	29).	
	
Figure	 29:	 MiR	 -155	 levels	 were	 measured	 at	 baseline,	 as	 well	 as	 1,	 2,	 3	 and	 5	 days	 after	 stimulation	 with	 either	
MS1_PSMA	(left	panel)	or	αCD3/αCD28	beads	(right	panel),	and	normalised	to	OT-1	SCR	levels	before	stimulation	
The	proliferative	ability	of	CAR_miR-155	T	cells	was	augmented	in	vitro	
CAR+	 CD8+	 T	 cells	 were	 marked	 with	 cell	 trace	 Violet	 dye	 and	 then	 stimulated	 either	
specifically	 by	 coculture	 with	 MS1_PSMA	 or	 non-specifically	 by	 αCD3/αCD28-coated	
magnetic	 beads.	 Three	 days	 after	 restimulation,	 the	 CAR_miR-155	 T	 cells	 had	 replicated	
more	than	the	CAR_SCR	controls,	both	when	stimulated	with	beads	or	with	the	PSMA+	cell	
line	(Figure	30).	This	shows	that	the	miR-155	transduced	CAR	cells	were	able	to	proliferate	
faster	than	their	SCR	counterparts.	
	
Figure	 30:	 Celltrace	 Violet	 dilution	 upon	 T	 cell	 proliferation	 measured	 3	 days	 after	 restimulation	 either	 with	
αCD3/αCD28	beads	or	MS1-PSMA	
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Lysis	of	target	cells	in	vitro	was	unchanged	upon	miR-155	overexpression	
The	 ability	 of	 CAR+	 T	 cells	 to	 lyse	 cells	 expressing	 the	 PSMA	 protein	 was	 measured	 by	
chromium	release	assay.	Cells	from	either	the	Cal	27	or	MS1	cell	line,	genetically	modified	to	
express	PSMA	or	not,	were	loaded	with	51Cr	for	1	hour	and	then	cocultured	with	different	
amounts	of	effector	cells	(CAR+)	for	4	hours.	The	CAR+	cells	were	able	to	lyse	efficiently	the	
cells	 expressing	 the	 PSMA	protein,	 and	 had	 a	 low	 level	 of	 non-specific	 lysis.	 However,	 all	
constructs	were	similar	in	their	ability	to	lyse	target	cells,	which	shows	that	overexpression	
of	 miR-155	 did	 not	 affect	 the	 lysis	 ability	 of	 the	 cells	 in	 vitro	 (Figure	 31).	
	
Figure	 31:	 (A)	 Cal	 27,	 (B)	 Cal	 27_PSMA,	 (C)	MS1	 and	 (D)	MS1-PSMA,	were	marked	with	 Cr51	 and	 then	 incubated	 at	
different	effector:T	cell	ratio	for	4	hours.	Specific	lysis	was	calculated	as	explained	in	the	methods	section.		
MiR-155	CAR	T	cells	did	not	 improve	 tumour	protection	 in	vivo	 compared	 to	SCR	
CAR	T	cells	
To	assess	the	ability	of	our	CAR+	T	cells	to	mediate	tumour	regression	in	vivo,	we	engrafted	
NSG	mice	with	a	mixture	of	MS1_PSMA	and	matrigel.	After	2	weeks,	tumours	were	palpable	
and	 their	 growth	was	measured	 every	week	 using	 the	 IVIS	 imager.	 Luciferin	was	 injected	
intraperitoneally	 and	 the	 luminescence	 was	 measured	 in	 anesthetized	 live	 animals(see	
Supplementary	 Figure	 35).	 4.5	 and	 5.5	 after	 tumour	 graft,	 two	 sequential	 intravenous	
transfers	 of	 respectively	 2.5x106	 and	 5x106	 CAR+	 T	 cells	 were	 done	 in	 tumour	 bearing	
animals	(Figure	32).	Mice	were	either	injected	with	SCR_CAR,	miR-155	CAR,	or	received	no	
cell	 transfer	 (PBS).	 Injection	 of	 anti-PSMA-CAR+	 T	 cells	 mediated	 a	 strong	 tumour	
regression.	Indeed,	a	20-fold	decrease	in	luminescence	was	observed	one	week	after	CAR	T	
cell	transfer.	However,	the	addition	of	miR-155	did	not	increase	the	ability	of	CAR+	T	cells	to	
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mediate	tumour	regression	in	this	model	(Figure	32).	Moreover,	the	long-term	tumour	was	
not	improved,	as	tumours	started	growing	back	in	both	groups	after	a	couple	of	weeks.		
	
											 	
Figure	32:	(A)	5x106	MS1_PSMA	cells	were	subcutaneously	engrafted	in	the	flank	of	NSG	mice.	4.5	and	5.5	weeks	after	
tumour	graft,	2.5x106	and	5x106	CAR+	T	cells	were	transferred	intravenously	in	tumour	bearing	mice.	(B)	Tumour	growth	
was	measured	via	 luminescence	every	week.	Statistical	significance	calculated	with	Tukey’s	multiple	comparisons	test	
(n=7-10)	
3. Discussion:	
In	 this	project	we	wanted	 to	assess	 the	ability	of	miR-155	overexpression	 to	 increase	 the	
antitumour	 efficiency	 of	 anti-PSMA	CAR	 CD8+	 T	 cells.	We	 observed	 that	 CD8+	 T	 cells	 co-
expressing	the	CAR	and	miR-155	had	a	higher	proliferative	ability	in	vitro,	but	did	not	differ	
in	 their	 tumour	 lysing	ability.	 In	mouse	 xenograft	model,	we	 showed	 that	 anti-PSMA	CAR	
CD8+	 T	 cells	 could	 efficiently	mediate	 tumour	 regression.	However,	 concomitant	miR-155	
overexpression	did	not	improve	the	antitumour	efficiency	of	the	CAR	in	this	model.	
The	lentiviral	construct	we	developed,	 incorporated	both	the	anti-PSMA	CAR	sequence,	as	
well	as	the	whole	miR-155,	so	that	both	the	CAR	and	the	microRNA	would	be	co-expressed.	
To	make	our	lentiviral	construct,	we	inserted	the	original	miR-155	pre-miRNA	sequence,	and	
added	 200	 bp	 on	 each	 side	 to	 ensure	 correct	 processing.	 It	 was	 shown	 in	 a	 previous	
publication	that	at	least	40bp	on	each	side	of	the	stem-loop	sequence	were	necessary	for	a	
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correct	processing	of	 the	pre-miRNA	 into	a	 functional	mature	microRNA46.	Moreover,	 the	
promoter	EF1α,	has	been	 shown	 to	be	able	 to	mediate	good	expression	of	microRNAs199.	
The	 miRNA	 sequence	 was	 added	 directly	 after	 the	 CAR	 sequence.	 Theoretically,	 the	
microRNA	miR-155	should	be	correctly	processed	from	the	CAR	mRNA,	as	it	was	shown	that	
it	 is	possible	 for	pri-miRNA	to	 function	both	as	mRNAs	as	well	as	microRNA	precursors200.	
However,	when	we	measured	the	 increase	 in	miR-155	expression	 in	cells	 transduced	with	
the	miR-155	construct,	 there	was	only	a	3-fold	 increase	compared	to	 the	cells	 transduced	
with	 the	 control	 plasmid.	 This	 is	 surprising,	 as	 in	 the	 retroviral	 construct	 p-MGP	miR-155	
used	in	OT-1	cells	to	overexpress	miR-155,	the	pri-miRNA	sequence	was	added	directly	after	
the	 GFP	 sequence,	 and	 both	 the	 protein	 and	 mature	 microRNA	 were	 very	 efficiently	
produced.	 Indeed	we	 could	measure	 a	 strong	GFP	 signal,	 as	well	 as	 a	 30-fold	 increase	 in	
miR-155	production	(Figure	19).	However,	one	cannot	exclude	that	CARs,	which	are	complex	
proteins,	might	impair	microRNA	processing.	In	another	study,	in	which	miR-17-92	and	the	
anti-EGFRvIII	CAR	were	co-expressed	in	human	T	cells,	the	CAR	and	microRNA	were	encoded	
in	different	lentiviral	plasmids97.	This	is	something	we	could	try	in	our	next	experiments.	
Another	possibility	is	that	the	endogenous	miR-155	was	highly	upregulated	in	CAR+	CD8+	T	
cells	in	culture,	and	hence	would	mask	the	expression	of	the	transgenic	miR-155.	It	is	likely	
that	 the	endogenous	miR-155	 is	high,	 since	CAR	CD8+	T	cells	were	kept	 in	vitro	with	high	
doses	of	 IL-2,	and	 frequently	 restimulated.	 Indeed,	 it	was	shown	 in	a	malignant	T	cell	 line	
that	the	presence	of	 Il-2	and	 IL-15	could	upregulate	miR-155	expression	via	an	 increase	 in	
STAT5	 signaling72.	 Of	 note,	when	 the	 endogenous	 levels	 of	miR-155	 in	 our	 CAR	 SCR	 cells	
were	 compared	 to	 that	 of	 naive	 cells	 from	 the	 peripheral	 blood,	 a	 two-fold	 increase	was	
observed	(data	not	shown).	Eventually,	we	do	not	know	how	many	extra	copies	of	miR-155	
this	baseline	3-fold	 increase	represents,	which	 is	why	we	decided	to	 investigate	anyway	 if	
this	increase	was	enough	to	induce	a	biological	difference	in	our	model.	
Indeed,	we	could	see	an	improvement	in	the	proliferative	ability	of	the	CAR	miR-155	cells	in	
vitro	compared	to	the	CAR	SCR	cells,	both	with	CAR	signalling	through	PSMA	binding	or	TCR	
cross	 linking	 via	 αCD3/αCD28	 binding.	 However,	 no	 increase	 in	 cytokine	 production	 or	
target	 cell	 killing	 was	 observed	 in	 vitro.	 Finally,	 we	 did	 not	 see	 an	 increase	 either	 in	
proliferation	or	 in	tumour	control	 in	vivo.	Hence,	miR-155	overexpression	did	not	 improve	
the	αPSMA	CAR	antitumour	effect	 in	 this	model.	However,	 there	are	 still	 some	questions	
that	 remain	 to	 be	 answered.	 Firstly,	 miR-155	 effect	 acts	 mainly	 by	 increasing	 cytokine	
signalling,	via	 the	downregulation	SOCS-1,	as	we	previously	discussed,	and	the	 increase	of	
phosphoSTAT5	 levels	 in	 response	 to	 IL-2.	 Extrinsic	 cytokines	 are	 crucial	 for	 the	miR-155-
mediated	 antitumour	 response.	 Indeed,	 the	 antitumour	 efficiency	 of	mouse	 CD8+	 T	 cells	
overexpressing	miR-155	was	strongly	reduced	when	those	cells	were	transferred	in	IL-15-/-	x	
IL-7-/-	KO	hosts83.	For	this	reason,	it	would	be	more	appropriate	to	test	the	proof	of	principle	
of	miR-155	and	CAR	co-expression	for	antitumour	therapy	in	a	complete	mouse	model,	and	
not	in	a	human	xenograft	model.	In	that	case	we	could	use	immunoreplete	animals,	because	
we	would	not	need	to	worry	about	the	transferred	human	CD8+	T	cells	being	rejected.	It	is	
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possible	that	the	overexpression	of	miR-155	does	not	bestow	an	advantage	to	CD8+	T	cells	
functionality	in	vivo	in	NSG	mice.		
Secondly,	we	now	know	that	the	affinity	of	the	TCR	to	its	peptide:MHC	complex	determines	
the	extent	of	miR-155	upregulation.	We	can	only	 speculate	as	whether	 the	affinity	of	 the	
CAR	 scFv	 to	 its	 ligand	 is	 also	 correlated	 to	 miR-155	 expression.	 And	 whether	 miR-155	
overexpression	would	be	more	helpful	in	a	CAR	bearing	a	scFv	of	lower	affinity,	in	the	same	
manner	that	overexpression	of	miR-155	was	more	beneficial	for	a	low	affinity	TCR.	
Researchers	have	become	 interested	 in	 low	affinity	CARs	 recently,	as	 they	might	be	more	
sensitive	in	their	discrimination	of	high	and	low	tissue	expression	of	the	target	antigen.	This	
is	indeed	an	issue,	as	many	antigens	that	are	overexpressed	in	tumours,	can	be	expressed	at	
low	levels	in	other	parts	of	the	body.	This	type	of	situation	can	have	dramatic	consequences.	
For	example,	 a	patient	 succumbed	 to	an	anti-HER2	CAR	 treatment,	 after	 the	CAR+	T	 cells	
started	 attacking	 their	 lungs,	 where	 low	 levels	 of	 HER2	were	 expressed.	 The	 subsequent	
pulmonary	oedema	was	fatal179.	In	the	case	of	low	affinity	CARs,	it	was	demonstrated	that	
they	 have	 the	 ability	 to	 discriminate	 between	 high	 and	 low	 surface	 expression	 of	 the	
antigen180.	 In	 this	 context,	 it	would	 be	 interesting	 to	 test	 if	 overexpression	 of	miR-155	 is	
helpful	for	low	affinity	CARs.	
4. Methods:	
4.1. Construction	of	a	chimeric	antigen	receptor	plasmid	containing	miR-155	
The	 group	 of	 G.Coukos	 in	 U-penn,	 Philadelphia,	 provided	 the	 anti-human	 PSMA	 chimeric	
antigen	 receptor197.	 It	 is	 composed	 of	 a	 mouse	 antibody	 scFv	 (J591)	 specific	 for	 an	
extracellular	 epitope	 of	 human	 PSMA201.	 This	 scFv	 is	 fused	 to	 a	 CD8	 hinge	 as	 the	
transmembrane	 domain	 and	 spacer195.	 In	 addition,	 it	 comprises	 the	 intracellular	 CD3ζ	
signalling	 domain	 as	 well	 as	 the	 CD28	 costimulatory	 domain202.	 To	 allow	 for	 proper	 CAR	
extracellular	 localisation	 and	 anchorage	 in	 the	 membrane,	 a	 CD8a	 leader	 sequence	 is	
present	at	the	5’	position	of	the	CAR.		
	
	
	
		
We	 subsequently	 inserted	 in	 the	original	 vector	 and	 inserted	either	 the	 full	 pri-microRNA	
sequence,	with	an	additional	200	base	pairs	on	each	side	of	the	mature	microRNA	to	ensure	
correct	 processing,	 or	 a	 scrambled	microRNA	 sequence	 as	 a	 control.	 Finally,	 we	made	 a	
vector	expressing	 the	Green	Fluorescent	Protein	 (GFP)	and	 the	CAR	under	 the	same	EF1α	
promoter,	separated	by	a	2A	sequence	(see	Figure	28A	page	77).	
4.2. Production	of	lentiviral	particles	for	transduction	
HEK	293T/17	cells	were	cultured	in	complete	RPMI.	107	cells	were	plated	in	the	afternoon	
before	 the	 day	 of	 transfection.	 The	 following	morning,	 the	 DNA	 construct	 containing	 the	
anti-PSMA	scFv 
Figure	33:	Chimeric	antigen	receptor	specific	for	PSMA	
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CAR	(15	μg),	 together	with	packaging	plasmids	Gag/pol	 (7μg),	Vsvg	 (7μg)	and	Rev	 (3.5μg),	
was	 transfected	 into	 the	cells	with	 the	 JetPEI®	kit	 (Chemie	Brunschwig	101-10).	Virus	was	
collected	at	24-	and	48	hours	and	concentrated	by	ultracentrifugation	at	11’000x	rcf	 for	2	
hours	before	use	or	freezing.	
4.3. Isolation	and	transduction	of	CD8+	T	cells	from	peripheral	blood	of	healthy	
patients	
Peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 were	 extracted	 from	 healthy	 donor	 blood	
provided	by	the	 local	blood	transfusion	centre.	15ml	of	buffycoat	was	mixed	with	15ml	of	
PBS	and	carefully	layered	on	top	of	15ml	of	a	density	gradient	media	(Lymphoprep,	Axonlab	
1114547)	 in	 a	 50ml	 Falcon	 tube.	 The	 cells	were	 subsequently	 centrifuged	 20min	 at	 2200	
rpm	 (600xg)	 without	 break.	 The	 PBMCs	 sedimented	 as	 an	 intermediate	 band,	 were	
recovered	and	washed	in	PBS	1x.	
Human	CD8+	T	cells	were	negatively	selected	from	PMBCs	by	magnetic	sorting	(STEMCELL	
19053).	 Then,	 they	were	activated	by	αCD3/αCD28	beads	 (Dynabeads	11161D)	 for	24h	 in	
human	 RPMI	 (see	 Supplemental	methods)	 containing	 150	 international	 units	 (IU)	 IL-2/ml	
before	 being	 infected	 by	 lentiviral	 particles.	 Infection	 was	 conducted	 by	 adding	 fresh	 or	
frozen	virus	on	the	cells	together	with	8μg/ml	polybrene,	followed	by	centrifugation	of	the	
cell	 plate	 for	 90	 minutes	 at	 800xg.	 The	 transduction	 efficiency	 was	 assessed	 by	 surface	
staining	 of	 the	 CAR	 for	 30min	 on	 ice,	 with	 an	 anti-mouse	 F(ab)2	 antibody	 from	 Jackson	
Immunosearch	(115-606-072).	
4.4. Human	CD8+	T	cell	maintenance	in	vitro	
Cells	were	kept	in	150IU	IL-2	in	human	RPMI	at	a	density	of	106	cells/ml	of	medium	for	7-12	
days	after	activation.	Once	the	cells	stopped	proliferating,	they	were	restimulated.	The	cells	
were	either	non-specifically	stimulated	with	irradiated	PBMCs	from	2	donors	(feeders)	at	a	
1:1	 ratio	 T	 cell:feeder	 and	 PHA	 (2μg/ml)	 or	 CAR+	 T	 cells	were	 specifically	 expanded	with	
MS1_PSMA	and	feeders	at	a	5:5:1	ratio	T	cell:feeder:MS1_PSMA.	
4.5. Cell	lines	
The	 MS1	 mouse	 pancreatic	 islet	 endothelial	 cell	 line	 was	 provided	 by	 the	 Prof.	 Coukos	
laboratory	 in	 U-Penn.	 The	 MS1_PSMA	 cell	 line	 was	 co-transduced	 with	 two	 lentiviral	
construct,	one	expressing	the	 firefly	 luciferase	and	the	fluorescent	protein	DsRed,	and	the	
other	expressing	the	human	PSMA.	The	Cal	27	human	epithelial	cell	line	was	provided	by	Dr.	
Rivals.	 Cal	 27_PSMA	 cells	 were	 obtained	 by	 transducing	 the	 Cal	 27	 cells	 with	 a	 lentiviral	
vector	expressing	the	human	PSMA.	
4.6. Mouse	tumour	models	
The	 severely	 immunosuppressed	 strain	of	mice	NOD	SCID	common	gamma	KO	 (NSG)	was	
used	as	a	xenograft	model.	6-10	weeks	old	mice	were	engrafted	with	5	million	of	either	MS-
1	 or	MS-1	 PSMA	 cells	 were	 engrafted.	 Injections	 were	 performed	 subcutaneously	 in	 the	
flank	in	a	1:1	mix	of	matrigel	(Chemie	Brunschwig	356234)	and	PBS.	Every	week,	tumour	size	
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was	measure	by	luminescence	by	intraperitoneal	injection	of	200μl	luciferin	(15μg/ml)	and	
using	 a	 the	 Xenogen	 IVIS	 Lumina	 II	 machine.	 The	 images	 were	 analysed	 using	 the	 Living	
Image®	Software.	
4-5	weeks	after	tumour	graft,	5	million	CAR+	T	cells	were	transferred	intravenously.	
4.7. qPCR	
Cells	were	 collected,	 resuspended	 in	 RNAlater	 (Ambion	 AM7020)	 and	 stored	 at	 -20°C	 for	
further	 RNA	 isolation.	 Subsequently,	 RNA	 was	 purified	 in	 40μl	 H2O	 using	 the	 miRVana	
(Ambion	 AM1561)	 kit	 and	 following	 manufacturer	 instructions.	 MiR-specific	 reverse	
transcription	was	performed	on	5μl	 of	 the	extracted	RNA	and	using	Taqman	primer	pairs	
(Taqman	RNU44	1094,	Taqman	hsa-miR155	2623)	and	the	Taqman	reverse	transcription	kit	
(Lifetechnologies	4366597)	following	manufacturer	instructions.	Finally,	qPCR	was	run	using	
96-well	 optical	 plates	 (Lifetechnologies	 4346906)	 in	 a	 7500	 Fast	 Real-Time	 PCR	 machine	
(Thermofisher	4351106).	The	qPCR	mix	volume	was	of	10μl/well	and	comprised	2μl	of	the	
RT	reaction	mixed	with	the	primers	and	Taqman	Fast	Universal	Master	Mix	(Lifetechnologies	
4352042).	All	qPCR	reactions	were	performed	in	2	technical	replicates,	and	the	values	were	
excluded	if	the	difference	in	CT	was	higher	than	0.2	or	if	one	of	the	CT	value	was	higher	than	
33.	The	mean	of	the	technical	replicates	of	the	control	gene	(RNU44)	was	substracted	to	the	
mean	of	the	technical	replicates	of	the	gene	of	interest	(miR-155)	to	calculate	the	ΔCT.	Fold	
changes	 in	 expression	where	 then	 calculated	 using	 a	 control	 sample	 for	 normalization	 as	
such:	𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑜𝑓 𝑚𝑖𝑅155 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑖𝑛 (𝑥) = 2!"# !"#$%"& !"#$%& !!"#(!"#$%& !)	
4.8. Functional	assays	
Celltrace	 staining:	 The	 proliferative	 capacity	 of	 transduced	 cells	 was	 assessed	 by	 staining	
them	 with	 the	 Celltrace	 Violet	 dye	 (Lifetechonologies	 C34557)	 following	 manufacturer’s	
instructions	and	culturing	the	cells	at	a	1:10	ratio	with	MS1	or	MS1_PSMA	or	at	a	1:1	ratio	
with	 anti-CD3/anti-CD28	beads	 or	 on	 their	 own.	After	 3	 days	 of	 coculture,	 the	 cells	were	
resuspended	 and	 stained	with	 an	 APC	 conjugated	 goat	 anti-mouse	 f(ab)2	 antibody	 and	 a	
dead	cell	marker.	The	samples	were	analysed	on	a	LSR-II	flow	cytometer.	
Chromium	release	assay:	Target	cells	were	loaded	with	chromium	51Cr,	and	then	cocultured	
with	 CAR-transduced	 T	 cells	 at	 different	 ratios.	 After	 4	 hours,	 the	 supernatants	 were	
collected	 and	 transferred	 to	 a	 LumaPlate-96	 for	 radioactivity	 detection	 from	 a	 TopCount	
NXT	 plate	 reader.	 The	 lysis	 percentage	 was	 calculated	 as	 follows:	100× !"#!$%&!'()*!!"#$%&$'#(! !"#"$%"!"!#$!!"#$%&$'#(! !"#"$%" .	Spontaneous	release	was	calculated	for	each	cell	line	
as	 the	 recorded	 signal	 in	 a	 well	 without	 target	 cells.	 Total	 release	 was	 calculated	 as	 the	
recorded	signal	for	a	well	where	all	the	cells	were	lysed	by	addition	of	HCl.	
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General	conclusion	
During	my	thesis	project,	I	studied	CD8+	T	cells	and	the	importance	of	microRNAs	on	their	
functionality	and	their	antitumour	ability.	
First,	 we	 used	 a	 CD4	 conditional	 knockout	 of	 the	 miR-17-92	 cluster,	 to	 observe	 the	
functionality	of	CD8+	T	cells	in	its	the	absence.	In	line	with	other	publications	using	similar	
models,	 we	 found	 that	 the	 absence	 of	 miR-17-92	 impaired	 the	 CD8+	 T	 cells	 in	 their	
proliferative	ability	upon	activation,	and	decreased	their	production	of	cytokines.	Moreover,	
the	 CD8+	 T	 cells	 were	 impaired	 in	 their	 effector	 cells	 differentiation,	 and	 showed	 a	
phenotype	 of	 central	memory	 cells	 CD127high	 KLRG1low.	Overexpression	 of	miR-17-92	was	
shown	by	other	groups	to	induce	more	terminal	differentiation	of	the	CD8+	T	cells	as	well	as	
increased	proliferation.	One	publication	showed	improved	efficiency	of	human	CAR+	T	cells	
that	were	 cotransduced	with	 a	 construct	 overexpressing	miR-17-92	 in	 a	mouse	 xenograft	
model.	However,	whether	overexpression	of	miR-17-92	improves	the	antitumour	efficiency	
of	CD8+	T	cells	 in	a	complete	mouse	model	 is	still	not	known	and	would	be	 interesting	to	
investigate.	
Second,	 we	 overexpressed	miR-155	 in	 OT-1	 CD8+	 T	 cells	 and	 assessed	 their	 response	 to	
infection	and	 their	ability	 to	 control	 tumour	growth.	CD8+	T	 cells	overexpressing	miR-155	
had	an	 increased	proliferative	capacity	and	cytokine	production	upon	activation.	However	
only	 the	 tumours	 that	expressed	 the	 low	affinity	SIITFEKL	 (T4)	OVA	altered	peptide	 ligand	
were	 controlled	 better	 by	miR-155	OT-1	 CD8+	 T	 cells.	 Our	 findings	 indicate	 that	miR-155	
overexpression	rescues	CD8+	T	cells	that	have	been	sub	optimally	activated	or	restimulated	
by	a	low	affinity	ligand.	Cytotoxic	T	cells	specific	to	tumour	antigens	are	often	of	low	affinity	
because	 of	 central	 tolerance.	 Hence,	 overexpressing	miR-155	 shows	 promise	 in	 restoring	
the	functionality	of	those	tumour-specific	low	affinity	T	cells.	
Third,	we	assessed	miR-155	overexpression	in	human	CD8+	T	cells	expressing	the	anti-PSMA	
CAR.	We	managed	to	induce	a	small	increase	of	miR-155	levels	in	those	cells.	This	increase	
was	 sufficient	 to	 improve	 the	 ability	 of	 CAR+	 CD8+	 T	 cells	 to	 proliferate	 in	 vitro	 upon	
activation.	We	then	measured	the	ability	of	miR-155	CAR+	CD8+	T	cells	to	mediate	tumour	
protection	in	a	mouse	xenograft	tumour	model.	Although	CAR+	CD8+	T	cells	could	mediate	
strong	tumour	regression,	overexpression	of	miR-155	did	not	improve	the	efficiency	of	the	
anti-PSMA	CAR	in	this	model.	
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Perspectives	
In	 this	 research,	we	demonstrated	 the	 importance	 of	microRNAs	 for	 efficient	 CD8+	 T	 cell	
effector	response	as	well	as	antitumour	efficiency.	We	were	able	to	show	that	it	is	possible	
to	modulate	the	expression	of	the	microRNA	miR-155	and	hence	increase	the	performances	
of	 effector	 CD8+	 T	 cells.	 Finally,	 we	 showed	 that	 overexpression	 of	miR-155	 impacts	 the	
antitumour	 efficiency	 of	 genetically	modified	 CD8+	 T	 cells	 in	 the	 context	 of	 adoptive	 cell	
transfer.	
Adoptive	cell	 transfer	has	gained	momentum	as	a	 treatment	against	cancer	 thanks	 to	 the	
recent	 results	 of	 clinical	 trials	 using	 tumour	 infiltrating	 lymphocytes	 or	 lymphocytes	
transduced	to	express	a	chimeric	antigen	receptor.	However,	both	of	these	methods	have	
proved	 successful	 only	 for	 a	 limited	 range	 of	 cancers.	 TILs	 transfer	 induced	 a	 complete	
response	 in	 22%	 of	 advanced	 melanoma	 patients,	 whereas	 CAR	 therapies	 were	 very	
successful	 for	 haematological	 cancers.	 In	 the	 case	 of	 TILs,	 most	 of	 the	 CD8+	 T	 cells	 are	
naturally	 cancer-specific	 because	 these	 cells	 are	 found	 within	 the	 tumour	
microenvironment.	In	the	case	of	CAR	therapy,	the	T	lymphocytes	are	genetically	modified	
to	 become	 cancer-specific	 via	 the	 expression	 of	 the	 chimeric	 receptor.	 In	 both	 case,	
modulating	the	expression	of	genes	to	improve	the	effector	performance	could	ameliorate	
currently	available	treatments.		
Although	 we	 could	 not	 demonstrate	 that	 overexpression	 of	 miR-155	 was	 therapeutically	
helpful	 in	 the	 case	 of	 CAR	 therapy,	 we	 argue	 that	 miR-155	 is	 a	 strong	 candidate	 for	
improving	the	antitumour	efficiency	of	CD8+	T	cells	in	the	context	of	adoptive	cell	transfer.	
Indeed,	we	showed	that	miR-155	overexpression	simultaneously	 impacted	several	aspects	
of	 the	T	cells	 functionality;	namely	the	response	to	 low	affinity	antigen,	 the	production	of	
cytokine	 upon	 activation,	 and	 the	metabolic	 program.	Moreover,	miR-155	 overexpressing	
cells	could	be	efficient	against	cancer	cells	expressing	a	low	affinity	antigen,	which	is	often	
the	case	 for	naturally	occurring	 tumour	associated	antigens,	and	 for	 some	neoantigens	as	
well.	
One	 important	 aspect	 that	 was	 not	 directly	 addressed	 in	 the	 scope	 of	 this	 thesis	 is	 the	
establishment	 of	 a	 long-term	 protection	 in	 cancer	 patients.	 Indeed,	 future	 treatments	
should	 not	 only	 be	 efficient	 in	 their	 immediate	 ability	 to	 reduce	 the	 cancer	 burden,	 but	
should	 also	 induce	 a	 complete	 curative	 response	 in	 patients.	 It	 has	 been	 proposed	 that	
immunotherapies	 are	 a	 good	 method	 to	 achieve	 such	 a	 goal	 if	 they	 can	 trigger	 the	
formation	 of	 long-lived	 memory	 lymphocytes.	 Modulating	 the	 expression	 of	 microRNAs	
might	actually	be	helpful	 in	 this	quest	of	memory	 lymphocytes.	 Indeed,	we	observed	 that	
the	 absence	of	miR-17-92	drove	 cells	 towards	 a	more	memory	 phenotype.	Other	 current	
research	 show	 that	 it	 is	 possible	 to	 tweak	 the	 CD8+	 T	 cells	 towards	 a	 more	 memory	
phenotype	by	blocking	the	mTOR	pathway.	Combining	the	expression	of	some	microRNAs	
to	 boost	 effector	 functions,	 with	 the	 expression	 or	 repression	 of	 others	 to	 induce	 more	
memory	might	be	an	interesting	approach	to	reach	the	goal	of	a	long-term	cure.	
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Another	 hurdle	 for	 the	 clinical	 application	of	 adoptive	 cell	 transfer	 therapies	 is	 their	 high	
cost	for	each	patient.	Indeed,	lymphocytes	have	to	be	isolated	and	cultured	for	each	patient	
individually,	and	this	sometimes	for	weeks.	Although	we	did	not	directly	address	this	aspect,	
the	fact	that	the	T	cells	overexpressing	miR-155	proliferate	more	could	mean	that	less	T	cells	
are	needed	to	reach	the	same	therapeutic	goal.	This	would	save	costs,	as	those	cells	would	
necessitate	less	time	in	vitro	before	the	transfer.	
Finally,	 cancer	 is	 a	 very	 dynamic	 disease,	 which	 is	 able	 to	 adapt	 rapidly	 to	 changing	
conditions.	 Consequently,	 a	 strong	 immune	 attack	 against	 malignant	 cells	 often	 induces	
them	 to	 differentiate	 into	 a	 more	 immunosuppressive	 phenotype.	 For	 this	 reason,	 using	
therapies	 in	 combination	 seem	 to	 be	 the	 best	 next	 step	 for	 cancer	 treatments.	
Simultaneously	 increasing	 the	 inflammation	 and	 depriving	 the	 cancer	 of	 its	
immunosuppressive	defences	shows	a	lot	of	promise.	It	 is,	to	my	knowledge,	the	way	that	
should	be	pursued	in	the	future	of	cancer	medicine.	
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Appendix	
1. Supplemental	methods:	
1.1. 	PCR	primers	
CD4-CRE	
FW	–	5’	GTT	CGC	AAG	AAC	CTG	ATG	CAC	A	3’	
Rev	–	5’	CTA	GAG	CCT	GTT	TTG	CAC	GTT	C	3’	
miR-17-92	
FW	-	5	‘	TCG	AGT	ATC	TGA	CAA	TGT	GG	3’	
Rev	-	5’	TAG	CCA	GAA	GTT	CCA	AAT	TGG	3’	
miR-155	
FW	:	5’	GTG	CTG	CAA	ACC	AGG	AAG	G	3’	
Rev	:	5’	CTG	GTT	GAA	TCA	TTG	AAG	ATG	G	3’	
Mut:	5’	CGG	CAA	ACG	ACT	GTC	CTG	GCC	G	3’	
1.2. PCR	programs:	
CD4	 CRE	
#1	 	 95°C	 	 5min	
#2	 	 95°C	 	 15sec	
#3	 	 60°C	 	 20sec	
#4	 	 72°C	 	 20sec		 	 repeat	from	#2	34	times	
#5	 	 72°C	 	 5min	
	
miR-17-92	
#1	 	 94°C	 	 5min	
#2	 	 94°C	 	 15sec	
#3	 	 60°C	 	 15sec	
#4	 	 72°C	 	 15sec		 	 repeat	from	#2	38	times	
#5	 	 72°C	 	 5min	
	
miR-155	
#1	 	 94°C	 	 5min	
#2	 	 94°C	 	 15sec	
#3	 	 61°C	 	 15sec	
#4	 	 72°C	 	 20sec		 	 repeat	from	#2	34	times	
#5	 	 72°C	 	 5min	
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1.3. Media	
Complete	RPMI	
500ml	RPMI	
50ml	FBS	(Gibco	10270106)	
5ml	Penicillin-streptomycin	(Gibco	15140-114)	
5ml	HEPES	(Animed	5-31F00-H)	
500μl	2β-mercaptoethanol	(Sigma	M-7522)	
Medium	for	primary	human	T	cells	(human	RPMI):	
500ml	RPMI	(Gibco	61870-010)	
5ml	Penicillin-streptomycin	(Gibco	15140-114)	
5ml	L-Glutamine	(Gibco	25030-024)	
5ml	Non	essential	amino	acids	(Gibco	11140-035)	
5ml	HEPES	(Animed	5-31F00-H)	
5ml	Na	Pyruvate	(Gibco	11360-039)	
500μl	2β-mercaptoethanol	(Sigma	M-7522)	
40	ml	Human	Serum	(isolated	in	house)	
Medium	for	primary	mouse	T	cells	(mouse	RPMI)	
500ml	RPMI	(Gibco	61870-010)	
50ml	FBS	(Dutscher	S1810-500)	
5ml	Penicillin-streptomycin	(Gibco	15140-114)	
5ml	L-Glutamine	(Gibco	25030-024)	
5ml	Non	essential	amino	acids	(Gibco	11140-035)	
5ml	HEPES	(Animed	5-31F00-H)	
5ml	Na	Pyruvate	(Gibco	11360-039)	
500μl	2β-mercaptoethanol	(Sigma	M-7522)	
1.4. LCMV	peptide	mix	
KAVYNFATM	 	 	 	 	 	 	 GP33 
FQPQNGQFI	 NP396	
SGVENPGGYCL	 GP276	
SLLNNQFGTM	 NP166	
CSANNSHHYI	 GP92	
ISHNFCNL	 GP118	
YTVKYPNL	 NP205	
NISGYNFSL	 NP235	
GVYQFKSV	 GP70	
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1.5. Sequences	of	miR-155	and	SCR	from	CAR	construct	
Mir-155	(pre-miRNA	in	capitals	+	200bp	flanking	sequences	on	each	side)	
aggatttaatgagctccttcctttcaacagaaaatggactattttcctttcagatttactatatgctgtcactccagctttataaccgcat
gtgcatacacaaacatttctttctctcttgcaggtggcacaaaccaggaaggggaaatctgtggtttaaattctttatgcctcatcctc
tgagtgctgaaggcctgctgtaggctgtatgCTGTTAATGCTAATCGTGATAGGGGTTTTTGCCTCCAACTGACT
CCTACATATTAGCATTAACAGtgtatgatgcctgttactagcattcacatggaacaaattgctgccgtgggaggatgacaa
agaagcatgagtcaccctgctggataaacttagacttcaggctttatcatttttcaatctgttaatcataatctggtcactgggatgttc
aaccttaaactaagttttgaaagtaaggttatttaaaagatttatcagtagtatcctaaatgcaaacattttc	
SCR	miR-155	(pre-miRNA	in	capitals	+	200bp	flanking	sequences	on	each	side)	
aggatttaatgagctccttcctttcaacagaaaatggactattttcctttcagatttactatatgctgtcactccagctttataaccgcat
gtgcatacacaaacatttctttctctcttgcaggtggcacaaaccaggaaggggaaatctgtggtttaaattctttatgcctcatcctc
tgagtgctgaaggcctgctgtaggctgtatgCTGAAGGTGACGGACGTTGCAATATCTTTTGCCTCCAACTGAG
ATATTGCAACGTCCGTCACCTTGtgtatgatgcctgttactagcattcacatggaacaaattgctgccgtgggaggatgac
aaagaagcatgagtcaccctgctggataaacttagacttcaggctttatcatttttcaatctgttaatcataatctggtcactgggatg
ttcaaccttaaactaagttttgaaagtaaggttatttaaaagatttatcagtagtatcctaaatgcaaacattttc	
2. Supplemental	Data:	
	
Figure	 34:	 (A)	 OT-3	 cells	 were	 transduced	 with	 either	 the	 pMGP-SCR	 (left	 panel)	 or	 pMGP-miR-155	 (right	 panel)	
construct.	 (B)	 The	expression	of	miR-155	was	measured	by	qPCR	 in	 resting	 cells	or	2	days	after	 coculture	with	either	
beads	(left	panel)	or	B16-OVA	cells	(right	panel).	
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Figure	35:	Living	Image®	analysis	of	pictures	taken	with	the	Xenogen	IVIS	Lumina	II.	On	the	left	are	untreated	animals,	
on	the	right,	treated	animals	with	either	CAR_SCR	or	CAR_miR-155.	
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3. Publication:	
I	was	 in	charge	of	measuring	 the	 levels	of	miR-155	 in	mouse	T	cells	via	qPCR	after	 in	vivo	
infection	 and	 cell	 sorting,	 or	 after	 in	 vitro	 stimulation	 with	 N4	 or	 T4	 peptides.	 I	 also	
measured	the	levels	of	the	SOCS1	mRNA	via	qPCR.	Consequently,	I	was	responsible	for	the	
figures	1B,	C	and	D	and	the	figure	6A.	
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SUMMARY
MicroRNAs (miRNAs) regulate the function of several
immune cells, but their role in promoting CD8+ T cell
immunity remains unknown. Here we report that
miRNA-155 is required for CD8+ T cell responses to
both virus and cancer. In the absence of miRNA-
155, accumulation of effector CD8+ T cells was
severely reduced during acute and chronic viral
infections and control of virus replication was
impaired. Similarly, Mir155!/! CD8+ T cells were
ineffective at controlling tumor growth, whereas
miRNA-155 overexpression enhanced the antitumor
response. miRNA-155 deficiency resulted in accu-
mulation of suppressor of cytokine signaling-1
(SOCS-1) causing defective cytokine signaling
through STAT5. Consistently, enforced expression
of SOCS-1 in CD8+ T cells phenocopied the miRNA-
155 deficiency, whereas SOCS-1 silencing aug-
mented tumor destruction. These findings identify
miRNA-155 and its target SOCS-1 as key regulators
of effector CD8+ T cells that can be modulated to
potentiate immunotherapies for infectious diseases
and cancer.
INTRODUCTION
CD8+ T cells are essential effectors in immune responses to
intracellular pathogens and cancer (Zhang and Bevan, 2011).
Upon stimulation, antigen-specific CD8+ T cells massively
expand and differentiate into inflammatory cytokine producing,
cytolytic T cells able to eliminate virally infected or transformed
cells. As the antigen is cleared, the majority of specific CD8+
effector T cells die (Marrack and Kappler, 2004), whereas only
a small number of memory cells survive. The CD8+ T cell
response is influenced by a series of costimulatory (and inhibi-
tory) ligands and by multiple soluble mediators such as inter-
leukin-2 (IL-2) (Boyman and Sprent, 2012). The latter is essential
for sustaining an efficient effector response, whereas other cyto-
kines such as IL-7 and IL-15 play crucial roles for the survival of
naive or memory T cells (Cui and Kaech, 2010). Several studies
have identified key molecular factors involved in the differentia-
tion from naive to effector CD8+ T cells, but the contribution of
microRNAs (miRNAs) has just begun to be investigated (Almanza
et al., 2010).
miRNAs are a class of small, noncoding RNAs that
impart posttranscriptional gene regulation (Bartel, 2004) through
several mechanisms including translational repression and
messenger RNA (mRNA) degradation (Djuranovic et al., 2011).
They are important in many physiological processes, in carcino-
genesis (Calin and Croce, 2006), and in the immune system (Xiao
and Rajewsky, 2009). Early studies in mice deficient for Dicer, an
RNase III enzyme important for mature miRNA production,
revealed that miRNAs are involved in CD4+ T cell differentiation
and strongly influence CD8+ T cell responses (Muljo et al.,
2005; Zhang and Bevan, 2010). Specific miRNAs were shown
to regulate both lymphocyte development and function. For
instance, miRNA-181a influences thymocyte selection bymodu-
lating the expression of molecules involved in T cell receptor
(TCR) signaling (Li et al., 2007). Moreover, the miRNA-17"92
cluster regulates B cell development (Ventura et al., 2008), auto-
immunity, and T helper 1 (Th1) cell differentiation (Jiang et al.,
2011; Xiao et al., 2008).
miRNA-155 is upregulated upon lymphocyte activation
(Haasch et al., 2002) to control cell proliferation and differentia-
tion (O’Connell et al., 2008; Turner and Vigorito, 2008). For
instance, miRNA-155 regulates B cell proliferation, malignancy,
and antibody production, at least in part through inhibition of
activation-induced cytidine deaminase and PU.1 expression
(Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007).
In CD4+ T cells, miRNA-155 has been shown to suppress differ-
entiation of naive cells into Th2 by downregulation of c-Maf, to
promote Th17 cell-mediated inflammation (Kurowska-Stolarska
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et al., 2011; O’Connell et al., 2010) and to inhibit interferon-gR
(IFN-gR) expression (Banerjee et al., 2010; Martinez-Nunez
et al., 2011). In addition to direct modulation of cytokine receptor
expression, miRNA-155 shapes cytokine signaling in several cell
subsets via downregulation of SMAD2 (Louafi et al., 2010) and
suppressor of cytokine signaling (SOCS-1) (Lu et al., 2009;
O’Connell et al., 2010; Wang et al., 2010). Despite the evidence
for an important role of miRNA-155 in a wide spectrum of im-
mune compartments, it is not known whether this miRNA, which
is highly expressed in antigen-experienced CD8+ T cells (Salaun
et al., 2011), influences CD8+ T cells in vivo. In the present study,
we have investigated the role of miRNA-155 during CD8+ T cell
responses to viral infection, vaccination, and cancer.
RESULTS
CD8+ T Cells Dynamically Regulate miRNA-155
Depending on theMagnitude of TCRStimulation or Their
Differentiation State
The strength of TCR signaling has a major impact on the magni-
tude of CD8+ T cell expansion, but not on their differentiation
(Zehn et al., 2009).We sought to investigate whether the strength
of TCR stimulation affects the expression of miRNA-155 in CD8+
T cells by transducing human CD8+ T cells with variants of a NY-
ESO-1-specific TCR of increasing affinity for its ligand (Derre´
et al., 2008; Schmid et al., 2010). Comparatively, a mutated
low-affinity TCR failed to upregulate miRNA-155 within 48 hr,
whereas TCR variants of higher affinities induced higher levels
of miRNA-155 than the wild-type (WT) (Figure 1A). Thus,
miRNA-155 expression increased in a TCR affinity-dependent
manner in human CD8+ T cells. A similar upregulation was
observed for the pri-miRNA-155 noncoding RNA transcript,
BIC (see Figure S1 available online). To see whether miRNA-
155 was also regulated in an affinity-dependent manner in
mouse CD8+ T cells, we activated naive OT-1 T cells with splenic
dendritic cells (DC) loaded with the WT peptide SIINFEKL (N4) or
the weaker altered peptide ligand SIITFEKL (T4) (Daniels et al.,
2006). To exclude miRNA-155 contamination from the DCs, we
used Mir155!/! DCs, which retain normal antigen-presenting
capabilities (O’Connell et al., 2010). Exposure of OT-1 cells to
the WT natural peptide resulted in a strong upregulation of
miRNA-155, whereas a weaker TCR stimulation by the T4
peptide was less effective (Figure 1B). To assess miRNA-155
regulation in vivo, we analyzed naive (CD62L+CD44–), effector
(CD62L–CD44+) and central memory (CD62L+CD44+) CD8+
T cells following lymphocytic choriomeningitis virus (LCMV)
infection (200 pfu ofWE strain). Compared to their naive counter-
parts, miRNA-155 was strongly upregulated in effector cells and
to a lower extent in central memory CD8+ T cells 8 days postin-
fection (Figure 1C). A more detailed kinetics of miRNA-155
regulation during LCMV infection revealed that numbers of
effector cells peaked on day 6 but stayed low in naive cells (Fig-
ure 1D). These results demonstrate that miRNA-155 is induced in
effector CD8+ T cells depending on the strength of stimulation
and differentiation.
miRNA-155 Promotes the Accumulation of Anti-Viral
Effector and Central Memory CD8+ T Cells
To determine the role ofmiRNA-155 in activatedCD8+ T cells, we
monitored the expansion of effector cells following acute LCMV
WE strain infection in the presence or absence of miRNA-155.
Percentage, number, and phenotype of naive Mir155!/! CD8+
Figure 1. miRNA-155 Expression Is Regu-
lated at Various Stages of CD8+ T Cell
Differentiation in a TCR-Affinity-Dependent
Manner
(A) Quantification of miRNA-155 in human CD8+
T cells transduced with TCRs of increasing affinity
following TCR stimulation with multimers (n = 3
experiments) as fold increase relative to un-
stimulated clones.
(B) miRNA-155 expression of naive mouse OT-1
T cells stimulated with splenic dendritic cells
pulsed with the natural SIINFEKL (N4) or
weaker SIITFEKL (T4) altered peptide ligand as
relative to day 0 unstimulated cells. Data are
representative for triplicates in one out of two
experiments.
(C) miRNA-155 concentrations in naive, central
memory, and effector CD8+ T cells sorted at day 8
after LCMVWE infection as fold change relative to
naive cells.
(D) Relative miRNA-155 expression in splenic
naive and effector CD8+ T cells sorted from
LCMV-infected mice. Symbols represent indi-
vidual mice and the line is the mean ± SEM.
Data are representative for two independent
experiments. For human BIC expression, also see
Figure S1.
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T cells in blood and spleen did not differ from those in WT mice
before infection (Figure S2A; data not shown). In contrast, both
percentage and number of total CD8+ T cells, as well as virus
gp33 tetramer specific CD8+ effector T cells, were substantially
reduced in spleen and blood of Mir155!/! mice at the peak of
the response (Figures 2A and 2B). Following the expansion of
CD44+ effector cells in the blood and spleen from days 6 to 8,
we observed impaired effector CD8+ cell accumulation in spleen,
liver, and blood of Mir155!/! mice (Figure 2C; data not shown).
Despite a defect in the magnitude of effector T cell responses,
Figure 2. miRNA-155 Is Required for Optimal Effector CD8+ T Cell Accumulation and Memory Cell Differentiation during Acute LCMV
Infection
(A) Splenocytes from day 8 infected WT and Mir155!/! mice were stained with Kb/LCMV gp33 tetramers and anti-CD8a.
(B) Blood percentages and numbers of CD8+ (upper panels) and gp33 tetramer+ cells (lower panels) on day 8 of infection.
(C) Percentages of CD44hiCD62Llo effector CD8+ T cells gated on lymphocytes in WT and Mir155!/! spleen cells (upper) and of gp33 tetramer+ cells within the
CD8+ T cells (lower panel) at days 6 to 8.
(D) Percentages of total CD8+ T cells (left) and CD127+ cells within tetramer gp33+ CD8+ cells (right panel) in blood at given time points.
(E) Percentage of liver CD127hiCD62Lhi tetramer gp33 and np396+ memory cells and (F) IL-2 production upon gp33 peptide restimulation of splenocytes within
IFN-g-positive CD8+ T cells at 3 months past infection. Symbols represent individual mice, and the line is the mean +/! SEM. Representative results of one out of
four (A–C) to two (D–F) independent experiments with three to five mice are pictured. Also see Figure S2.
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Mir155!/! animals were capable of controlling viral replication
and clearing the virus (Figure S2B), as also confirmed by the
lack of CD44 upregulation on adoptively transferred naive
LCMV-specific P14 T cells (Figure S2C). In line with this result,
CD8+ T cells differentiated into phenotypically and functionally
cytolytic effector cells similar to WT cells during LCMV infection
(Figures S2A, S2D, and S2E). Interestingly, circulating T cells in
Mir155!/! mice exhibited not only a defect in the expansion at
the peak of the immune response but also a more rapid contrac-
tion compared to WT animals (Figure 2D). Moreover, CD127+
CD62L+KLRG1– memory cells were strongly reduced in the
gp33 and np396 tetramer+ CD8+ T cells in blood, liver, and
spleen ofMir155!/!mice 3months after infection (Figure 2E; Fig-
ure S2F; data not shown). Consistent with these findings, IL-2
production, a hallmark of central memory cells, was strongly
diminished inMir155!/!mice after stimulation with gp33 peptide
(Figure 2F; Figure S2F). In this immune memory context, it is of
interest that we observed a deficient CD4+ effector T cell activa-
tion on day 8 of the response inMir155!/!mice (data not shown).
Altogether, these results demonstrate that miRNA-155 is crucial
for a robust T cell expansion, but not effector functions, as well
as for a memory phenotype response upon an acute LCMV
infection.
Figure 3. A Cell Intrinsic Role for miRNA-
155 in Promoting Effector CD8+ T Cells
(A) Congenically marked WT and Mir155!/! OT-1
cells were competitively cocultured with peptide-
pulsed dendritic cells, and the ratio of populations
is pictured at indicated time points (left). On day 5,
percentage of trypan blue cells harvested from
either WT orMir155!/! cultures was counted (right
graph). Pooled data from three representative
experiments are pictured.
(B) CD8+ T cells fromWT andMir155!/!mice were
cotransferred into WT or deficient hosts before
LCMV WE infection, and percentages in blood at
day 8 were measured.
(C) A 1:1 mix of WT and Mir155!/! splenocytes
was adoptively transferred into Rag2 and IL2Rg
double deficient mice, which were infected with
LCMV WE 2 months after transfer. CD8+ effector
T cell ratios at days !1 and 8 postinfection are
pictured.
(D) Proliferating BrdU-positive splenic CD44hi
CD8+ effector T cells at days 6 and 7 postinfection.
(E and F) At the same time, (E) cells were stained
for the proliferation marker Ki67 (day 7) and (F)
apoptotic cells were identified by AnnexinV stain-
ing. Symbols represent individual mice, and the
line is the mean ± SEM. Representative results
from two (B and C) to three (D–F) experiments are
pictured.
Intrinsic Expression of miRNA-155
in CD8+ T Cells Promotes
Proliferation and Limits Apoptosis
of Effector CD8+ T Cells
To investigate whether the defective
expansion of CD8+ T cells was cell
intrinsic, we cocultured naive WT and
congenic Mir155!/! OT-1 CD8+ T cells
together with peptide pulsed dendritic cells and analyzed the
OT-1 cell ratio. After 5 days, WT CD8+ T cells outnumbered
Mir155!/! cells and the abundance of dead cells was strongly
increased amongMir155!/! T cells (Figure 3A). To assess these
parameters in vivo, we cotransferred equal numbers of congenic
polyclonal WT and Mir155!/! CD8+ T cells into either WT or
Mir155!/! hosts, which were then infected with LCMV. Despite
the initial low frequency of WT CD8+ T cells transferred in
miRNA-155 ablated hosts (about 1% of CD8+ T cells in blood
before infection), these cells expanded to about 30% of the
CD8+ T cells at the peak of the response. In contrast, the fre-
quency ofMir155!/! CD8+ T cells that transferred into WT hosts
decreased upon infection (Figure 3B), clearly demonstrating a
stronger response of WT compared to Mir155!/! CD8+ T cells.
When Rag2 and g common (gc) chain deficient hosts were
engrafted with a 1:1 mix of WT and Mir155!/! splenocytes,
both populations reached similar frequencies after 2 months,
indicating comparable homeostatic expansion (Figure 3C). How-
ever, following LCMV infection, WT T cells again showed an
advantage in expansion over their Mir155!/! counterparts. To
determine the basis for the impaired accumulation of virus-spe-
cific CD8+ T cells in the absence ofmiRNA-155, we pulsed LCMV
infectedWT andMir155!/!mice with bromodeoxyuridine (BrdU)
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and measured proliferation and apoptosis 4 hr later. We found
that the proliferation of Mir155!/! CD44+ effector CD8+ T cells
was decreased compared to WT cells 6 days after infection (Fig-
ure 3D). Additionally, the frequency of proliferating Ki67+ cells
within the CD44+CD62L– effector CD8+ T cells was reduced in
Mir155!/! mice (Figure 3E). Finally, we observed an increased
frequency of AnnexinV+ apoptotic cells in Mir155!/! compared
to WT effector CD8+ T cells 7 days after infection (Figure 3F).
Altogether, these data demonstrate a cell-intrinsic role of
miRNA-155 in the proliferation and survival of effector CD8+
T cells in response to LCMV infection, but not for homeostatic
expansion in lymphopenic hosts.
miRNA-155 Is Crucial for Effector CD8+ T Cell
Accumulation and Virus Control in Chronic LCMV
Infection
On the basis of the strong impairment of effector CD8+ T cell
accumulation in low dose LCMV infection, we asked how
Mir155!/! mice would respond to high dose and long-lasting
Figure 4. miRNA-155 Drives Survival of
Effector Cells and Sustains the Anti-Viral
Response in a Chronic LCMV Infection
WT and Mir155!/! mice were infected with LCMV
clone 13 and phenotype and expansion of effector
cells was monitored by flow cytometry.
(A) Effector CD44hiCD62Llo within blood CD8+
T cells at indicated time points.
(B and C) At 5 weeks, splenic CD8+ cells were
analyzed for the indicated activation markers and
gp33 tetramer+ cells shown as (B) flow cytometry
dot blots from representative mice and (C) graph
from one representative out of three experiments.
(D) Virus titer and (E) cytokine response upon
stimulation with a peptide cocktail was deter-
mined in the blood at 2 and 3 months after infec-
tion, respectively.
(F) Weight of mice was monitored the first 2 weeks
postinfection. Symbols represent individual mice,
and the line is the mean (C and D). Error bars are
given as ± SEM. Shown are representative results
from one out of two experiments with three to five
mice per group.
antigen exposure, which characterizes
chronic infections and cancer. Mice
were inoculated with 2 3 106 pfu of
LCMV clone 13, causing a chronic infec-
tion for several weeks (Moskophidis
et al., 1993; Salvato et al., 1991).Whereas
WTmice mounted a robust effector CD8+
T cell response with high percentages of
CD44+CD62L– effector cells that were
maintained over time, Mir155!/! mice
progressively lost effector CD8+ T cells
(Figure 4A). Interestingly, the remaining
CD44+ cells in spleen showed high
CD127 and CD62L expression, reminis-
cent of a memory phenotype (Figure 4B).
Percentages and numbers of gp33
tetramer-positive cells were also strongly
decreased in deficient mice 5 weeks and 3 months postinfection
(Figures 4B and 4C; data not shown). At this time, we could not
detect cells capable of producing effector cytokines in response
to a cocktail of LCMV peptides in miRNA-155 ablated mice,
confirming the loss of most virus-specific Mir155!/! CD8+
T cells and ruling out TCR downregulation that may appear as
tetramer-negative T cells (Figure 4E; data not shown). Whereas
about 50% of WT cells remained positive for PD-1, associated
with T cell exhaustion, PD-1 was barely detectable onMir155!/!
CD8+ T cells 5 weeks after infection (Figure 4C). Importantly,
virus titers were elevated 5 weeks and 2 months postinfection
in miRNA-155 ablated mice (Figure 4D; data not shown). Finally,
WT but not miRNA-155 ablated mice showed symptoms of
immunopathology such as shivering, hunching, and weight
loss, suggesting a lower inflammatory response in the absence
of miRNA-155 (Figure 4F; data not shown). These data demon-
strate an important role of miRNA-155 in maintenance and sur-
vival of CD8+ effector T cells, as well as virus control in chronic
virus infections.
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and measured proliferation and apoptosis 4 hr later. We found
that the proliferation of Mir155!/! CD44+ effector CD8+ T cells
was decreased compared to WT cells 6 days after infection (Fig-
ure 3D). Additionally, the frequency of proliferating Ki67+ cells
within the CD44+CD62L– effector CD8+ T cells was reduced in
Mir155!/! mice (Figure 3E). Finally, we observed an increased
frequency of AnnexinV+ apoptotic cells in Mir155!/! compared
to WT effector CD8+ T cells 7 days after infection (Figure 3F).
Altogether, these data demonstrate a cell-intrinsic role of
miRNA-155 in the proliferation and survival of effector CD8+
T cells in response to LCMV infection, but not for homeostatic
expansion in lymphopenic hosts.
miRNA-155 Is Crucial for Effector CD8+ T Cell
Accumulation and Virus Control in Chronic LCMV
Infection
On the basis of the strong impairment of effector CD8+ T cell
accumulation in low dose LCMV infection, we asked how
Mir155!/! mice would respond to high dose and long-lasting
Figure 4. miRNA-155 Drives Survival of
Effector Cells and Sustains the Anti-Viral
Response in a Chronic LCMV Infection
WT and Mir155!/! mice were infected with LCMV
clone 13 and phenotype and expansion of effector
cells was monitored by flow cytometry.
(A) Effector CD44hiCD62Llo within blood CD8+
T cells at indicated time points.
(B and C) At 5 weeks, splenic CD8+ cells were
analyzed for the indicated activation markers and
gp33 tetramer+ cells shown as (B) flow cytometry
dot blots from representative mice and (C) graph
from one representative out of three experiments.
(D) Virus titer and (E) cytokine response upon
stimulation with a peptide cocktail was deter-
mined in the blood at 2 and 3 months after infec-
tion, respectively.
(F) Weight of mice was monitored the first 2 weeks
postinfection. Symbols represent individual mice,
and the line is the mean (C and D). Error bars are
given as ± SEM. Shown are representative results
from one out of two experiments with three to five
mice per group.
antigen exposure, which characterizes
chronic infections and cancer. Mice
were inoculated with 2 3 106 pfu of
LCMV clone 13, causing a chronic infec-
tion for several weeks (Moskophidis
et al., 1993; Salvato et al., 1991).Whereas
WTmice mounted a robust effector CD8+
T cell response with high percentages of
CD44+CD62L– effector cells that were
maintained over time, Mir155!/! mice
progressively lost effector CD8+ T cells
(Figure 4A). Interestingly, the remaining
CD44+ cells in spleen showed high
CD127 and CD62L expression, reminis-
cent of a memory phenotype (Figure 4B).
Percentages and numbers of gp33
tetramer-positive cells were also strongly
decreased in deficient mice 5 weeks and 3 months postinfection
(Figures 4B and 4C; data not shown). At this time, we could not
detect cells capable of producing effector cytokines in response
to a cocktail of LCMV peptides in miRNA-155 ablated mice,
confirming the loss of most virus-specific Mir155!/! CD8+
T cells and ruling out TCR downregulation that may appear as
tetramer-negative T cells (Figure 4E; data not shown). Whereas
about 50% of WT cells remained positive for PD-1, associated
with T cell exhaustion, PD-1 was barely detectable onMir155!/!
CD8+ T cells 5 weeks after infection (Figure 4C). Importantly,
virus titers were elevated 5 weeks and 2 months postinfection
in miRNA-155 ablated mice (Figure 4D; data not shown). Finally,
WT but not miRNA-155 ablated mice showed symptoms of
immunopathology such as shivering, hunching, and weight
loss, suggesting a lower inflammatory response in the absence
of miRNA-155 (Figure 4F; data not shown). These data demon-
strate an important role of miRNA-155 in maintenance and sur-
vival of CD8+ effector T cells, as well as virus control in chronic
virus infections.
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miRNA-155 Expression in CD8+ T Cells Is Crucial for
Efficient Immunization and Cancer Immunotherapy
Becausewe observed an important role of miRNA-155 to sustain
CD8+ T cell responses to chronic infection, we looked at the
impact of miRNA-155 on CD8+ T cell-dependent antitumor
immunity, which requires robust CD8+ T cell responses. We
examined the role of miRNA-155 in CD8+ T cells for vaccination,
a clinically relevant setting characterized by limited adjuvant-
induced inflammation. Polyclonal and OVA-specific OT-1 CD8+
T cells (either WT or Mir155!/!) were cotransferred into WT
mice before immunization with OVA peptide adjuvanted with
IFA and CpG-ODNs. While the ratio of WT OT-1 to polyclonal
cells strongly increased following immunization, there was only
a minor increment in the ratio of Mir155!/! OT-1 to polyclonal
WT cells (Figure 5A). We next cotransferred OT-1 cells from
both WT and Mir155!/! backgrounds into WT mice before
immunization. WT andMir155!/! cells were found in similar pro-
portions indicating a comparable survival after adoptive transfer.
Following immunization, however, WT cells accumulated more
efficiently thanMir155!/! cells (Figure 5B), whereas upregulation
of CD44 and the proportion of cells producing IFN-g were com-
parable (Figures S3A and S3B). Now we were interested to see
Figure 5. miRNA-155 Is Crucial for the CD8+
T Cell Response to Peptide Vaccination and
Tumor Challenge
(A) Congenically marked OT-1 and polyclonal
CD8+ T cells from WT or Mir155!/! backgrounds
were transferred into WT hosts, which were
immunized with OVA peptide and CpG in IFA.
Shown is the ratio of antigen-specific versus
polyclonal cells in the draining lymph nodes 4 days
later. Symbols represent individual mice, and the
line is the mean ± SEM.
(B) Ratio of blood WT and Mir155!/! OT-1 CD8+
T cells cotransferred into WT hosts, which were
immunized as in (A) on day 7. Symbols represent
individual mice, and the line is the mean ± SEM.
Data from one out of two (A) to three (B) inde-
pendent experiments are pictured.
(C and D) Upon adoptive transfer of WT or
Mir155!/! OT-1 cells, mice were engrafted with
B16 melanoma cells expressing OVA and immu-
nized 1 week later. Tumor growth (C) and survival
(D) are pictured (n = 5–9 mice per group, data from
one out of two independent experiments) dis-
played as mean ± SEM.
(E and F) TCR transgenic pmel CD8+ T over-
expressing miRNA-155 or control scrambled
miRNA were transferred into B16 tumor-bearing
mice and (E) tumor growth and (F) survival of mice
are shown from one representative out of two
experiments with five to eight mice per group
displayed as mean ± SEM. Also see Figure S3.
whethermiRNA-155would also be critical
for tumor control by CD8+ T cells and
engrafted B16 melanoma upon transfer
of naive WT or Mir155!/! OT-1 T cells
and therapeutic vaccination 1 week later.
Compared to WT, Mir155!/! CD8+
T cells were less effective in inhibiting
tumor growth and ensuring the survival of tumor-challenged
mice (Figures 5C and 3D). Given the inability of T cells to expand
and control tumor growth in the absence of miRNA-155, we
hypothesized that enforcing miRNA-155 expression would
augment theantitumor activity ofCD8+Tcells. Pmel-1 TCR trans-
genic CD8+ T cells specific for themelanoma antigen gp100were
transduced with a retrovirus encoding miRNA-155 or scrambled
miRNA and adoptively transferred into tumor-bearing mice in
conjunction with gp100 vaccination and IL-2. There were no
phenotypic differences between control andmiRNA-155 overex-
pressing T cells prior to adoptive transfer (Figure S3C). However,
overexpression of miRNA-155 greatly enhanced the antitumor
responses compared to scrambled miRNA control (Figure 5E).
Notably, 80% of mice receiving miRNA-155 transduced T cells
survived for over 60 days, whereas all mice treated with control
cells or left untreated had to be euthanized after less than
40 days due to tumor size (Figure 5F). Taken together, these re-
sults show that upon vaccination,Mir155!/! CD8+ T cells differ-
entiated into effector cells but failed to accumulate in normal
numbers. Consequently, the antitumor response was strongly
dependent on miRNA-155 and could be therapeutically boosted
by enforced miRNA-155 expression.
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Targeting of SOCS-1 by miRNA-155 in Effector CD8+
T Cells Enables Cytokine Responsiveness and
Accumulation
miRNA-155 has been shown to regulate gc chain cytokine
signaling by targeting SOCS-1 expression (D’Souza and Lefran-
c¸ois, 2003; Lu et al., 2009; Wang et al., 2010). We assessed
SOCS-1 regulation in splenic effector CD44+CD62L–CD8+
T cells during the response to acute LCMV infection of WT and
Mir155!/! mice. We found that both WT and Mir155!/! CD8+
T cells downregulated SOCS-1 on days 6 and 8 compared to
CD62L+CD44– naive CD8+ T cells from noninfected mice (Fig-
ure 6A). To more directly test whether SOCS-1 was regulated
Figure 6. SOCS-1 and miRNA-155 Modulate the Antiviral CD8+ T Cell Response and Cytokine Signaling
(A) SOCS-1mRNA concentrations weremeasured upon LCMVWE infection in purified effector (CD44hiCD62Llo) WT andMir155!/! splenic CD8+ T cells by qPCR
relative to naive CD8+ T cells from noninfected mice.
(B and C) Regulation of SOCS-1 by miRNA-155 in naive CD8+ T cells from WT and miRNA-155 deleted mice, as well as after retroviral transfection with miRNA-
155 overexpressing or control vectors, was tested by (B) qPCR (shown as relative to b-actin) and (C) immunoblot.
(D) Naive or effector T cells from LCMV-infected mice were stimulated with indicated cytokines, and pSTAT5 was measured by flow cytometry.
(E) WT andMir155!/! T cells were transduced with control or shSOCS-1 lentivirus and pSTAT5 response to IL-2 is shown. The table gives the percentages of MFI
normalized to the MFI measured in WT sh-control cells set to 100%. Representative data from two (A–C) to three (D and E) experiments are pictured as mean ±
SEM. Also see Figure S4.
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by miRNA-155, we measured SOCS-1 mRNA in WT and
Mir155!/! CD8+ T cells, as well as in cells overexpressing
miRNA-155 or scrambled control miRNA. We found that the
amounts of SOCS-1 transcripts were inversely related to the
cellular content of miRNA-155, with the highest concentration
of SOCS-1 in Mir155!/! cells and the lowest in miRNA-155
transduced cells (Figure 6B). These results were further
confirmed at the protein level, indicating that miRNA-155 is a
critical regulator of SOCS-1 translation in CD8+ T cells (Fig-
ure 6C). To test whether the loss of miRNA-155 impaired gc
chain cytokine signaling in CD8+ T cells by upregulating
SOCS-1, we compared STAT5 phosphorylation in response to
IL-2, IL-7, or IL-15 in WT and Mir155!/! cells. Stimulation of
naive and effector CD8+ T cells isolated 8 days after LCMV
infection resulted in a limited phosphorylation of STAT5 in
miRNA-155 ablated cells, demonstrating an impaired cytokine
signaling (Figure 6D). Diminished STAT5 phosphorylation was
not due to differential expression of the cytokine receptor
chains CD25, CD122, CD127, or CD132 (Figure S4). To further
investigate whether the impaired cytokine signaling was depen-
dent on the higher SOCS-1 concentration in Mir155!/! CD8+
T cells, we transduced WT and Mir155!/! CD8+ T cells with
control or shSOCS-1 lentivirus. Although in vitro activation of
T cells diminished the impact of miRNA-155 on cytokine
signaling, we consistently detected a rescue of pSTAT5 gener-
ation in shSOCS-1 transfected Mir155!/! cells (Figure 6E).
Interestingly, baseline pSTAT5 expression was already higher
in WT than inMir155!/! cells without additional IL-2 stimulation.
The difference between WT and Mir155!/! cells was still
apparent with intermediate but disappeared with high IL-2 con-
centrations, demonstrating that saturating amounts of IL-2
overcome the miRNA-155 and SOCS-1-dependent inhibition
Figure 7. SOCS-1 Limits the CD8+ T Cell
Response to Virus and Cancer
(A) TCR transgenic P14 CD8+ T cells over-
expressing SOCS-1 (P14xSOCS-1) or not were
adoptively transferred before LCMV WE infection.
Data show the percentage of transferred cells in
the lymphocyte gate at days 6, 7, and 8 post-
infection as mean ± SEM.
(B) Apoptotic cells within P14 T cells 7 days after
infection. Symbols represent single mice, and the
line is the mean.
(C and D) TCR transgenic pmel CD8+ T cells
were transduced with a retrovirus encoding
for a scrambled control or shSOCS-1 mRNA
and adoptively transferred into tumor-bearing
mice. (C) Absolute numbers of donor CD8+
T cells were determined in spleen at days 4 to
6 after adoptive transfer and (D) tumor size of
mice was monitored. Data are from one repre-
sentative out of two independent experiments
with two (C) to five mice (D) per group and
displayed as mean ± SEM. Please also see
Figure S5.
of cytokine signaling, as shown for regu-
latory T cells (Lu et al., 2009). Together,
these results demonstrate a dynamic
and differentiation-dependent regulation of SOCS-1 during
the response to LCMV and suggest that Mir155!/! CD8+
T cells have impaired cytokine signaling due to increased
SOCS-1.
SOCS-1 Restrains CD8+ T Cell Responses to Virus and
Cancer
To test whether increased SOCS-1 expression recapitulated the
impaired antigen-driven expansion of Mir155!/! CD8+ T cells,
we adoptively transferred SOCS-1 transgenic or WT P14 CD8+
T cells into congenicmice prior to infection with LCMVWE strain.
The expansion of SOCS-1 transgenic P14 T cells in blood and
spleen was reduced compared to P14 WT cells (Figure 7A;
data not shown). Whereas effector phenotype, granzyme B,
and cytokine production were not impaired (Figures S5A–S5C),
we detected enhanced apoptosis of SOCS-1-overexpressing
cells (Figure 7B), thus phenocopying Mir155!/! CD8+ T cells
(Figures 2 and 3; Figure S2). To test whether suppression of
SOCS-1 could be therapeutically exploited to enhance the
CD8+ T cell antitumor response, we adoptively transferred
Pmel CD8+ T cells transduced with shSOCS-1 into tumor-
bearing mice. SOCS-1 depletion by the construct was verified
by immunoblot analysis (Figure S5D). An increased expansion
of cells expressing shSOCS-1 was detected in the spleen on
day 4 compared to control (Figure 7C), associated with profound
tumor regression in mice that received shSOCS-1 transduced
cells compared to untreated mice or mice treated with control
cells (Figure 7D). Together, these results demonstrate that
SOCS-1 is negatively regulating the effector CD8+ T cell
response to virus and cancer and highlight the importance of
SOCS-1 downregulation by miRNA-155 for efficient CD8+
T cell responses.
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DISCUSSION
We have shown that miRNA-155 expression is essential for
optimal CD8+ T cell responses toward virus infection, vaccina-
tion, and cancer. Interestingly, the phenotype of Mir155!/!
CD8+ T cells was similar to Dicer-deficient CD8+ T cells (Zhang
and Bevan, 2010), suggesting that miRNA-155 is an important,
likely nonredundant miRNA for CD8+ effector T cells. Recently,
we and others found differential miRNA-155 expression associ-
ated with discrete differentiation stages in CD8+ T cells (Almanza
et al., 2010; Salaun et al., 2011; Wu et al., 2007). Here, we
showed that miRNA-155 is highly upregulated in effector CD8+
T cells responding to viral infection but at intermediate concen-
tration in memory cells. This dynamic modulation of miRNA-
155 raises the question of the nature of the regulating factors
that are involved. miRNA-155 is induced by NF-kB-dependent
factors (Kluiver et al., 2007) and AP-1 downstream of B and
T cell receptors (Haasch et al., 2002; Yin et al., 2008). Interest-
ingly, we observed that miRNA-155 expression was proportional
to the strength of TCR signaling, suggesting that miRNA-155
provides competitive fitness to the most avid antigen-specific
CD8+ T cells.
Whereas others reported a disadvantage of Mir155!/! naive
CD8+ T cells in bone-marrow chimeras (Lu et al., 2009), we found
that expansion and long-term survival of naive Mir155!/! CD8+
T cells transferred into lymphopenic hosts were not different
from WT cells. miRNA-155 was crucial for effector CD8+ T cell
proliferation and survival during the peak of LCMV infection,
but it did not influence cell survival upon antigen clearance. In
contrast to the reported role of miRNA-155 in other immune
cells, CD8+ T cells were not affected in effector functions such
as killing or cytokine production, and miRNA-155 deleted mice
readily cleared low doses of LCMV. Interestingly, we detected
an impaired generation of virus-specific central memory CD8+
T cells because most Mir155!/! cells displayed a terminally
differentiated phenotype. Whether this was due to a lack of
CD4+ T cell help (Janssen et al., 2003; Shedlock and Shen,
2003), lower cytokine signaling due to higher SOCS-1 expres-
sion, and/or additional miRNA-155 targets will be subject of
further investigation. In contrast to low-dose LCMV infection,
we found that virus-specific Mir155!/! effector cells disap-
peared during chronic LCMV infection by using high doses of
clone 13. Under these conditions, WT CD8+ T cells undergo pro-
gressive attrition and display an ‘‘exhausted’’ phenotype with
impaired effector functions and high PD-1 expression (Jin
et al., 2010; Mueller and Ahmed, 2009; Wherry et al., 2003).
We hypothesize that miRNA-155 is key for the survival of
effector CD8+ T cells in conditions of long-term exposure to
antigen and inflammation as found in chronic viral infections or
cancer. Consistent with the impaired virus control, lack of
miRNA-155 protected from LCMV-induced severe immunopa-
thology, which is in line with reports demonstrating a pivotal
role of miRNA-155 in autoimmune inflammation (Murugaiyan
et al., 2011; O’Connell et al., 2010). With regard to T cell survival,
miRNA-155 was shown to inhibit caspase 3 activity in Jurkat
T cells (Ovcharenko et al., 2007) and FADD expression in macro-
phages (Tili et al., 2007). Whether the increased apoptosis of
Mir155!/! CD8+ T cells was due to such mechanisms remains
to be determined.
In line with our results in virus infection, we demonstrate a
central role for miRNA-155 in tumor-specific CD8+ T cells. First,
the efficient accumulation of CD8+ T cells by vaccination with
adjuvanted peptide required intrinsic miRNA-155 function, reca-
pitulating our observations in LCMV infection. More importantly,
Mir155!/! effector cells were severely impaired in their ability to
curb tumor growth. Because these cells acquired full effector
functions independently of miRNA-155, the different tumor con-
trol was likely due to defect in the magnitude of tumor-specific
T cells or to higher susceptibility to the suppressive tumor-micro-
environment (Klebanoff et al., 2011). Conversely, overexpression
of miRNA-155 greatly increased tumor killing by WT CD8+
T cells. This indicates that tumor-specific CD8+ T cell activity is
directly dependent on miRNA-155 expression.
The accumulation of effector CD8+ T cells is influenced by the
cytokine milieu; e.g., their initial expansion is promoted by gc
cytokines, which signaling is regulated by SOCS-1 (Cornish
et al., 2003). More specifically, CD8+ effector cell accumulation
in the LCMV response is reduced if cells lack gc signaling (Dec-
aluwe et al., 2010). Interestingly, IL-2 was found to be critical for
the maintenance of effector CD8+ T cells in chronic LCMV infec-
tions (Bachmann et al., 2007). Here we show thatmiRNA-155 en-
hances cytokine signaling in CD8+ T cells by targeting SOCS-1.
Consequently, Mir155!/! naive and effector CD8+ T cells failed
to mount physiologic levels of pSTAT5 in response to gc cyto-
kines. In line with in vitro experiments using CD4+ T cells (Lu
et al., 2009), we observed strong and transient in vivo downregu-
lation of SOCS-1 mRNA in virus-specific CD8+ T cells at day 6 of
the response. Interestingly, this occurred in a partially miRNA-
155 independent manner, whereas SOCS-1 protein concentra-
tions of naive and effector CD8+ T cells were found to be clearly
dependent on miRNA-155. Moreover, we did not detect an
impact of miRNA-155 on pSTAT5 in response to IL-2 in the early
effector response in vivo as well as after in vitro priming (data
not shown), whereas the effect was pronounced in naive and
late effector cells. This suggests a miRNA-155 independent
mechanism allowing full cytokine signaling early in the effector
response, whereas miRNA-155 is modulating cytokine signaling
in naive and late effector cells, promoting their accumulation and
survival. Interestingly, at the peak of the response, effector CD8+
T cells are reportedly dependent on IL-2 and IL-15 for sustained
expansion (D’Souza and Lefranc¸ois, 2003; Sanjabi et al., 2009).
We were able to confirm a SOCS-1-dependent inhibition of
cytokine signaling in Mir155!/! T cells by transduction with a
shSOCS-1 lentivirus in in vitro experiments. Although the formal
proof that loss of SOCS-1 inMir155!/!CD8+ T cells in vivowould
restore their function remains to be shown, the observed rescue
of STAT5 phosphorylation in Mir155!/! cells back to WT levels
suggests that suppression of SOCS-1 in WT, but not Mir155!/!
T cells, caused the differences in pSTAT5 signaling. This
hypothesis was further supported by our observation that
virus-specific, SOCS-1 transgenic CD8+ T cells fully differenti-
ated but failed to accumulate to normal numbers at the peak of
the LCMV response, which mirrors the phenotype of Mir155!/!
T cells and identifies SOCS-1 as an important regulator of
CD8+ T cell responses in vivo. Conversely, suppression of
SOCS-1 in tumor-specific cells increased the accumulation
of transferred cells and subsequently was highly therapeutic
in limiting growth of established melanoma. Thus, although a
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negative role for SOCS-1 in CD8+ T cell responses has been sug-
gested before (Chong et al., 2003; Cornish et al., 2003; Davey
et al., 2005; Marine et al., 1999; Palmer and Restifo, 2009), we
here demonstrate a cell-intrinsic role of SOCS-1 in responses
to virus and cancer. Our results of the highly dynamic regulation
of SOCS-1 expression in vivo and the strong impact of SOCS-1
alterations in responses to virus and tumor suggests that a major
part of the effects caused in CD8+ T cells by miRNA-155 deletion
are due to increased SOCS-1 expression.
In summary, the results presented here identified a crucial cell-
intrinsic role of miRNA-155 and its target SOCS-1 in effector
CD8+ T cells and demonstrated that this miRNA is required for
an optimal CTL response to both virus and tumor. Moreover,
miRNA-155 overexpression in tumor-specific CD8+ T cells
substantially increased their potency, thus providing strong
evidence for a clinical potential in the context of therapeutic
adoptive T cell transfer.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6mice were fromHarlan.Mir155–/– andRag2–/–Il2rg–/–, TCR transgenic
OT-I, and P14 mice bearing a transgenic TCR-specific for Kb/OVA257–264 or
LCMV Db/GP33–41 MHC-I/peptide complexes, respectively, were from Jack-
son and were bred under specific pathogen-free conditions. P14xSOCS-1
transgenic (Seki et al., 2007) and Pmel-1 transgenic mice expressing a TCR-
specific for an H-2Db-restricted CD8+ T cells epitope from the murine mela-
noma tumor antigen gp10025–33 or human gp10025–33 have been described
(Overwijk et al., 2003). All animal experiments were conducted with the
approval of the Lemanic Animal Facility Network (RESAL), NCI (protocol SB-
126) or NIAID (protocol LI-10) Animal Use and Care Committees.
Quantitative PCR
Total RNA from subsets was extracted with the miRNAVana kit (Ambion), and
mature microRNAs (miRNA-155 and controls RNU44 and snoRNA202) were
reverse transcribed with TaqMan RT MicroRNA Kit (Applied Biosystems)
and amplified by using Universal Fast Start Rox Probe Master Mix (Roche)
and microRNA assay kits in 384-well plates (Applied Biosystems) on an ABI
Prism 7900 HT device (Applied Biosystems). RT-PCR for Socs1 was per-
formed with primers from Applied Biosystems. Gene expression was calcu-
lated relative to G6PDX.
In Vitro Priming with Dendritic Cells
T cells were purified from lymphoid tissues by using anti-CD8a beads (Miltenyi)
and cocultured with peptide pulsed Mir155!/! DC. In competition experi-
ments, equal numbers of WT and Mir155!/! OT-1 CD8+ T cells were cocul-
tured with WT DC.
Differential Stimulation of Human CD8+ T Cells and Microarray
Human T cells transduced with NY-ESO-1 TCR variants (Schmid et al., 2010)
were stimulated with 0.01 mg/ml (for miRNA-155 quantification) or 0.002 mg/ml
(for BIC microarray) NY-ESO-1157–165 multimer. BIC quantification was done
by Miltenyi Biotec.
LCMV Infection
Mice were infected intravenously with 200 pfu of the WE strain or 2 3 106 pfu
clone 13 of LCMV. Cell counts in blood were performed with TrueCount tubes
according to the manufacturer’s instructions (BD). Viral titrations were per-
formed by a standard plaque assay.
Cytokine and Cytotoxicity Assays
Splenocytes were stimulated with indicated peptides or a mix of LCMV pep-
tides (gp33, gp70, gp92, gp118, gp276, np166, np205, np235, np396) at
5 mM each or PMA (50 ng/mL) and Ionomycin (500 ng/mL) in the presence of
GolgiStop (BD PharMingen) for analysis in flow cytometry. Cytolytic activity
was assessed by using the chromium release assay with EL4 pulsed with
1 mM GP33–41 peptide and measured with a TopCount reader (Canberra
Packard).
Adoptive Cell Transfers
Before LCMV infection, CD8+ T cells were purified by magnetic beads sorting
(Miltenyi Biotec) and 1 3 106 purified CD8+ T cells were injected into the tail
vein. In the P14xSOCS-1 experiments, 33 104 cells were injected normalized
to gp33 tetramer-positive populations. For vaccination and tumor challenge,
OT-1cells were purified and 1 3 106 cells were injected intravenously 3 days
before subdermal injection of 1 3 105 B16 melanoma cells expressing
OVA. Seven days later, mice were vaccinated subcutaneously with 25 mg
OVA257–264 peptide and 50 mg CPG-ODN in PBS.
T Cell Transduction and Transfers into Tumor Bearing Mice
Pmel CD8+ T cells were stimulated with anti-CD3 (2mg/ml) and anti-CD28
(1mg/ml) for 24 hr, transduced with retrovirus expressingmiRNA-155 or scram-
bled miRNA, and expanded for 4 days. To knock down SOCS-1, we trans-
duced pmel CD8+ T cells 2 days after stimulation with lentivirus expressing
shSOCS-1 or empty vector and selected in puromycin from days 4 to 7 prior
to transfer into tumor-bearing hosts. We injected 107 cells (miRNA-155 exper-
iments) or 106 (shSOCS-1 experiments) intravenously into mice bearing B16
tumor in conjunction with 2 3 107 pfu rvvhgp100 and IL-2 (6X6e4 cu). In
shSOCS-1 experiments, mice were sublethally irradiated prior to cell transfer.
Tumor volumes were plotted as the product of perpendicular diameters. For
rescue of pSTAT5 in miRNA-155 cells, WT and Mir155!/! CD8+ T cells were
transduced with lentivirus encoding shSOCS-1 or control sh and cultured for
1 week with IL-2 or IL-15 (R&D systems, 20 ng/ml) before cytokine stimulation
(vector sequences upon request).
Flow Cytometry and pSTAT5 Measurements
Cells were stained with antibodies of the indicated specificities (eBioscience)
or H-2 Db/peptide-loaded MHC. PD-1 PE-Cy7 antibody was from Biolegend.
For detection of pSTAT5, cells were stimulated with indicated cytokines
(R&D systems) for 18 min and fixed with 0.5% formaldehyde in PBS for
15 min. Upon washing in medium containing 10% FCS, cells were permeabi-
lized in 80% methanol for 20 min, washed, and stained with pSTAT5 antibody
(BD Biosciences) and additional markers (eBiosciences). Labeled cells were
analyzed on LSR-II (Becton Dickinson).
Immunoblot
Cells were lysed (Cell Signaling Technologies) and immunoblotting was per-
formed by using Bio-Rad TGX reagents and protocols on nitrocellulose paper,
incubated with antibodies against SOCS-1 (Lifespan Biosciences [Figure 6C]
or Imgenex [Figure S6]) and with appropriate HRP-conjugated secondary
antibodies (Cell Signal Technologies). Blots were developed by using chemilu-
minescence (Pierce), gel images were captured with Gel Doc XRS (Bio-Rad),
and densitometry was evaluated using Quantity One software (Bio-Rad).
Proliferation and Apoptosis Assay
Mice were injected intraperitoneally with 200 mg BrdU, and proliferation was
measured in spleen cells 1 hr (P14xSOCS-1 experiments) or 4 h (miRNA-155
experiments) later by staining with anti-BrdU and anti-ki67+ antibodies.
Apoptotic cells were detected by staining splenocytes for AnnexinV upon
1 hr in vitro incubation at 37"C (all BD PharMingen).
Statistics
The two-tailed Student’s t test was used to compare two groups; multiple
groups’ comparisons were performed with one-way ANOVA corrected with
Bonferroni’s multiple-comparison test factor. Statistical survival differences
in the tumor experiments were analyzed with the log rank test. Statistical
significance is displayed as *p < 0.05, **p < 0.01, and ***p < 0.001. Data are dis-
played as mean and SEM if not indicated otherwise.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2012.12.006.
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